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Chapter 1 
General introduction 
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1.1 General characteristics of Alzheimer's disease 
Alzheimer's disease (AD), named after the German psychiatrist Alois Alzheimer who in 
1907 was the first to describe changes in the brain of a woman dying after a history of 
progressive dementia [1], is a neurodegenerative disorder of the brain affecting many 
people of age over 65. The prevalence of AD increases from 0.5% at age 65, via 10-20% 
at age 85 to 40% or more at even higher ages [2,3]. Since the size of the age group 
affected by AD is increasing, the disease will continue to impose an increasing demand 
on health and medical programs. AD accounts for approximately 50% of all cases of 
dementia and its clinical symptoms include decline of cognitive functions, severe memory 
loss and personality and behavorial changes. For the purpose of this introduction the term 
Alzheimer's disease or AD will be used for both presenile and senile dementia of the 
Alzheimer type (SDAT), that may be distinguished by the age of onset of clinical 
symptoms (before or after the age of 65, respectively), but are likely to be clinically and 
pathologically identical. Sporadic AD is much more abundant than familial AD and may 
account for approximately 90% of all AD cases. 
A definitive diagnostic test for AD during the patient's life is not yet available. 
Diagnosis of AD can still only be made after histopathological examination of the brain, 
usually after autopsy, allowing a discrimination between AD and other types of dementia 
such as vascular dementia (multi-infarct dementia and other forms), dementia with 
Parkinson's disease, Pick's disease and alcoholic dementia. A number of methodologies 
for the post mortem diagnosis of AD have been described in the past. Some years ago a 
since then widely used standardized and pragmatic protocol has been developed by a 
workshop of neuropathologists [4] that, based on both clinical and neuropathological 
criteria, leads to a diagnosis of normal ageing, or definite, probable or possible AD. 
During the last ten years an impressive amount of research has been performed 
aimed at understanding the molecular pathology of AD. In this introduction an overview 
on recent developments in AD research will be presented. 
1.2 Neuropathologic characteristics of AD 
Neuropathological examination of the brain after autopsy of an AD patient will reveal a 
number of characteristic pathological changes. After macroscópica! examination of the 
brain it is clear that its weight is often diminished compared to age-matched controls, due 
to shrinkage of the brain, widening of the sulci and atrophy and blunting of the gyri [5]. 
Microscopic examination of the brain reveals a number of characteristic histological 
lesions, comprising senile plaques, neurofibrillary tangles (NFTs), congophilic angiopathy 
(CA) of the vessels, neuropil threads and neuronal cell loss. Usually, the hippocampus is 
the most severely affected structure in the AD brain. Historically, the silver impregnation 
techniques according to Bielschowsky [6] or Bodian [7] or the Congo red and thioflavin S 
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stains have been used to visualize these microscopical pathological lesions of the AD 
brain The structure and composition of senile plaques and NFTs will be described in the 
following sections In paragraph 1 9 the pathology of CA will be described in more 
detail 
1.2.1 Senile plaques 
Although also found in the brains of non-demented elderly people, the distribution and 
density of these lesions is strongly increased in the brains of AD patients and they are not 
found in other neurologic disorders that occur spontaneously The brain regions that are 
most severely affected by senile plaque formation are all neocortical regions, the 
hippocampus and the amygdala [5,8] 
Several types of senile plaques can be distinguished The first type of senile plaque 
is the classic senile plaque a spherical deposit, approximately 200 μτη in diameter, 
consisting of a central core of amyloid surrounded by a halo of degenerating and 
dystrophic neuntes Amyloid is a general term used for insoluble fibrous material 
deposited in human tissue, made up of proteins folded into a 0-pleated sheet structure 
The binding of the histologic dyes Congo red and thioflavin S to amyloid is based on 
their interaction with these fibrils Apart from the argentophilic altered neuronal processes 
in the halo, also activated microglial cells (see par 1 8) and reactive astrocytes, readily 
identified by their strong expression of glial fibrillar acidic protein (GFAP) and heat 
shock proteins [9], surround the amyloid core [10] Thin-section electronmicroscopical 
analysis of classic senile plaques confirmed the presence of fibrillar material in the central 
amyloid core, consisting of fibrils with a diameter of 6-10 nm [8] 
The second type of senile plaque is strongly related to the classic senile plaque, 
but is rarely seen This so-called burned out senile plaque solely consists of an amyloid 
core, and lacks the other characteristics of the classic senile plaque It can be identified 
with the same histological techniques, however 
Until 1984 the histological identification of senile plaques entirely relied on the 
classic staining techniques mentioned above At this time, a major breakthrough in AD 
research was accomplished by Glenner and Wong [11], who purified and partially 
sequenced the major component of cerebrovascular amyloid from AD brains that also 
appeared to be the major component of senile plaques This 39-43 amino acid protein, 
with a molecular weight of approximately 4 kDa, was designated as the A4-protein or 
amyloid β protein (A/3), referring to its ability to assume the characteristic β pleated sheet 
structure of amyloid [12,13] An important consequence of this discovery was the 
development of specific antibodies directed against Aß that thus allowed for 
immunohistochemical analysis of AD brains Soon this lead to the discovery of another 
type of senile plaque, the diffuse (or amorphous) senile plaque [14,15] This type of 
plaque lacks a fibrillar amyloid core and neuntic or glial changes, and could thus not be 
identified with the classic staining techniques, but it does contain non-fibnllar A/3 The 
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importance of this discovery is that diffuse senile plaques are much more abundant in AD 
brains than classic senile plaques and that Aß may be deposited in two physically different 
forms. In contrast to the classic senile plaque, diffuse senile plaques can be found in the 
cerebellar cortex [16,17] Modifications of the existing Bielschowsky [18,19] and 
thioflavin S stains [20] and lmmunostaining with proper anti-A/3 antibodies after 
pretreatment with formic acid [21] are considered to be the most sensitive techniques to 
detect diffuse senile plaques 
The primitive senile plaque is the fourth type of senile plaque, composed of wisps 
of amyloid between normal and abnormal neuronal and glial processes, but without a 
central amyloid core or reactive cells [8,22], and morphologically represents an 
intermediate type of senile plaque. 
Ultrastructural analysis of cortical diffuse senile plaques [23] and of cerebellar 
diffuse senile plaques [24] revealed labeling of amorphous material with anti-A/3 
antibodies [25] and little or no fibrils in these lesions. In contrast to these observations, 
Mann [26] claimed that diffuse/primitive senile plaques of both the cerebral and cerebellar 
cortex examined in biopsy tissue all contained fine fibrillar material. Probably very few 
"true" diffuse senile plaques exist, and many of these plaques contain fine fibrils that can 
not be identified with amyloid stains Senile plaques are also found in Down syndrome 
brains Assuming that identical processes take place in these and in AD brains, temporal 
changes in senile plaque formation can be followed in Down syndrome brains of different 
ages. Brains of young Down syndrome patients ( < 50 years) display mostly diffuse senile 
plaques and with increasing age, the number of classic senile plaques as well as neuntic 
and glial changes increase [27,28]. This is consistent with a gradular transformation of 
the soluble Aß of diffuse and primitive senile plaques into the fibrils of classic senile 
plaques [29,30] as suggested by many authors (see par. 1.10) 
1.2.2 Neurofibrillary tangles (NFTs) 
NFTs are intraneuronal fibrillar deposits that occupy part or most of the cytoplasm of 
large pyramidal neurons [5,31], preventing normal functioning of the cell NFTs are 
easily identified with the previously mentioned silver impregnation techniques and Congo 
red and thioflavin S stains They are found in most parts of the cerebral cortex, but are 
absent from the cerebellum. NFT-laden neurons eventually die, leaving extracellular or 
"ghost" tangles behind, that are frequently observed in AD brains. Ultrastructurally, 
NFTs are composed of closely packed bundles of twisted filaments, called paired helical 
filaments (PHFs). Each PHF is 10 nm wide and twists around its twin at regular intervals 
of 80 nm, creating filaments of maximal 20-22 nm wide, narrowing to 10-13 nm at its 
minimum [32,33], and are thus clearly distinct from the Aß fibrils in senile plaques The 
major component of PHF is a hyper-phosphorylated form of the microtubule-associated 
protein tau [34-36], and is designated as A68 Ubiquitin is also a component of NFTs and 
ghost tangles may also contain Aß [31] and apolipoprotein E (ApoE) [37] 
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1.2.3 Specificity of senile plaques and NFTs for AD 
Both lesions are also found in the brains of non-demented elderly people, but in much 
smaller numbers than in AD patients [31] Furthermore, senile plaques are also found in 
the brains of patients with Down syndrome and a rare familial disorder called hereditary 
cerebral haemorrhage with amyloidosis of the Dutch type (HCHWA D), but both these 
diseases have an etiology that is closely related to AD (see par 1 7) NFTs are even less 
specific for AD, since they can be identified in neurodegenerative diseases other than AD, 
such as progressive supranuclear palsy syndrome, postencephalitic parkinsonism and 
many others [31,38,39] It has been suggested however, that the number of cytoskeletal 
changes, including NFTs [40,41], classic senile plaques [42] and neuropil threads, 
correlate better with the clinical symptoms of AD than the number of senile plaques In 
agreement with these observations, the number of neurofibrillary changes is much lower 
in non demented elderly individuals than in AD patients [43,44] 
1.3 Aß is part of the amyloid precursor protein (APP) 
After the discovery of Aß as the central component of amyloid deposits in both AD and 
Down syndrome [11,45], research focussed on the identification of the gene responsible 
for the production of A/3 It was speculated that this gene could be found on chromosome 
21, since Down syndrome patients carry an extra copy of this chromosome Still, it took 
several years to discover that Aß is part of a large membrane-spanning protein, 
designated as the amyloid precursor protein (APP), indeed encoded by a gene on 
chromosome 21 [46-48] (Figure 1) At least three different gene products Іід е been 
identified to date, designated as APP695, APP75, and APP770, according to the number of 
amino acids, and resulting from alternative splicing of exons 7 and 8 Both the 751 and 
770 splice variants contain an insert with strong similarity with the Kunitz type of serine 
proteases [49] Other splice variants of APP, lacking exon 15, have been identified in 
leukocytes (L-APP) [50] APP is inserted in the membrane with its C-terminal end at the 
cytoplasmic site of the membrane and the large N-terminus, containing a cysteine rich 
region, two glycosylation sites, a zinc-binding domain [51] and a signal sequence, 
extending at the extracellular site The cytoplasmic and transmembrane domains comprise 
47 and 24 amino acids, respectively The 39-43 amino acid Aß includes 28 residues of 
the extracellular domain and 11 15 residues of the transmembrane region [46] 
APP is post-translationally modified by N- and O-glycosylation [46,52,53], and 
usually both mature and immature forms of APP can be identified in cell lysates [52-54] 
In certain neuronal and glial cell lines modification of APP into a proteoglycan with 
glycosaminoglycan side chains attached to the protein backbone, have been demonstrated 
[55,56] In brains, APP products with molecular weights ranging from 105-135 kDa 
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Figure 1. Schematic diagram of the APP molecule and its various isoforms The position of the 
molecule in the membrane and its functional domains are indicated The Aß domain is shown in 
black The position of the Kunitz protease inhibitor and the OX-2 inserts are shown by dashed and 
dotted boxes, respectively 
[52,57] have been detected. The APP7J1/770 transcripts are found in brain as well as 
peripheral tissue, but the APP695 isoform lacking the Kunitz protease inhibitor (KPI) 
domain is only found in neuronal tissue or cells of neuronal ongin [49,58]. In situ 
hybridisation studies of APP expression in brain showed that mRNA encoding for APP69, 
and APP751/770 was predominantly found in cortical pyramidal neurons [59,60] in both 
normal and AD brains, but not in glial or endothelial cells [61,62]. Early studies 
suggested that the APP695/APP7,1/770 transcript ratio is reduced in AD brains [60,61,63], 
but regarding the small changes that were observed it is questionable whether this has 
mechanistic consequences. Immunohistochemical staining of brain sections for APP 
confirmed that neurons of normal and AD brains, but not microglial cells or astrocytes, 
expressed APP [64-67]. Also smooth muscle cells, but not endothelial cells, in the 
cerebral vasculature, expressed APP [57,64,66] and enhanced APP immunoreactivity is 
observed in vessels of HCHWA-D brains [64] Furthermore, in classic senile plaques 
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dystrophic neuntes are APP-positive [57,64,66,68,69]. These data indicate that neurons 
and smooth muscle cells are the major candidates for the production of APP and Aß in 
senile plaques and CA, respectively. APP is expressed in a number of peripheral tissues 
[47,49,70], but Aß deposition is almost exclusively restricted to the brain. 
It was found that APP is a member of a family of transmembrane molecules that 
also include human and mouse amyloid precursor-like protein-2 (APLP2), mapped to 
chromosome 11 [71-73], and mouse APLP1 [74]. The APLPs have a strong homology 
with APP and they contain similar glycosylation sites, cysteine-rich and zinc-binding 
domains and may contain a KPI-domain, but, interestingly, the APLPs do not contain the 
Aß sequence [71]. Although these proteins can not give rise to the production of Aß, 
their similarities with APP indicate that these proteins share common functions and 
interactions with other proteins, and the study of these APLPs may help to understand the 
biology of APP. 
1.4 Processing and secretion of APP and Aß formation 
1.4.1 Secretion of APP 
Aß is partially inserted in the membrane part of APP, immediately raising the question 
how this fragment can be released from its precursor. "Normal" processing of APP 
involves cleavage of the molecule at the cell surface between residues 16 and 17 of Aß 
[75-77], precluding Aß formation. Thus a soluble form of APP (APPJ is produced [78]. 
The secreted isoforms of APP containing the KPI-insert are identical to the protease 
inhibitor protease nexin-2 (PN-2) [79,80]. Secretory processing of APP leading to APPS 
can occur both at the cell-surface [81] and intracellularly [82,83]. Regarding this normal 
secretory processing of APP straight through the Aß domain, it was thought that Aß 
production was the result of aberrant cleavage of APP [84]. However, it was soon 
discovered that Aß was continuously produced in a soluble form by cultured cells [85,86] 
and that soluble Aß could also be detected in cerebrospinal fluid (CSF) of normal 
individuals and AD patients [85,87], indicating that its production is part of a 
physiological process in vivo and in vitro. Besides, a truncated form of APPS, resulting 
from cleavage at the N-terminus of Aß and that would be expected together with A/3 
production, was demonstrated in mixed brain cell cultures [88]. 
1.4.2 Intracellular trafficking of APP and Aß production 
Despite the fact that APP is a transmembrane molecule, the number of APP molecules 
expressed on the cell surface membrane is low and only a fraction (30-50%) [89,90] of 
APP is converted into APPS [52,91]. Therefore, and regarding the limited access for 
proteolytic enzymes to release Aß from the membrane, an intracellular degradation 
mechanism for APP leading to Aß production has been proposed. Initial evidence that 
endosomes or lysosomes may be involved in the processing of APP came from the 
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identification of APP in intracellular compartments [91,92] including lysosomes [93] and 
the accumulation of APP in lysosomes after treatment with inhibitors of lysosomal 
proteases [92,94] 
The intracellular transport or trafficking of APP became the subject of several 
studies aimed at the identification of the subcellular site of A/3 production [90,95] Mature 
full-length APP inserted in the cell-surface membrane has been demonstrated to function 
as a precursor molecule for A/3 production after re-internalization from the cell-surface 
and intracellular transport to, for instance, endosomes or lysosomes [94,96,97] 
Endocytosis of cell surface-APP may be mediated by clathnn coated pit formation 
[96,98] A 10 kDa C-terminal fragment (CTF) of APP, resulting from secretory cleavage 
of APP, is also reinternalized to lysosomes [94] and subjected to further degradation, that 
may result in the production of a truncated form of A/3, called p3 [97] 
Cell-surface full-length APP is probably not the only direct source for A/3, since 
deletion of the cytoplasmic tail of APP, that contains a motif for coated pit mediated 
internalization, results in enhanced production of the "secretory" products APP, and p3, 
but does not completely abolish A/3 formation [96,97] Thus, an alternative mechanism 
for the production of A/3 may exist, that parallels the secretory production of APP, Using 
inhibitors of specific cellular functions the potential involvement of specific organelles in 
A/3 production was studied The pH-decreasing agent ammonium chloride decreased A/3 
production [85,97], indicating the involvement of an acidic organelle, although the 
absence of any effect has been reported as well [99] Lysosomes, organelles with an 
acidic pH, are not necessarily involved in this process, however, since the lysosomal 
protease inhibitors leupeptin and chloroquine did not affect A/3 production [85,97,99] 
The same agents caused an accumulation of CTFs of APP with varying length, some 
encompassing the entire A/3 sequence, in lysosomes [94,97,99-101], indicating that these 
fragments are probably not the actual precursors of A/3 Treating cells with the drugs 
brefeldin A, that disconnects the Golgi compartment from the endoplasmatic reticulum 
(ER), or monensin, that inhibits protein processing within the Golgi and prevents 
transport of secretory and membrane proteins to the cell surface, blocked A/3 and APP, 
production, indicating that A/3 is not produced in the ER or early Golgi [53,97,99] and 
that a secretory route is involved in the processing of APP into A/3 Final arguments in 
favour of A/3 production during the secretory pathway, are the facts that APP„ A/3 and p3 
are all secreted with similar kinetics [97,99] and that most studies consistently describe 
that A/3 is detected only in the culture supernatant [85,86,96,97,99], with the exception of 
a single report of intracellular accumulation of A/3 [102] 
Together, these data are compatible with an acidic organelle, other than 
lysosomes, ER or early Golgi, as the subcellular site of A/3 production This A/3-
producing organelle may include endosomal vesicles, containing re-internalized cell 
surface APP, that may recycle to the cell surface, but A/3 may also accumulate in 
secretory transport vesicles leaving the Golgi compartment heading for the cell surface, 
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followed by rapid release of A/3 into the culture supernatant [97]. It is possible that, on 
their way to the cell surface, these organelles eventually meet in the same pathway 
Besides, it is also possible that CTFs of APP that reach the lysosomes do not give rise to 
A/3, whereas CTFs that escape this fate and are diverted to a secretory route may serve as 
precursors for A/3 
Caution should be taken in generalizing the above described data that are mostly 
obtained with cell cultures without physiological relevance to the brain and usually 
transfected with APP or APP constructs and therefore overexpressing the corresponding 
proteins The processing of APP is cell-specific [99,103], emphasizing the need for the 
study of APP metabolism in human brain-denved cell types that have a relevance to the 
pathology of AD, such as neuronal, glial and vascular cells 
1.4.3 Proteases involved in APP processing 
Normal processing of APP through the secretory pathway, leading to the secretion of 
APPS involves cleavage between residues 16 and 17 of the Aß sequence, by an enzyme or 
a group of enzymes putatively referred to as a-secretase [76] (Figure 2) A membrane-
bound protease capable of α-secretase activity has been described [81], possibly belonging 
to the class of metallo-endopeptidases [104], but the exact nature of potential a-secretases 
has not been identified yet. 
Release of A/3 from its precursor requires cleavage at both the N-terminal and C-
terminal side of A/3 Proteases capable of cleaving at these sites are tentatively designated 
as /3-secretase and 7-secretase, respectively Proteases with a /3-secretase activity that 
have been identified so far include a calcium-activated serine protease [105], metallo-
endopeptidase 24 15 [106] and metalloprotease MP 100 [107] Cathepsin G and 
chymotrypsin have also been investigated for their ability to act as a /3-secretase, because 
they are target molecules of the senile plaque-associated protease α,-antichymotrypsin (a,-
ACT, see par. 1 8) [108]. Cathepsin G may be found in astrocytes [109] but this 
observation is not confirmed by others [HO] Potential 7 secretases, include a prolyl 
endopeptidase [111] and cathepsin D [112] All these enzymes have been identified using 
in vitro assays with model peptides, but hardly anything is known about the expression 
levels in brain and their ability to cleave the full-length APP In contrast, cathepsin S has 
been demonstrated to be associated with a subset of senile plaques and NFTs in AD and 
Down syndrome brains, but it is not known whether this enzyme may cut APP to release 
Aß [113] Thus, more research is needed to establish the significance of these enzymes 
for the pathogenesis of AD Furthermore, it is not unlikely that multiple enzymes are 
responsible for the proteolytic cleavage of APP, eventually resulting in the generation of 
A/3 During the intracellular trafficking of APP, the molecule passes through various 
intracellular compartments with different pH levels and is exposed to different enzymes 
that may act on APP, resulting for instance in the formation of CTFs of APP and, 
ultimately, Aß 
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1.5 Functions ofAPP, 
Understanding the normal function of APP, АРР
Я
 and A/3 may help to decipher the role 
of these proteins under pathological conditions such as AD Most is known of the 
function of APPS, especially the KPI-containing isoforms (PN-2) [79,80]. PN-2 may form 
stable inhibitory complexes with trypsin [48,79], chymotrypsin [80] and the coagulation 
factors XIa and IXa [114] It is an abundant protein of platelet α-granules that is secreted 
upon activation and therefore it is considered important in wound healing and in 
maintaining hemostasis Furthermore, the overexpression of PN-2 in the cerebral 
vasculature of HCHWA-D patients [64], and its anti-coagulant properties, may explain the 
spontaneous cerebral hemorrhages occurring in these patients [114] Moreover, a role for 
PN-2 in mediating cell-cell and cell-substrate adhesion [115-118] and in cell growth [119] 
has been suggested, indicating that aberrant functioning of APP, in AD may cause 
impaired neuronal functioning 
1.6 Characteristics of Aß and its effects on cells 
1.6.1 Characteristics of Aß 
The A/3 peptide that accumulates in AD brains is heterogeneous at its C-terminus, 
resulting in peptides of 39-43 amino acids long. Attempts to establish the exact 
composition of CA and senile plaque amyloid by chromatographic and mass spectrometry 
techniques [120-123] or by immunohistochemistry using antibodies specifically 
recognizing either A/3M0 or А/3
М2мэ [124-126] leaded to confusing results The conclusion 
from these studies is that it is likely that senile plaques as well as CA contain both A0MO 
and AßlA2/4i, but probably not in equal amounts It is likely that, in general, A/3M2/43 and 
A/3M0 are the major components of diffuse senile plaques and CA, respectively, and that 
both isoforms are present in classic senile plaques [124,125,127], suggesting that the Aß 
in CA and in senile plaques is derived by distinct mechanisms. The absence of A/3M, as 
reported by some investigators [120,122,123] may be due to techniques that were 
insufficient to dissolve this relatively insoluble isoform 
Aß may exist in a soluble form as well as in a /3-pleated sheet conformation [128], 
basically through the /3-sheet structure of the residues 14 21 and 29-39/42 [128,129] 
Synthetic peptides varying in length from 1-28 to 1-42 can form fibrils in vitro, depending 
on concentration, time, pH, type of solvent and salt concentration [128,130] The 
resulting amyloid fibrils are resistant to several proteases [131] A/3M2 is less soluble and 
forms fibrils faster than shorter isoforms [128,130,132], thus the С terminal sequence of 
Aß is critical in determining the solubility of the peptide 
The process of amyloid formation in vivo may be seeded or nucleated by trace 
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Figure 2. Schematic presentation of the site and nature of the pathogenic mutations in the APP 
molecule (indicated below the Aß sequence) and of the sites of secretase cleavage (indicated by 
arrows). The Aß sequence is boxed; the one-letter code for amino acids is used. The position of 
the APP mutations is according to the APPm amino acid numbering (see text for details) 
amounts of amyloid fibrils [132,133]. Progression of amyloid formation involves the 
incorporation of, in itself, soluble A/3 peptides that aggregate to the initially formed seed. 
Since A/3M2 is relatively insoluble compared to A/?M0, small seeds of A/3M2 fibrils may 
rapidly grow by assembly of AßiA0, the isoform that is predominantly produced by 
cultured cells [134] and is present in brain CSF [87]. Formation of the fibril seed is then 
the rate-limiting step of amyloidogenesis [133]. It has been demonstrated in Down 
syndrome brains that A0M2 deposition precedes Κβ
ίΛ0 deposition [135], supporting this 
theory. 
Several A/3-binding factors may influence the formation of /3-amyloid, such as 
ApoE, a,-ACT (see par 1.8) [136-138] and zinc [139]. A/3-aggregates modified into 
advanced glycation end-products, may also function as potent seeds for amyloid formation 
[140]. 
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1.6.2 Effects of Aß on cells 
Aß may exert both protective and toxic effects on neuronal cells. Soluble A/3, added in 
low doses to cultures of freshly isolated neurons, may enhance their survival rates 
[141,142], and, in combination with components of the extracellular matrix, may promote 
neunte outgrowth [143]. The number of reports describing a toxic effect of A/3 on cells 
are more abundant, however. Isolated human amyloid cores, containing aggregated Aß, 
or synthetic A/3 injected into rat brains induced neurodegeneration [144,145], indicating 
that the peptide has a direct toxic effect on the neural environment. When A/3 is 
administered in relatively high doses to cultured neurons, aggregated A/3 peptides induce 
neurotoxicity, loss of presynaptic terminals and the development of dystrophic neuntes 
[146-149]. The formation of A/3 fibrils is essential for these effects, that are not observed 
with soluble A/3 [148,149]. The neurotoxic effect of pre-aggregated A/3 can be blocked by 
the amyloid-binding dye Congo red [148], which may inhibit fibnl formation or bind to 
preformed fibrils These in vitro data on neuronal toxicity correlate well with the 
pathology of the AD brain Diffuse senile plaques that are composed of non-fibnllar A/3 
lack any sign of neuronal degeneration, whereas in classic senile plaques A/3 fibrils and 
neurodegenerative changes coincide. A/3 may also cause neurodegeneration via indirect 
pathways. A/3-induced, aggregation-dependent degeneration of microglial cell cultures and 
induction of gliosis in astrocyte cultures has been described [150-152] Simultaneous 
incubation of microglial cells with IFN-7 and A/3 triggers the production of TNF-a and 
reactive nitrogen intermediates that lead to neuronal degeneration [153], and A/3-induced 
astrocytosis may lead to the production of growth inhibitory compounds that impair 
neunte outgrowth [152]. 
Sharply in contrast with the effects of A/3 peptides on neurons are the experiments 
described by Davis-Salinas [154]. Whereas degeneration of cultured neurons can be 
induced by different A/3 peptides (A/3,39, A/3M0 or A/3M2), only A/3M2, but not A/3140, 
caused degeneration of cultured leptomeningeal smooth muscle cells Moreover, only 
soluble Aß was found to induce these effects and pre-aggregation of the peptide 
completely abolished its effects [155] These studies clearly indicate that the mechanisms 
leading to the degeneration of either neuronal or vascular cells may be essentially 
different and that the pathology of senile plaques and CA may have an independent 
etiology. 
1.7 Genetic and risk factors for AD 
It is well known that approximately 10% of all Alzheimer patients have a family history 
of the disease During the last decade, researchers have tried to identify the genes that are 
responsible for these inherited forms of AD, a search that only very recently seemed to 
be completed The best known, and most obvious, genetic association with the 
development of AD is that of patients with Down syndrome These individuals carry an 
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extra copy of chromosome 21, that also encodes for APP Down syndrome patients 
develop diffuse senile plaques containing Aß as early as in the second and third decade of 
life, which is likely to be induced by the increased gene dosage of APP 
A number of autosomal dominantly inherited forms of AD or related disorders 
with early onset of the disease have been linked to mutations in the APP gene (Figure 2) 
The first mutation was discovered in families with the rare familial disorder HCHWA-D 
A mutation at position 22 of the Aß sequence, substituting a glutamine for a glutamic acid 
at codon 693 of APP [156], may be the direct cause of the deposition of Aß in diffuse 
senile plaques and the abnormal formation of cerebrovascular amyloid, but the underlying 
mechanism is not known Although no classic senile plaques develop, these studies 
provide a direct link between APP and the development of A/3-containing lesions also 
observed in the AD brain Besides, many of these patients show signs of dementia due to 
multiple cerebral hemorrhages [157], but cognitive decline was also observed in a patient 
independent from cerebral hemorrhages [158] The second set of mutations included point 
mutations in the APP gene of several AD families causing a change in amino acid 717, 
located C-terminal to the Aß sequence, from valine to isoleucine [159], glycine [160] or 
phenylalanine [161] Another mutation in APP, resulting in substition of alanine for 
glycine at codon 692 next to the mutation found in HCHWA D, is found in a Dutch 
family with either severe pre senile dementia or cerebral hemorrhages [162] Finally, a 
double mutation in codons 670 (lysine to asparagine) and 671 (methionine to leucine), just 
amino terminal to Aß, was detected in two Swedish families with AD [163] The effect of 
these mutations has been further studied in transfected cell systems with regard to Aß 
production Cells transfected with the mutation in residue 692 produced more Aß than 
control cells [164] and the mutations in codon 717 caused a small increase in the 
production of the more fibnllogenic A/3M2 relative to A/3M0 [134] Cells transfected with 
the Swedish double mutation secreted six to eight times more A/3 than control cells 
[165,166] and cultured fibroblasts isolated from affected family members produced three 
times more A/3 than similar cells from unaffected family members [167] These data 
indicate that mutations in the APP gene are the primary cause of enhanced A/3 production 
and that this is not a secondary event in AD brains 
A genetic linkage of familial late onset AD with a gene on chromosome 19 could 
be assigned to the apolipoprotein E (ApoE) gene on this chromosome Three alleles of 
ApoE have been identified, ApoE2, 3 and 4, differing from each other only in two amino 
acids The АроЕЗ allele is most common in humans The ApoE4 allele is associated with 
both familial [168,169] and sporadic late-onset AD [170,171] In contrast to the above 
mentioned mutations in APP, the association of ApoE4 with AD is not causative for the 
disease but should be considered as a risk factor, since homozygous ApoE4 carriers do 
not necessarily develop AD and individuals without this allele may become affected 
Initially, it was reported that the risk for developing AD increases from 20% to 90% and 
the mean age of onset decreases from approximately 84 to 68 years with increasing 
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number of ApoE4 alleles in familial [169] and sporadic late onset AD [172] However, in 
a more recent study of a large population sample the prevalence of AD among carriers of 
1 and 2 ApoE4 alleles was only 40% and 50%, respectively [173] The ApoE2 allele has 
a protective effect on development of AD [174] ApoE is associated with A/3 in senile 
plaques and CA and is found in NFTs [37,175] Late-onset AD patients with one or two 
ApoE4 alleles have increased levels of A/3 deposition in CA and senile plaques [176] 
ApoE binds A/3 and tau in a isoform-specific manner [168,177-179] An important role 
for ApoE, and ApoE4 in particular, may be the acceleration of aggregation of A/3 into 
amyloid fibrils [136-138] thus augmenting the formation of neurotoxic amyloid, but it is 
not known whether ApoE may affect APP processing and production 
Two very recently identified genes complete this list of genes associated with 
familial forms of AD The linkage of familial early-onset AD to chromosome 14 
[180,181], that may account for approximately 70-80% of all familial AD cases, has been 
assigned to the S182 or presenilin-1 (PS-1) gene [182], that encodes for a integral 
membrane protein traversing the membrane seven times, suggesting a receptor or channel 
function for this protein Shortly after this discovery, a gene on chromosome 1 encoding a 
protein with strong homology with the S182 product, has been identified and designated 
as STM2 or presemlin-2 (PS-2) [183] The functions of these proteins, their interactions 
with (derivatives of) APP and ApoE and their role in the pathogenesis of AD need to be 
established yet, but a possible role for these proteins in intracellular transport has already 
been suggested 
1.8 Role of inflammatory processes in Alzheimer's disease 
Apart from A/3, that forms the actual amyloid of classic senile plaques and CA, several 
senile plaque-associated proteins have been identified These include heparan sulfate 
proteoglycan (HSPG) [184,185], ApoE [168,175,176], advanced glycation products [186] 
and a protein designated as non-Aß component [187] The discovery that several 
inflammatory proteins are associated with senile plaques lead to the hypothesis that a 
cerebral acute phase reaction may occur in AD brains [188,189] These inflammatory 
proteins comprise the complement factors Clq, C3 and C4 [190-193], the acute phase 
proteins apantichymotrypsin (α,-ACT) [194-196], a2-macroglobulin [197] and 
interleukin-6 (IL-6) [197] Besides, IL-6 is the major inducer of the acute phase proteins 
a2-macroglobuhn and α,-ACT [198,199], although the latter can also be induced by IL-1 
in human astrocytes [200] The deposition of these acute phase proteins seems to be 
restricted to cortical senile plaques, since they are not or to a lesser extent expressed in 
cerebellar senile plaques [193,201,202] 
The acute phase reaction is accompanied by a response of microglial cells 
Microglial cells are resident cells of the brain that are strongly related to, but distinct 
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from, cells of the monocyte/macrophage lineage [203,204] Resting microglial cells have 
a ramified appearance, but upon activation their cell processes become shorter and 
thicker, together with a swelling of the cell body [205]. Clusters of activated microglial 
cells are associated with classic senile plaques [29,206-208], supporting the theory of a 
local chronic inflammatory process in the AD brain. Activation of microglial cells is 
accompanied by increased expression of members of the /32-integrin family, that include 
leukocyte function antigen-1 (LFA-1) and complement receptors [209-211], the major 
histocompatibility complex antigen HLA-DR [205,207,210,212-214] and Fc receptors 
[211,215]. Besides, microglial cells in AD and Down syndrome brains, particularly 
activated microglia, express elevated levels of IL-1 and tumor necrosis factor-α 
[216-218]. IL-1, in turn, can induce α,-ACT [200,219] and APP expression [220-223]. 
These data strongly indicate that inflammatory processes, involving the generation of pro­
inflammatory cytokines and products of acute phase reactions as well as the activation of 
immunologically active cells, are tightly linked to the formation of senile plaques in AD 
brains. However, these processes are not mediated by a classic immune response as 
defined by the involvement of Τ cells or immunoglobulins, since these components of the 
immune system have not consistently been identified in the senile plaques of AD brains 
[189]. 
Further support for inflammation-mediated formation of senile plaques is found in 
the study of brains of individuals who died after severe head injury. It is well-known that 
repeated head trauma as experienced by boxers may lead to a demential syndrome 
(dementia pugilistica) [224]. Neuropalhological examination of boxers' brains has lead to 
the identification of numerous NFTs, that are structurally and immunologically identical 
to the NFTs of AD brains [225], and diffuse A/3-containing senile plaques [224,226]. 
Furthermore, A/3 deposits have been identified in the cortex of 30% of patients dying of a 
single incidence of severe head injury [227,228] These deposits were accompanied by 
increased neuronal APP expression [228] and increased microglial IL-1 expression, 
associated with APP-positive dystrophic neuntes [229]. A/3 deposits could be identified as 
early as several days or even 12 hours after injury [227,230], indicating that they may be 
produced in an acute response to injury Head injury is also identified as a major 
environmental risk factor for the development of Alzheimer's disease [231-234], 
synergistically acting with the effects of the ApoE4 allele [235,236] These studies 
indicate that an acute phase réponse of the brain, probably mediated by IL-1, may 
subsequently result in the rapid overexpression of APP, the deposition of A/3 and the 
development of NFTs 
The concept that inflammatory processes may contribute to the pathology of AD, 
has lead to retrospective studies as well as clinical trials in which the effects of anti-
inflammatory drugs were evaluated for their ability to decelerate the process of dementia 
The incidence of AD is unusually low in a group of patients diagnosed with rheumatoid 
arthritis [237] and in a large group of Japanese leprose patients [238] probably due to the 
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protective effect of taking anti-inflammatory drugs. The onset of AD in a co-twin study 
was inversely associated with the use of anti-inflammatory drugs [239]. Other 
retrospective studies showed that non-steroidal anti-inflammatory drugs (NSAID) have a 
protective role in AD [240,241]. A small clinicaJ trial indicated that the NSAID 
indomethacin decelerates the progress of AD [242]. 
A potential role for inflammatory proteins may be the acceleration of A/3 fibril 
formation. Such a role has been descnbed for the acute phase proteins α,-ACT [138] and 
Clq [243], but also for other senile plaque-associated proteins such as ApoE [136-138] 
and HSPG [244]. A/3 can bind to the complement factor Clq and activate the complement 
cascade [245-247] leading to expression of the early complement components Clq, C3 
and C4 [248]. However, the senile plaque-associated proteins ApoJ (clusterin, SP40.40) 
[249,250], amyloid Ρ component [202,249] and also α,-ACT have been descnbed to 
inhibit A/3 fibnl formation [251-253]. Therefore, A/3 fibnllogenesis is determined by a 
balance between A/3 fibril-promoting and fibnl-preventing factors. Administration of anti­
inflammatory drugs may block the production of acute phase proteins and direct this 
balance towards a reduction of A/3 fibnl formation This presumed fibnl-promoting role 
of senile plaque-associated components is in accordance with the observation that some of 
these factors are absent from diffuse senile plaques of the cerebellum [193,201,249], that, 
according to a number of studies, usually do not develop into classic, fibnl-containing, 
senile plaques, although certain controversy exists regarding the expression of acute phase 
proteins in these lesions [194,202] Furthermore, anti-inflammatory drugs may interfere 
with microglial activation and the production of harmful cytokines, proteases and reactive 
oxygen and nitrogen species [153,254,255] 
1.9 The pathology of congophilic angiopathy 
The accumulation of A/3 in the brain vasculature (congophilic angiopathy or 
cerebrovascular amyloidosis (CA)) is an important characteristic of AD and Down 
syndrome brains, and may have an incidence of more than 70% among AD patients 
[256,257]. In AD brains CA can be observed in different types of vessels [256]. Cortical 
capillanes, arterioles and small arteries as well as leptomeningeal vessels become 
infiltrated with amyloid materni [258], consisting primarily of A/3 fibrils [11,256] 
Particularly in the smaller-sized vessels the amyloid may fill the entire vessel wall, giving 
it a thickened appearance [256] In leptomeningeal vessels the amyloid is mostly 
concentrated in and between the smooth muscle cells of the tunica media and in the 
adventitia [256], accompanied by medial thickening and excess collagen deposition in the 
adventitia. Leptomeningeal veins are less frequently affected CA is observed in AD 
brains in the same brain regions as senile plaques. Vessels affected by CA, show apple-
green birefringence after staining with Congo red and viewing under polarized light 
[256,258,259], the classic method to demonstrate the presence of amyloid, but can also be 
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visualized by thioflavin S stains and by immunohistochemistry using anti-A/3 antibodies 
In patients with HCHWA-D, severe cerebrovascular A/3 deposition is observed in 
approximately a quarter of small cortical arteries and arterioles and in leplomeningeal 
vessels These lesions lead to small infarcts and to, often fatal, hemorrhages in these 
patients [260] 
Another type of A/3 deposition is observed in cortical vessels and is characterized 
by the infiltration of fine radiating deposits of amyloid into the nearby neuropil, called 
"drusige Entartung" [261] or "dyshonc angiopathy" [262] The incidence of this type of 
CA is increased proportionally to the seventy of CA [256] and is usually found in 
conjunction with amyloid deposition in pre-capillary arterioles [8] 
It was known for years that CA was made up of amyloid, since it could be 
demonstrated by Congo red staining, but it was not until 1984 when Glenner and Wong 
partially sequenced the protein that actually formed the amyloid fibrils the amyloid β 
protein (A/3) [11] Most of the A/3 in CA accumulates as fibrils, but also non-fibnllar A/3 
has been identified between the smooth muscle cells of the tunica media [263] It has been 
suggested that fibrils may start to develop at the abluminal basement membrane and, 
during later stages of amyloid formation, eventually fill the entire vessel wall [264] The 
exact length of A/3 in CA remains obscure [120,122], but it is likely that CA consists of 
both A/3M0 and A/3M2 [121,125], the majority of the molecules being of the latter form 
[121] This is in accordance with the observations that CA mostly consists of A/3 fibrils 
and that AßlA2 aggregates more rapidly into fibrils than other isoforms [128,130,132] 
Since both senile plaques and CA contain Aß, it has been suggested that senile 
plaques may have a vascular origin [265], but it has been demonstrated that the 
association of microvessels with senile plaques is non-specific and largely determined by 
chance contact [265,266] This observation and the differences in physical and chemical 
properties indicate that CA may have a pathogenesis that is different and independent of 
the development of senile plaques Apart from A/3, also its precursor APP has been 
immunohistochemically identified in the cerebral vascular wall [57], localized in smooth 
muscle cells [267] Therefore, and because of their close association with early Aß 
deposits in CA, an important role for smooth muscle cells in the production of A/3 has 
been suggested [263,264] Besides, cultured smooth muscle cells, isolated from 
leptomemnges, produce and secrete APP [78] and brain microvessels contain a 22 kDa, 
A/3-spanning APP fragment [263,268], indicating that APP is proteolysed within the 
cerebral vasculature 
The mechanism of A/3 fibril formation in CA is not yet clear Wisniewski 
suggested that two different mechanisms may apply to the formation of amyloid in either 
large vessels or in capillaries Aß fibrils of the larger vessels may be produced by smooth 
muscle cells alone [269], in accordance with the above described findings In his opinion, 
the situation in capillaries may be different, however It may be that two different cell 
types are involved in the production of A/3 and the processing of soluble A/3 into fibrils, 
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respectively [257]. In favour of this hypothesis is that for the formation of systemic 
amyloids two cell types seem to be responsible, ι e. the precursor-producing population 
and the fibni-making population [12,257] Perivascular microglial cells or so-called 
perivascular cells [270], another cell type originating from the monocyte-hneage, may be 
engaged in the processing of Aß, transforming it from a soluble form into fibrils [64] 
The actual producer of APP and Aß may be another cell type, however. Pericytes are a 
prominent and ubiquitous cellular component of the microvasculature, with functions 
comparable to smooth muscle cells [271,272] In analogy to the putative involvement of 
smooth muscle cells in Aß formation in large vessels, pericytes may very well be the cell 
type responsible for the production of APP and Aß in small-sized arterioles and 
capillaries, but this possibility has not been discussed by Wismewski [273] Furthermore, 
a possible involvement of pericytes in Aß fibril formation, just like smooth muscle cells, 
can not be excluded. Besides, since the close association of perivascular cells and 
perivascular microglial cells with Aß fibrils is solely based on morphological examination 
of AD brains, these cells may as well be involved in the phagocytosis of Aß fibrils, in 
stead of producing them, a role compatible with their functional relationship with 
macrophages. 
In contrast to senile plaques of the cortex, CA does not contain the whole 
spectrum of senile plaque-associated proteins as described above. In a study using seven 
different anti-a,-ACT antibodies this protein as well as a2-macroglobuhn, were not 
detected in CA [196], although another study reported α,-ACT reactivity in some vessels 
[194] Thus, it is possible that CA is not accompanied by an acute phase response In 
contrast, HSPG [184,185] and ApoE [37] are found in vessels affected by CA ApoE is 
present in leptomeningeal vessels even before Aß deposition could be observed, 
underlining its potential role in Aß deposition and fibril formation [136,137] Since early 
Aß deposits in CA have been identified close to the abluminal basement membrane 
[264,269], an important mechanism in the formation of CA may be the interaction of 
components of the basement membrane [274] as well as HSPG [244] with APP or Aß 
Since basement membrane components are not found in the neuropil, this may contribute 
to the differential pathology of CA and senile plaques 
An important feature of CA is the degeneration of the cells of the vascular wall 
Several ultrastructural and îmmunohistochemical studies have demonstrated that 
endothelial cells [256,273,275], pericytes [273] and smooth muscle cells [269,276] 
underwent degeneration in amyloid-laden vessels A recent study [154] indicated that 
degeneration of cultured smooth muscle cells followed Aß formation since it can be 
induced by AßlA2, but not by A/3,^0, and is accompanied by increased endogenous 
production of APP and Aß Endothelial cells and, to a lesser extent, pericytes are 
involved in maintaining the blood-brain barrier [277,278], thus degeneration of these cells 
in vessels affected by CA may lead to an impaired functioning of the blood-brain barrier 
in AD patients [279] 
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1.10 A model for the genesis of senile plaques: the amyloid hypothesis 
In 1991 Selkoe proposed a model for the molecular pathology of familial AD involving a 
sequence of reactions that may lead to the development of senile plaques and NFTs [30] 
Much of the progress made in AD research since 1991, as described above, may fit in 
with this model, and apply to cases of sporadic AD This paragraph will deal with a 
description of the model and the implication of recent findings for this model (Figure 3) 
A critical step in the formation of senile plaques is the initial production of A/? in 
the brain, forming diffuse senile plaques Both the discovery that several mutations in the 
APP gene are linked to familial AD and the increased APP gene dosage of Down 
syndrome patients, has established a direct link between APP and the formation of diffuse 
senile plaques Selkoe hypothesized that the availability of excess or mutant APP 
molecules presents a substrate for alternative processing into A/3 that normally only 
operates at very low levels Indeed, it has been shown that mutations in the APP gene 
lead to increased A/? production However, it is unclear how other gene products linked 
to familial AD, such as ApoE, S182/PS-1 and STM2/PS-2 relate to aberrant APP and Aß 
production Since Aß production seems to be part of a normal physiological process, it 
remains unclear what factors actually cause excessive Aß production or its impaired 
removal in AD brains Abnormal intracellular trafficking of APP, diverting it into the 
amyloidogenic pathway, may be a factor related to sporadic AD, but so far no evidence 
for this hypothesis is available Several other factors have been identified that may affect 
APP processing in vitro, but it is not clear whether these factors operate in vivo too An 
exception may be the stimulation of protein kinase С resulting in enhanced APPS and 
decreased Aß production [98,280 283] Indeed, several studies provided evidence for a 
diminished protein kinase С activity in the brain of Alzheimer patients [284 286] 
Although it is not clear why and how excess Aß is produced and what induces it, it is 
possible that neurons are its principal producers in the neuropil, since APP expression is 
found in neurons in both normal and AD brain as well as in dystrophic neuntes of AD 
brains [68,93,208,287] Besides, in situ hybridisation studies showed that APP mRNA is 
primarily detected in neurons [59,60] Aß deposition is brain-specific, despite a single 
unconfirmed report of Aß deposition in peripheral tissue [288], indicating that 
interactions between the Aß producing cell and its neural environment are essential for 
the development of senile plaques 
The second step in the model is the gradual transformation of these diffuse Aß 
deposits into filamentous classic senile plaques, during which process primitive senile 
plaques may occur as an intermediate stage In vitro studies indeed showed that Aß can 
form fibrils Evidence that the formation of diffuse senile plaques precedes neuntic and 
glial alterations came from the study of Down syndrome patients [27,28] Diffuse senile 
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Figure 3. A model for the pathogenesis of Alzheimer's disease. A central role is assigned to the 
formation of senile plaques and the acute phase response. Changes in the APP metabolism may 
lead to increased Aß production and diffuse senile plaque formation This process evokes an acute 
phase response involving the activation of microglial cells and the production of senile plaque-
associated proteins, that may contribute to the flbrillogenesis of Aß and, consequently, classic 
senile plaques formation. Aß fibrils as well as products of activated microglial cells are neurotoxic 
and may lead to neuronal cell damage and the formation of NFTs, that are clinically manifested as 
dementia. 
plaques develop as early as in the third decade of life, but no classic senile plaques, 
dystrophic neuntes or NFTs are detected at this stage. However, older patients do 
develop these neuritic changes similar to the ones observed in AD brains. Also, in 
HCHWA-D patients, most of the senile plaques remain of the diffuse type and do not 
develop into classic senile plaques. Probably, it is this transformation from diffuse to 
classic senile plaques that may take years. In contrast, studies on head trauma patients 
(see par. 1.8) and a comparative study of control and AD brains [42], suggested that 
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diffuse senile plaques may develop in a short time interval Assuming that the 
transformation of A/3 into fibrils is a time-consuming process, the age at which the initial 
diffuse plaques develop may therefore be critical in the disease process [42] 
Somewhere along the process of A/3 fibnlhzation, senile plaque-associated 
proteins, probably as a result of an acute phase reaction, become incorporated in senile 
plaques As most, if not all, diffuse senile plaques in the cortex, but not in the 
cerebellum, contain these components, this seems to be an early and region-specific 
process As already predicted by Selkoe, several senile plaque-associated proteins may 
accelerate A/3 fibril formation, like has been described for α,-ACT, ApoE, HSPG and 
Clq But also other factors may influence A/3 fibril formation, such as the concentration 
of A/3 and the ratio of А/3
Ы2 to А/Зыо that has been formed Another event associated 
with the formation of classic senile plaques, indicative of a chronic local inflammation, is 
the activation of microglial cells and astrocytes Selkoe did not address to the question at 
what time in the formation of senile plaques microglial cells become activated Clusters of 
activated microglial cells are specifically associated with classic senile plaques only and 
not with diffuse senile plaques [29,289], indicating that microglial activation is a 
secondary event in the formation of senile plaques They may be involved in the removal 
of amorphous or aggregated A/3, as was demonstrated in vitro [290] The appearance of 
reactive astrocytes around classic senile plaques is probably a non-specific event since it 
appears only after A/3 formation [28], and the formation of a "glial scar" in response to 
neural tissue injury has been observed in many neurodegenerative diseases [291] 
However, more subtle changes in microglial cells and astrocytes may precede the 
appearance of their "full blown" activated morphology, regarding the expression of the 
astrocyte product α,-ACT in diffuse senile plaques, that may be triggered by enhanced 
microglial IL-1 production Furthermore, in Down syndrome, activated microglial cells 
are observed after diffuse senile plaques have been formed, but prior to the appearance of 
classic senile plaques [28] 
The third step in the cascade of events is the effect of Aß and other agents on the 
neural cells A/3 itself, in particular when aggregated into fibrils, is toxic for neurons and 
induces their degeneration Also products of activated microglial cells, such as cytokines, 
proteases and free radicals [153,189] may cause neuronal damage Neuronal degeneration 
is visible by the the loss of synapses, formation of dystrophic neuntes and alterations of 
cyloskeletal proteins, resulting in the formation of NFTs, eventually leading to neuronal 
death and deficiencies in neurotransmitter levels, observed in AD brains According to 
this model, cytoskeletal changes are only secondary events following Aß formation and 
aggregation, which is in accordance with the formation of tangles as a general response to 
neural tissue injury However, cytoskeletal changes, including NFTs and dystrophic or 
altered neuntes are the pathological lesions that correlate best with the clinical symptoms 
of dementia Diffuse senile plaques seem to be relatively harmless and do not cause 
demential symptoms like in young Down syndrome patients and HCHWA-D patients 
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This model assigns a pivotal role for Aß in the generation of senile plaques, an acute 
phase réponse and, finally, the formation of NFTs. However, it can not be entirely ruled 
out that NFTs could develop independently 
At several points in this model positive feedback mechanisms may occur, 
complicating the above described sequence of events Cytokines, produced by activated 
microglial cells, may also induce APP expression, providing more substrate for Aß 
formation Aß may induce its own production via degeneration of cells and increased 
APP production, as shown for smooth muscle cells Activation of microglial cells and 
astrocytes may also involve APP production by these cells contributing to the process of 
senile plaque formation [292]. Also, it may be possible that neurons containing NFTs 
produce compounds that affect their environment 
1.11 Outline of this thesis 
The first part of this thesis, comprising chapters 2, 3 and 4, involved the study of 
inflammatory processes in the formation of senile plaques and cerebrovascular 
amyloidosis, using an îmmunohistochemical approach. The following hypotheses formed 
the basis for these chapters: 
1 Diffuse senile plaques mature into classic senile plaques, in accordance with 
Selkoe's amyloid hypothesis 
2 Inflammatory reactions occur in senile plaques, and may influence the maturation 
of diffuse senile plaques into the classic type Therefore, inflammatory products 
may be differentially expressed in brain regions where either both types of senile 
plaques occur or where classic senile plaques are absent 
3 CA and senile plaques may have an independent etiology, that may be related to 
the occurrence of inflammatory reactions. 
4 Microglial cells become activated as a response to Aß production, and their role 
may be the phagocytosis of Aß 
In the chapters 2 and 3, for a comparison of the involvement of inflammatory 
reactions in senile plaques and CA, the expression of the cytokine-inducible adhesion 
molecule ICAM-1 was studied Furthermore, its expression was investigated in both the 
cerebral cortex and the cerebellum, since in the latter region classic senile plaques are 
rarely observed Finally, the role of microglial cells, and activated microglial cells in 
particular, and the possibility of a phagocytic function for these cells, was investigated in 
chapter 4 
28 
The second part of the thesis, chapters 5, 6 and 7, concentrated on the 
involvement of vascular cells in brain diseases and in AD in particular, and was based on 
the following hypotheses: 
1 APP metabolism may be cell-specific, therefore cells derived from the human 
brain vasculature are essential to study the process of CA formation in vitro. 
2 In analogy to the presumed role of smooth muscle cells in the formation of CA in 
leptomeningeal vessels, pericytes may be responsible for the formation of CA in 
the microvasculature. 
In chapter 5, human brain pericytes were isolated and characterized to set up an in 
vitro system for the study of these cells in disease processes. They were studied for their 
role and function in the microvascular proliferation observed in brain tumors. Once these 
cultured pericytes were characterized, they were used as an in vitro model for the study 
of APP metabolism in vascular cells. In chapter 6 we studied the intracellular metabolism 
and routing of APP in pericytes and smooth muscle cells, since aberrant intracellular 
transport has been proposed as an important factor in the production of A/3. Finally, in 
chapter 7 the functional characteristics of adhesion molecules expressed by pericytes have 
been investigated in relation to mononuclear cell infiltration into the brain. 
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Abstract 
The still unsolved pathogenesis of Alzheimer's disease (AD) has been the subject of 
extensive speculation Some years ago, a local acute phase reaction involving production 
of interleukin-1 (IL-1) and IL-6 was proposed as the triggering event in AD Since it has 
been reported that these cytokines induce expression of intercellular adhesion molecule 1 
(ICAM-1), we analyzed AD brain tissue cryosections for the presence of ICAM-1 by 
immunostaining and for ICAM-2 expression as a control In senile plaques a marked 
diffuse or granular staining for the ICAM 1 domains 1, 4 and 5 was observed, whereas 
ICAM-2 expression was observed in microglial cells Immunoprecipitation analysis 
demonstrated the presence of a 85 kDa ICAM-1 molecule in AD frontal cortex Our 
findings indicate that ICAM-1 accumulates in senile plaques as a complete 5 domain 
molecule at a relatively early stage of senile plaque formation Our results are in support 
of a cytokine-mediated pathogenesis of senile plaque formation 
Introduction 
Typical neuropathological features of Alzheimer's disease (AD) comprise the presence of 
numerous senile plaques, neurofibrillary tangles (NFT) and cerebrovascular amyloidosis 
(CA) in various regions of the cortex, hippocampus and amygdala of the brain [1] 
Several components of senile plaques (including the classic, diffuse and burned-out 
types of plaques) have been identified in the past few years The 4 2 kDa amyloid β 
protein (A/3) is the major constituent of the diverse types of senile plaques and of CA 
[2-4] It has been assumed that the degenerative lesions in AD arise by the deposition of 
A/3, which may be formed by proteolytic processing of the amyloid precursor protein 
(APP) in the endosomal lysosomal system [5-11] Apart from Aß, a number of Aß-
associated proteins [12] has been identified by immunostaining of Alzheimer brain 
specimens Thus, the presence of α,-antichymotrypsin (α,-ACT) [2,13], complement 
factors [14], serum amyloid P-component [15] and heparan sulfate proteoglycans (HSPG) 
[16,17] in all types of senile plaques and in CA could be demonstrated Also a2-
macroglobulin (a2-M), C-reactive protein (CRP) and IL-6 have been found in different 
subsets of senile plaques in Alzheimer brains [18] 
The possible role of each of these components in the pathogenesis of AD has been 
the subject of extensive speculation In particular, the presence of the acute phase proteins 
a
r
ACT, a2-M and CRP and of IL-6 in the senile plaque has drawn attention to the 
possibility of an IL-1 or IL-6 mediated pathogenesis of AD, with several components 
within the senile plaque originating from a cerebral acute phase response [19,20] Both 
IL-1 and IL-6 are known as inducers of the acute phase reaction and there is indirect 
evidence that the synthesis of both APP and a, ACT might be induced by IL 6 [21,22] 
In cultured human endothelial cells, IL-1 upregulated the expression of both APP 
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mRNA [23] and ICAM-1 protein [24] In tissue, both IL-1 and IL-6 induced the 
expression of, amongst other molecules, ICAM-1 on the vascular endothelium [24,25] 
Unlike ICAM-1, the recently discovered adhesion molecule ICAM-2 is constitutively 
expressed on vascular endothelium, lymphocytes and monocytes and is not inducible by 
several cytokines [26,27] On the basis of these previous findings, we decided to analyze 
a senes of brain tissue samples from patients with AD, senile dementia of the Alzheimer 
type (SDAT), non-Alzheimer dementia (NAD) and from control cases for expression of 
ICAM-1 on brain cortical capillaries For this purpose, we used a set of anli-ICAM-1 
monoclonal antibodies (MAb) raised in our own laboratory, in addition to a senes of 
already established anti-ICAM-1 MAb Antibodies directed against the closely related 
ICAM-2 molecule were used as controls 
Both anti-ICAM-1 and anti-ICAM-2 antibodies showed the expected vascular stai­
ning, but with anti-ICAM-1, a marked reaction with the senile plaques in Alzheimer brain 
tissue was observed as well Besides, a variable ICAM-2 reactivity was observed with 
microglial cells An accumulation of ICAM-2-positive microglial cells in senile plaques 
was observed 
Materials and methods 
Tissue samples 
Brain tissue from patients with clinically diagnosed and neuropathologically confirmed 
Alzheimer's disease (AD, n=7), senile dementia of the Alzheimer type (SDAT, n = 13), 
non Alzheimer dementia (NAD, η = 6), and from normal controls (n = 8) were obtained 
from autopsy material with post mortem delays between 20 min and 9 h 
Neuropathological diagnosis of AD or SDAT was based on established criteria [28] 
Differentiation between AD and SDAT was based on the age of onset of dementia The 
age of 65 was chosen as critical value to differentiate between AD and SDAT Tissue 
samples from parietal, frontal and temporal cortex and hippocampus were frozen in liquid 
nitrogen immediately after removal (see Table 1) 
Antibodies 
MAb CL203 was a kind gitt of Dr S Ferrane (Valhalla, NY, USA) [29], MAb RR1/1 
and CA7 were a kind gift of Dr R Rothlein (Boehnnger Ingelheim, Ridgefield, CO, 
USA), MAb P3 58 clones 11, 14 and 19 were a kind gift of Dr J Johnson 
(München,Germany), MAb WT32 was a kind gift of Dr W Tax (Nijmegen, The 
Netherlands), MAb CBR IC2/2 was a kind gift of Dr Τ Springer (Boston, MA, USA), 
MAb бОЧ was a kind gift of Dr С Gahmberg (Helsinki, Finland), MAb H3/5-47, 
A10/33, EN7/44, RM3/1 and 27E10 and the PAb MRP8 and MRP14 were kind gifts of 
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Table 1. Brain tissue investigated 
Case no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
Sex 
(yr) 
F 
M 
F 
M 
F 
F 
M 
F 
F 
M 
M 
F 
F 
F 
M 
F 
F 
F 
F 
M 
M 
F 
F 
F 
F 
F 
F 
M 
F 
F 
F 
F 
M 
F 
Age 
(h) 
16 
73 
66 
49 
96 
85 
81 
87 
73 
87 
79 
64 
68 
85 
65 
69 
67 
72 
63 
59 
64 
93 
89 
87 
77 
77 
78 
79 
90 
88 
94 
83 
84 
81 
PMD1 
4 5 
9 0 
6 0 
3 5 
3 5 
2 5 
3 0 
5 5 
0 7 
2 5 
0 8 
3 0 
3 0 
2 0 
1 1 
1 3 
0 3 
0 7 
2 0 
3 0 
3 0 
1 3 
1 6 
0 7 
0 8 
0 6 
0 5 
1 0 
1 3 
3 0 
4 0 
5 0 
5 0 
3 5 
Diagnosis-
Control 
Control 
Control 
Control 
Control 
Control4 
Control 
PD 
NAD 
PD, NAD 
NAD 
NPH.NAD 
NAD 
NAD 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
SDAT 
region 
F 
F 
F 
F 
F 
F 
F 
F 
Τ 
F 
Ρ 
F 
F 
F 
Ρ 
F 
F 
F 
F 
F,HC 
F,T 
Ρ 
Ρ 
τ 
Ρ 
F 
F 
F 
F 
F 
F,T 
F,HC 
F,HC 
F,P 
Abbreviations 'PMD post mortem delay 2NAD non-Alzheimer dementia, AD Alzheimer's 
disease, SDAT senile dementia of Alzheimer type, PD Parkinson's disease, NPH normal 
pressure hydrocephalus 3F frontal cortex, Τ temporal cortex, Ρ parietal cortex, HC 
hippocampus 4non-demented person with numerous plaques in cortex 
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Dr. С. Sorg (Münster, Germany). MAb 4B9 was a kind gift of Dr. T. Carlos (Seattle, 
WA, USA) [30]; MAb ENA-1 was a kind gift of Dr. J. Leeuwenberg (Maastricht, The 
Netherlands) [31]; MAb NKI-L12 was a kind gift of Dr. С Figdor (Dutch Cancer 
Institute, Amsterdam, The Netherlands); Anti-Aß antibodies were purchased from 
Boehringer Mannheim, Almere, The Netherlands, and affinity-purified anti-A/3 polyclonal 
antibodies were a kind gift of Dr. W.E. Van Nostrand (Irvine, CA, USA) (Table 2). 
Hybridoma production 
Seven weeks old female BALB/c mice were injected intraperitoneal!y with 5x10* tumor 
necrosis factor-α (TNF-a)-stimulated (1 nM for 72 h) human umbilical vein endothelial 
cells (HUVEC) in 0.25 ml PBS on the left side of the body, and the same amount of cells 
in 0.25 ml CFA on the right side of the body. The HUVEC were washed twice with PBS 
before they were released from the culture flask by treatment with 0.02 % EDTA in PBS 
and harvested with a rubber policeman. After 2 months the mice received, on four 
subsequent days, a boost of 3xl06 TNF-a-stimulated HUVEC in 0.3 ml PBS 
(intravenously). On the fifth day splenocytes were obtained by removing and mincing the 
spleen of an immunized animal. Hybridomas were generated by fusing splenocytes with 
the SP2/0 fusion partner. An ELISA on unstimulated vs TNF-a-treated HUVEC was used 
to screen hybridoma culture supernatants. Hybridomas showing a differential reaction 
pattern were analyzed more closely. 
ELISA 
HUVEC were seeded in gelatin-coated 96-wells microtiter plates (Costar, Cambridge, 
MA, USA) at a density of 2xlf/ cells/well, and allowed to grow to confluence in the 
appropriate medium for 3 days. In some experiments cells were incubated with TNF-a (1 
nM, a kind gift of Boehringer Ingelheim) during culture in the microtiterplate. Cells were 
fixed with 0.025% glutaraldehyde in PBS for 10 min at room temperature, and the wells 
were incubated with 1% gelatin in PBS for 30 min at 37°C to prevent non-specific 
binding of antibody. After washing with PBS the wells were successively incubated for 30 
min at 37°C with MAb, and with peroxidase-labeled goat-anti-mouse immunoglobulin 
heavy and light chain (Nordic, Tilburg, The Netherlands), both diluted 1:500 in PBS/1% 
gelatin. Enzyme substrate was then added (8 mg/ml 5-aminosaIicylic acid (Sigma, St. 
Louis, MO, USA) in 50 mM phosphate buffer with 0.025% H202). Colour development 
was measured after 30 min by reading the OD at 450 nm in a Titertek ELISA plate 
reader (Flow Laboratories, Irvine, Scotland). 
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Table 2. 
Antibody 
PN-E4 
PN-E8 
PN-E12 
RRl/1 
CL203 
CA7 
P3.58C111 
P3.58C114 
P3.58C119 
CBR-IC2/2 
6D5 
NKI-L12 
6F2 
4B9 
ENA-1 
PN-E2 
PAL-E 
H3/5-47 
A10/33 
EN7/44 
RM3/1 
27E10 
OKT9 
W6/32 
WT32 
MRP8 
MRP14 
vWF-FVIII 
Antibodies used in this study and their specificities. 
MAb/PAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
PAb 
PAb 
PAb 
Specificity 
Domain 1 of ICAM-1 
Domain 1 of ICAM-1 
Domain 1 or 2 of ICAM-1 
Domain 1 of ICAM-1 
Domain 4 of ICAM-1 
Domain 5 of ICAM-1 
Domain 5 of ICAM-1 
Domain 5 of ICAM-1 
Domain 5 of ICAM-1 
ICAM-2 
Domain 1 of ICAM-2 
α-chain of LFA-1 (CD 11 a) 
GFAP 
VCAM-1 
E-Selectin 
Endoglin 
Uncharactenzed endothelial antigen 
Uncharactenzed endothelial antigen 
Uncharactenzed endothelial antigen 
Uncharactenzed endothelial antigen 
Uncharacterized monocyte/macrophage antigen 
Uncharacterized monocyte antigen 
Transferrin receptor (CD38) 
MHC Class I 
CD3 
Uncharacterized macrophage antigen 
Uncharacterized macrophage antigen 
von Willebrand Factor 
Transfection of COS cells and flow cytometry analysis 
ICAM-1 deletion mutants were generated by ligation of polymerase chain reaction 
fragments coding for different parts of the ICAM-1 molecule. Guided by the assignment 
of domain boundaries by Staunton et al [32,33], polymerase chain reaction primers were 
made to generate different ICAM-1 fragments, which were ligated by a newly introduced 
EcoRV restriction site. These fragments were constructed by 10 cycles of polymerase 
chain reaction amplification by using human ICAM-1 cDNA [34] as template. The human 
ICAM-1 cDNA in the CDM8 expression vector [35] was kindly provided by Dr. B. Seed 
(Harvard Medical School, Boston, MA, USA). In this way cDNA was generated coding 
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for ICAM-1 deletion mutants lacking the NH
r
terminal domains, domain 1 or 2. The 
hgated fragments were digested with appropriate restriction enzymes, gel purified and 
ligated into the CDM8 expression vector Appropriate clones were identified by restricti­
on mapping COS-7 cells were transfected with different ICAM-1 cDNAs in the expressi­
on vector CDM8. Anti-ICAM-1 MAb were analyzed using flow cytometry as described 
by Bloemen et al [36] (in case of COS cells transfected with complete ICAM-1 cDNA) or 
by intracellular staining (in case of COS cells transfected with ICAM-1 deletion mutants) 
Immunohistochetnical staining 
Sections from frozen tissue (4 μη\) on aminopropyltnetoxysilane-coated glass slides were 
fixed with acetone for 10 minutes at room temperature The sections were incubated with 
appropriate dilutions of the primary antibodies for 1 h at room temperature or overnight 
at 4°C in the dark. All dilutions were made in PBS containing 1% BSA, which also 
served as a negative control The preparations were washed twice for 8 minutes with PBS 
and incubated with peroxidase-conjugated rabbit anti-mouse IgG (dilution 1:80, Dako, 
Glostrup, Denmark) for 30 minutes at room temperature in the dark The peroxidase reac­
tion was performed by incubating the sections 5 - 8 minutes with 0 6 mg/ml diamino-
benzidin (DAB, Sigma, St. Louis, MO, USA) in PBS with 0.015% H202 Nickel 
ammonium sulfate was added to this solution where indicated, resulting in a purple 
reaction product. Where indicated, the slides were incubated for 5 minutes in 0 5% 
CuSO,, in saline and again washed with tap water, counterstained with hematoxyhne for 1 
- 3 minutes, and thoroughly washed with tap water for 10 minutes. After dehydration in 
96% alcohol and xylol the preparations were enclosed in Permount. Adjacent sections 
were used when the staining patterns obtained with the MAb had to be compared with the 
anti-A/3 staining or with each other. 
Double immunostaining was performed as described previously [37] with some 
modifications After the DAB/Ni reaction of the first cycle the sections were treated for 
30 minutes with 0.5% H202 in PBS to destroy residual peroxidase activity. Subsequently 
the sections were incubated with a mixture of unlabeled rabbit-anti-mouse antibodies 
(Dako) and FITC-labeled sheep-anti-mouse antibodies (Cappel, Boxtel, The Netherlands) 
to block residual free binding sites on the mouse antibodies from the first cycle. The 
blocking was checked by immunofluorescence microscopy and by omitting secondary 
antibodies from the first cycle. By doing so it could be verified that the blocking was 
successfull. The second staining cycle was performed as described above without the 
addition of nickel ammonium sulfate in the DAB mixture, resulting in a brown reaction 
product Reversing the order of incubation of the primary antibodies did not affect the 
results 
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Ann-Aß immunostaining 
Sections from frozen tissue (4 μιη) on aminopropyltnetoxysilane-coated glass slides were 
fixed in acetone for 4 minutes, followed by another 6 minutes of fixation in acetone 
supplied with 0.15% H202 to block endogenous peroxidase. Sections were then treated 
with 50% formic acid for 15-30 minutes, washed in PBS and incubated with 20% normal 
swine serum for 10 minutes. Primary rabbit anti-Aj3 antibody solution at 20 μg/ml 
(Boehnnger Mannheim) or 1:300 (gift from W.E. Van Nostrand) was incubated overnight 
at 4CC in the dark. The preparations were washed twice for 8 minutes with PBS and 
incubated with swine anti-rabbit antibodies (dilution 1:20, Dako) for 30 minutes, washed 
again in PBS and incubated with peroxidase anti-peroxidase complex (dilution 1:800, 
Dako) for 30 minutes The peroxidase reaction was performed as described above. 
Thwflavin S staining 
Sections stained for ICAM-1 were subsequently stained with thioflavin S as described 
[38]. In short, sections were nnsed in 50% ethanol and stained for 5 minutes with 0 01% 
thioflavin S (Sigma) in 50% ethanol Subsequently, the sections were washed twice in 
50% ethanol and twice in water. 
Immunoprecipuation and SDS-PAGE 
To determine the molecular weight of the MAb, HUVEC were metabolically labeled for 4 
h with 150 μΟ 35S-methionine (Amersham, Houten, The Netherlands) in 5 ml 
methionine-free EMEM, supplemented with 15% dialysed FCS, gentamycin and glutami-
ne, after an initial incubation for 4 h in the same medium without 35S-methionine After 
three washes with PBS, cells were removed from the tissue culture flask non-enzymatical-
ly (see above), and treated with lysis buffer (0.1% SDS, 1% NP-40, 0 5% Na-
deoxycholate, ImM PMSF, ImM Benzamidine, 500 IE/ml aprotinin in PBS) After 
centnfugation to remove nuclear debris, radiolabeled HUVEC lysates were lmmunopreci-
pitated essentially as described by Tamura et al [39]. Briefly, Costar 96-wells EIA plates 
were coated with 100 μΐ of a 100 μg/mI solution of affinity-purified goat-anti-mouse anti­
body (Cappel, Boxtel, The Netherlands) for 18 h at 4°C After washing with PBS/0.05% 
Tween-20, specific MAb was added to the wells and incubated for 4 h at 4°C, followed 
by another washing step. Wells were then incubated with 200 μΐ/well PBS/1% BSA/1% 
normal mouse serum for 2 h at room temperature, and, after washing, radio-labeled cell 
lysate was added at 2xl06 cpm/well After incubation of the plate for 18 h at 4CC, wells 
were washed extensively with lysis buffer Bound antigen was extracted from the wells by 
incubation with sample buffer for 15 min at 60°C, and analyzed by SDS-PAGE Gels 
were dried and exposed for autoradiography 
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For ICAM-1 immunoprecipitation from brain tissue, small pieces of frontal cortex 
(SDAT n=3, control n = 3) were thawn, homogenized in lysis buffer without SDS, NP-
40 and Na-deoxycholate, and left for 30 minutes at 0°C After centnfugation at 12,000g 
for 10 minutes, the pellet was treated with complete lysis buffer for 30 minutes at 0°C 
After centnfugation the supernatants were radioiodinated as follows To four Iodobeads 
(Pierce, Rockford, IL, USA) in 200 μ\ PBS 1 0 mCi Na125I was added and allowed to 
react for 5 minutes 200 μ\ of lysate was added and incubated for 15 minutes. Unbound 
125I was separated from the labeled proteins on a G25 Sephadex column Radiolabeled 
proteins were eluted with lysis buffer, incubated on a pretreated ELISA-plate and 
subsequently analyzed as described above TNF-a-stimulated HUVEC, expressing high 
levels of ICAM 1, were used as controls and were harvested as described above The 
endothelial cell lysate was labeled with 0 5 mCi 125I and processed as described 
Results 
Generation and characterization of ¡CAM-1-specific MAbs 
MAbs were raised against TNF-a treated HUVEC Three MAb were selected that showed 
a stronger reaction with TNF-a-stimulated than with unstimulated HUVEC in the ELISA 
These MAbs, designated as PN-E4, PN-E8 and PN-E12, immunoprecipitated a 96 kDa 
antigen from TNF-a-stimulated HUVEC A molecule with identical M, was recognized 
by the anti-ICAM-1 MAb CL203 (Figure 1) 
To confirm the nature of the antigen recognized by the MAb, binding studies were 
performed with COS cells transiently transfected with cDNA encoding for ICAM-1 The 
four MAbs reacted positively with these transfected COS cells (Table 3) Transfection of 
COS cells with ICAM-1 cDNA deletion mutants lacking a specific domain, revealed that 
the MAbs PN-E4 and PN-E8 are reactive with domain 1 of the ICAM-1 molecule, and 
MAb PN E12 is directed against an epitope between domains 1 and 2 or is reactive with 
parts of both domains (data not shown) Immunohistological analysis on a number of 
tissues with inflammatory lesions showed identical staining patterns with all four MAbs 
(not shown). From these results we concluded that the MAbs PN-E4, PN-E8 and PN-E12 
are directed against ICAM-1 
¡CAM 1 immunohistochemistry 
Serial frozen sections of brain tissue of 13 SDAT patients, 7 AD patients, 6 NAD patients 
and 8 controls (Table 1) were immunostained with 9 different anti-ICAM-1 MAbs 
(CL203, CA7, PN-E4, PN-E8, PN E12, the P3 58 clones 11, 14 and 19, and RR 1/1), 
with two different anti-ICAM-2 MAbs (CBR-IC2/2 and 6D5) and several MAbs directed 
against other adhesion molecules or control antigens (Table 2) In 12 out of 13 SDAT and 
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in all 7 AD tissue specimens, with all anti-ICAM-1 MAbs foci with a diffuse or diffuse 
granular staining were observed in cortical gray matter from the frontal, parietal and 
temporal region, and in the hippocampus. These foci colocalized exactly with Aß-positive 
senile plaques (Figure 2A-D). Incidentally, fibrillar ICAM-1 staining projecting from the 
diffusely stained plaques was observed (Figure 2). In the one case of SD AT that was 
negative for ICAM-1 staining, no senile plaques were present in the available frozen 
tissue specimen. In NAD and control tissue, no staining with anti-ICAM-1 M Ab was 
observed, except for a few cases where a sporadic positive spot was present. This finding 
is explained by the appearance of incidental senile plaques in brains of elderly controls 
without dementia [28]. No plaque-associated staining was observed when brain tissue 
sections were tested with a large number of unrelated monoclonal or polyclonal antibodies 
(Table 2), including antibodies against ICAM-2, which is a molecule functionally closely 
related to ICAM-1, and with 35% homology with the two amino-terminal domains of 
ICAM-1. 
Anti-ICAM-1 M Ab stained the classic, diffuse and burned-out type of senile 
plaques as is shown by comparison with anti-Aj3 stain in serial sections (Figure 2E and 
F). From the micrographs in Figure 2 it is also evident that the amyloid deposits in a 
senile plaque are surrounded by a large tissue area affected by ICAM-1 accumulation. In 
addition, the Figures 2G and H show an example of a plaque-like spot which was 
positively labeled by anti-ICAM-1 MAb, but not by the commercially available anti-A/3 
antibody. It may be possible that this antibody was not sensitive enough to detect low 
levels of A/3 in early plaques. Therefore, we checked the results by thioflavin S staining, 
Figure 1. Analysis of indirect 
immunoprecipitates by SDS-PAGE under 
reducing conditions. Autoradiography of a 
dried 10% gel containing "S-labeled 
endothelial cell lysates precipitated by: 
Lane 1: anti-CD3 MAb WT32 (negative 
control); lane 2; MAb PN-E2, directed 
against endoglin on endothelial cells [60]; 
Lanes 3 and 8: Molecular weight markers; 
Lane 4: MAb PN-E4; Lane 5: MAb PN-E8; 
Lane 6: MAb PN-E12; Lane 7: MAb 
CL203; Lane 9; MAb W6/32. Molecular 
sizes of the standards are indicated at the 
right in kilodaltons. 
-200 
-97 
-69 
-46 
-30 
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Table 3. Binding of anti-ICAM-1 MAb to COS cells transfected with ICAM-l cDNA 
Antibody % Positive Mean Fluorescence 
Intensity 
Control 10 9 54 
PN-E4 39 6 513 
PN E8 42 8 465 
PN-E12 40 5 681 
CL203 43 5 663 
which is a sensitive method of detecting amyloid, and by staining with a highly sensitive 
affinity-punfied non-commercial anti-A/3 antibody (see Materials and methods) Using 
these techniques, all 1С AM-1-positive structures appeared to colocalize with A/3-
accumulation, indicating that all plaques, including those containing low levels of Aj3, are 
positive for ICAM-l staining as well (data not shown) 
We were able to demonstrate the presence of ICAM-l in senile plaques by MAb 
directed specifically against domain 1 (PN-E4, PN-E8 and RR1/1), domain 4 (CL203) 
and domain 5 (CA7 and P3 58) of the ICAM-l molecule, implying that the complete 
ICAM-l molecule containing all 5 domains is present 
In all cases examined, the anti-ICAM-1 antibodies stained the endothelium and, 
incidentally, perivascular cells in capillanes and larger blood vessels, with varying 
intensities, when stained in a series of sections under identical conditions No staining 
was observed when the anti-ICAM-1 MAbs were applied to routinely formalin-fixed and 
paraffin-embedded tissue Also, no neurofibrillary tangles or CA were visualized by 
antibodies against ICAM-l 
As controls, we also studied several other tissue specimens (kidney, intestine, 
cerebrum) affected by non A/3 amyloidosis These amyloid deposits were never 
accompanied by ICAM-l accumulation, indicating that this phenomenon is specific for the 
A/3-formation in senile plaques (results not shown) Besides, other neuropathologically 
affected brain tissues lacking A/3-deposits (e g neuropathologically diagnosed patients 
with Parkinson's disease and normal pressure hydrocephalus) also failed to reveal plaque­
like staining with anti-ICAM-1 MAb as observed in Alzheimer brain tissue (results not 
shown) 
Immunopreapitation analysis 
To confirm the presence of ICAM-l molecules in Alzheimer frontal cortex tissue, extracts 
of tissue samples were prepared, radioiodinated and immunoprecipitated with anti ICAM-
1 MAb Figure 3 shows that MAb PN E12 detected a specific 85 kDa band which is 
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Figure 2. Comparison of indirect ICAM-Ì and Aß immunostaining in serial cryosections of AD 
brain tissue. Α-D: Anti-ICAM-1 MAb stain senile plaques in AD brain tissue. Serial sections of 
hippocampus of AD brain stained with MAb CL203 (A), MAb PN-E12 (B), MAb PN-E8 (C) or 
anti-Aß (Boehringer Mannheim) (D). Arrows indicate a plaque from which fibrillar ICAM-1 
staining is extending from the plaque into the surrounding tissue. Ε-F: Classic plaques (open 
arrows), a diffuse plaque (closed arrow) and burned-out plaques (arrowheads) are all labeled with 
anti-ICAM-1 MAb. Note that anti-ICAM-1 MAbs stained a larger tissue area compared with anti-
Aß antibodies. Sections of frontal cortex of AD brain stained with MAb CL203 (E) or with anti-Aß 
(Boehringer Mannheim) (F). G-Η: An ¡CAM-1-positive spot is not labeled with anti-Aß antibodies 
(Boehringer). Serial sections of hippocampus of AD brain stained with MAb CL203 (G) or with 
anti-Aß (H). All sections were stained with DAB as chromogen and counterstained with 
hematoxylin. Magnifications: Α-F: xl50, G-Η: ХІ40. 
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Figure 3. Analysis of radioiodinated lysates 
of SDAT frontal cortex (lanes 1-6) or 
endothelial cells (lanes 7-9) by SDS-PAGE 
under non-reducing conditions. 
Autoradiography of a 10% gel after 4 
weeks of exposure. A 85 kDa form of the 
ICAM-1 molecule is immunoprecipitated by 
MAb PN-E12 from SDAT frontal cortex. 
Lane 1: MAb W6/32; lanes 2 and 7: MAb 
CL203; lanes 3 and 8: MAb PN-E12; lanes 
4 and 9: MAb PN-E8; lane 5: MAb PN-E4; 
lane 6: MAb CA 7. Molecular sizes of the 
standards are indicated at the right in 
kilodaltons. 
within the range of Mr described for ICAM-1. The other anti-ICAM-1 MAb did not 
detect a specific band in this assay. This was probably due to the lower affinity of these 
MAb for ICAM-1 as can be seen from the immunoprecipitation of ICAM-1 from 
HUVEC. From control brain tissue lysates, no detectable ICAM-1 could be precipitated 
(not shown), probably indicating that the amount of vascular ICAM-1 extractable from 
control brain tissue was below the detection threshold. 
ICAM-2 immunohistochemistry 
The M Abs CBR-IC2/2 and 6D5 showed staining of small, mononuclear, and 
predominantly dendritic cells dispersed in the neural tissue and in a perivascular position 
in control and Alzheimer gray and white matter (Figure 4A). Morphologically similar 
cells were stained by the anti-LFA-la MAb NKI-L12 (compare Figure 4A and B), while 
distinct cell types were stained by anti-GFAP and anti-ICAM-2 MAb (Figure 4A and C). 
On basis of these findings the ICAM-2-positive cells were considered as microglial cells. 
However, we could not completely exclude that a small subset of astrocytes also 
contributed to the observed ICAM-2 expression (Figure 4C). 
A remarkable accumulation of microglial cells was observed in senile plaques as is 
shown in Figure 5A. Serial sections stained for ICAM-2 and ICAM-1 respectively, 
clearly showed the differences between the cell-associated ICAM-2 staining and the 
diffuse ICAM-1 staining in senile plaques (Figures 5A and B). Similar as observed with 
the anti-ICAM-1 MAb, the anti-ICAM-2 MAb stained the endothelium of capillaries 
(Figure 5A) and larger blood vessels (not shown). 
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Figure 4. Staining of AD brain tissue with microglial and astrocyte markers. Cryosections were 
stained with MAb NKI-L12 (anti-LFA-la), MAb CBR-IC2/2 (anti-¡CAM-2) and MAb 6F2 (anti-
GFAP). Microglial cells were stained for ICAM-2 (A) and LFA-la (В), С Double-staining of AD 
brain tissue with anti-ICAM-2 (purple) and anti-GFAP (brown). Note that most of the ICAM-2-
positive cells (small arrows) were not stained by the astrocyte marker GFAP (large arrows). A 
small number of cells showed staining for both markers (arrowheads). All sections were stained 
with DAB as chromogen with or without the addition of nickel ammonium sulphate (purple and 
brown reaction product, respectively). Magnifications: x375 (See also colour display on page 166, 
top). 
Discussion 
In this study we investigated the localization of 1С AM-1 and ICAM-2 in brain tissue from 
Alzheimer and control patients by immunohistochemical staining of cryosections. By 
immunoprecipitation, the identity of the ICAM-1 molecule from SDAT brain tissue was 
confirmed. 
ICAM-1 was detected in all subsets of senile plaques, including classic, diffuse 
and burned-out plaques, and thus colocalized with fibrillar as well as non-fibrillar Aß. 
Anti-IC AM-1 MAb even stained a small population of plaques containing low levels of 
Aß. Moreover, ICAM-1 was found in tissue surrounding Aß deposition in senile plaques, 
suggesting that larger areas of brain tissue are involved in senile plaque formation than 
would be expected on the basis of Aß distribution. These findings indicate that ICAM-1 
aggregation may be an early event in senile plaque formation. 
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Figure S. Comparison of indirect ICAM-1 and ICAM-2 immunostaining in cryosections of AD 
brain tissue. Serial sections of AD brain tissue, stained with anti-ICAM-2 MAb CBR-IC2/2 (A) 
and anti-ICAM-1 MAb PN-E8 (B). Note the accumulation of microglial cells stained for ICAM-2 
in senile plaques (arrows). Also, capillary endothelial cells were stained for ICAM-2 
(arrowheads). MAb PN-E8 strongly stained senile plaques. All sections were stained with DAB as 
chromogen, and were counterstained with hematoxylin. Magnifications: x250. 
As expected, ICAM-2 was expressed by the cerebrovascular endothelium, but, in 
contrast to ICAM-1, was not observed diffusely in senile plaques. Furthermore, ICAM-2 
reactivity was found in microglial cells in gray and white matter in control brain tissue as 
well as in Alzheimer brain tissue. In the latter, an accumulation of microglial cells was 
observed in and around senile plaques. 
ICAM-1 and ICAM-2 are both cell-surface glycoproteins belonging to the im­
munoglobulin superfamily of adhesion molecules and they are expressed on various cell 
types. ICAM-1, consisting of five immunoglobulin-like domains, is expressed on en­
dothelial cells, leukocytes, tissue macrophages and dendritic cells [25]. ICAM-2, a two-
domain molecule, is expressed on endothelial cells, lymphocytes and monocytes [27]. 
Both molecules play an important role in the tethering of neutrophils, lymphocytes and 
monocytes to the vessel wall endothelium, which is a key event allowing both normal 
recirculation of lymphocytes and extravasation of these cells into inflamed tissue. Local 
immune responses in tissue resulted in an increase of ICAM-1 on a wide variety of cells 
[25,40]. In cell cultures ICAM-1 could be upregulated on a variety of cells by inflam­
matory factors like LPS, interferon-γ, TNF-a and IL-6 [25,41-44]. 
Only a few studies report about the distribution of ICAM-1 in the brain. ICAM-1 
is expressed at a low level on cerebral endothelial cells [45,46], but could not be 
demonstrated on pericytes or smooth muscle cells [45]. In inflammatory and necrotic 
lesions in the central nervous system, ICAM-1 may be upregulated on brain mononuclear, 
endothelial and microglial cells [45]. In brains from multiple sclerosis patients, multiple 
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sclerosis plaques showed an increased number of ICAM-1-positive microvessels [45]. In a 
few reports the presence of ICAM-1 in senile plaques was mentioned [37,47,48] Our 
results do not support the observation of Akiyama et al [37] that the majority of diffuse 
senile plaques are negative for ICAM-1. In our study all types of senile plaques (diffuse, 
classic and burned-out) were ICAM-1-positive. A small number of plaques showed 
fibrillar staining for ICAM-1, which extended from the stained plaque. These fibrils may 
be the processes of a subpopulation of reactive astrocytes as described previously [37]. 
Compared to ICAM-1, much less is known about ICAM-2 and hardly any study 
has been published about the distribution of ICAM-2 in the central nervous system It has 
been described that, apart from vascular staining, reactivity with ICAM-2 MAb is not 
observed in brain tissue [27,48] In the present study, however, in both control and AD 
brain tissue ICAM-2 reactivity was also found in microglial cells localized in a perivascu­
lar position as well as dispersed in the neural tissue [49]. In senile plaques an accumu­
lation of ICAM-2-positive microglial cells was seen, probably due to an activation of 
microglial cells by a yet unknown mechanism or a recruitment of these cells to the site of 
senile plaque formation. The presence of microglial cells in senile plaques was demonstra­
ted previously by staining with MAb against the a and β chains of LFA 1, Mac-1 and 
pl50,95 [37,47] and their possible involvement in senile plaque formation has been 
discussed [48,50] A minor contribution of astrocytes to the observed ICAM-2 reactivity 
could not be completely excluded, however. 
Initially, ICAM-1 was described as a membrane-bound cell adhesion molecule, but 
it has also been detected in a soluble form [51,52] The ICAM-1 in senile plaques neither 
seems to be cell-associated nor it is likely to be in a soluble form We lmmunoprecipita-
ted a 85 kDa form of the ICAM-1 molecule from brain tissue of Alzheimer patients, but 
not from control brains The molecular weight of ICAM-1 varies between 55 kDa and 
114 kDa, depending on the degree of glycosylation [53]. The precipitated ICAM-1 
molecule probably contains all five domains and is, in view of its M,, rather highly 
glycosylated. The presence of the entire 5-domain molecule does not exclude that the 
ICAM-1 in senile plaques has the primary structure of soluble ICAM-1, but we assume 
that the molecule has been aggregated into an insoluble form The exact nature of the 
ICAM-1 aggregates and their interaction with other plaque components remain unknown, 
however. It is possible that the ICAM-1 in senile plaques interacts with its counter-
structures LFA-1, Mac-1 and pl50,95 expressed by microglial cells, but a more cell-
associated distribution pattern of ICAM-1 would be expected then. 
The question arises whether the ICAM-1 deposited in senile plaques is of vascular 
or of neural origin. In all cases examined, anti-ICAM-1 MAb stained the endothelium 
(and incidentally perivascular cells) in the microvasculature of the brain tissue. ICAM-1 is 
expressed at the luminal side of endothelial cells When the blood-brain barrier is intact, 
it seems less likely that the ICAM-1 in senile plaques is derived from an endothelial 
origin. ICAM-1 might be of neural origin as well and this idea is supported by the finding 
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that cultured neural cells [41] and astrocytes [54] can be induced to express ICAM-1 by 
mediators like TNF-a, IL-1 and IFN-7 So far we do not have direct evidence for an 
increased neural ICAM-1 production and subsequent deposition in senile plaques in 
Alzheimer's disease 
Some years ago, a cerebral acute phase reaction was proposed as a pathogenic 
mechanism of Alzheimer's disease [13,19] Upon stimulation by bacteria, viruses or 
immune complexes, cytokines like IL-1, IL-6 and TNF-a are produced to induce this 
complex reaction These cytokines also induce expression of ICAM-1 We found ICAM-1 
in all types of plaques, either containing fibrillar or nonfibnllar A/3, as detected by 
sensitive A/3 immunohistochemistry and thioflavin S stain [38,55] However, the ICAM-1 
depositions covered a larger area than A/3 does, and anti-ICAM-1 MAb also stained 
plaque-like structures containing low levels of A/3 This seemed to indicate that ICAM-1 
deposition is a relatively early event in senile plaque formation The presence of acute 
phase-related proteins (like a2-M, C-reactive protein, IL 6 [18] and α,-ACT [2,13]) 
together with the presumed early appearance of ICAM-1 in senile plaques as described 
here, favours the suggestion that a cerebral acute phase response caused by an increased 
IL-1 or IL-6 production in the brain is the underlying mechanism for the early 
accumulation of ICAM-1 and aggregation of A/3 and other plaque components, although a 
neuroinflammatory effect of Aß itself can not be excluded [56] Support for this hypothe-
sis comes from the observations that astrocytes [57] and microglial cells [58] are potential 
sources of IL-1 or IL-6 In addition, it was reported very recently that treatment of 
Alzheimer patients with anti-inflammatory drugs might slow the advance of dementia 
[20] This study gave clinical support to the idea that Alzheimer is a chronic 
inflammatory disease 
From our results it appeared that ICAM-1, together with α,-ACT [2,13,59] and 
complement proteins [14,59], may be regarded as proteins specifically associated with Aß 
deposits These proteins are, in contrast to HSPG and P-component, not associated with 
various other types of amyloid formation ICAM-1 staining therefore seems to be an early 
and specific indicator of senile plaque formation 
In our hands, the ICAM-1 staining proved to be a useful instrument for detecting 
senile plaques that was comparable to staining with Aß antibodies on frozen sections 
However, more study is needed to establish the use of anti-ICAM-1 M Abs as diagnostic 
markers in Alzheimer's disease 
Taken together, a series of events starting with the acute phase reaction may lead 
to the accumulation of various plaque components and may also lead to an abnormal 
processing of APP, resulting in the deposition of A/3 in senile plaques and in the 
cerebrovasculature Synthesis of IL-1 or IL-6 and the subsequent induction of acute phase 
proteins and ICAM-1 requires previous stimulation of the IL-1 or IL-6 producing cells 
Until now, it is not known what factor may initiate these reactions in brains of patients 
who ultimately develop Alzheimer's disease 
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Abstract 
Inflammatory processes have been implicated in the formation of senile plaques in the 
cerebral cortex of patients with dementia of the Alzheimer type (DAT) patients, since 
several inflammation-induced proteins are present within these plaques The relation 
between inflammatory components and other amyloid β (Aß)-containing lesions of the 
DAT brain (cerebrovascular amyloidosis (CA) and cerebellar senile plaques) is unclear 
We studied the distribution of the inflammation-inducible protein intercellular adhesion 
molecule-1 (ICAM-1) in CA and in senile plaques of the cerebellum, using an 
immunohistochemical approach We observed striking differences in ICAM-1 reactivity 
between the different types of A/8-containing lesions ICAM-1 was only expressed in 
classic senile plaques in the granular and Purkinje cell layer of the cerebellum, but not in 
diffuse senile plaques of the molecular layer Also, ICAM-1 was not associated with CA, 
only when the vascular amyloid extended into the neuropil (dyshonc angiopathy, DA) 
perivascular ICAM 1 reactivity was observed This is in contrast to the putative primary 
involvement of inflammation in the formation of cerebrocortical classic and diffuse senile 
plaques Our findings indicate that ICAM-1 expression, which may be an indicator of an 
inflammatory reaction, is induced in the neuropil depending on the specific site of Aß 
production 
Introduction 
The amyloid β protein (Aß) is the major component of senile plaques and cerebrovascular 
amyloidosis (CA) [1], two of the histopathological hallmarks of dementia of the 
Alzheimer type (DAT) [2] Proteolytic processing of the membrane-spanning amyloid 
precursor protein (APP) may result either in the formation of soluble APP or in the 
production of the 4 kDa protein Aß [3 6] Aß is produced in a soluble form, but can also 
aggregate to form fibrils Both forms are present in DAT brains 
The majority of extracellular Aß found in CA is aggregated into Congo-red-
positive fibrils, although some non-fibnllar Aß has been demonstrated intracellularly in 
smooth muscle cells [7] In contrast, most of the Aß formed in the cerebral cortex is 
deposited as diffuse senile plaques in a non-fibnllar form, although this view has been 
recently debated [8] The diffuse senile plaque is supposed to mature into the classic 
senile plaque, consisting of a core of fibrillar Aß and a corona of dystrophic neuntes [9] 
Senile plaques are also formed in the cerebellum In the molecular layer they are 
exclusively of the diffuse type, but in the Purkinje cell and granular layer classic senile 
plaques have been identified [10-13] Beside differences in the aggregation state of Aß, 
the exact length of Aß accumulating in CA or senile plaques has been described to vary 
between these lesions [14-17] 
Regarding these differences, it is not clear if the pathogenesis of Aß formation in 
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CA and in the several types of senile plaques is identical. The presence or absence of 
inflammatory proteins may help to explain the differences observed in physical and 
chemical composition of CA and senile plaques. The importance of inflammatory 
processes in DAT pathogenesis is illustrated by the presence of several inflammation-
induced proteins in cerebrocortical senile plaques, such as apantichymotrypsin (α,-ACT) 
[18-20], C-reactive protein (CRP) [21], complement factors [22] and intercellular 
adhesion molecule-1 (ICAM-1) [23], as well as by the intimate association of clusters of 
activated microglial cells with classic senile plaques [24-27]. Inflammation might play an 
important role in the putative maturation of diffuse senile plaques into classic senile 
plaques, during which transformation of non-fibrillar Aß into fibrils occurs. α,-ACT has 
indeed been demonstrated to accelerate the process of Aß fibril formation in vitro [28]. 
Moreover, a growing amount of clinical data is available indicating that therapy with anti-
inflammatory drugs may be beneficial for DAT patients [29,30]. 
Most of the immunohistochemical studies on the distribution of inflammation-
associated proteins in DAT brains have focussed on the cerebral cortex. It is unclear to 
what extent inflammatory processes are linked to other types of A/3 deposition. Therefore, 
we investigated the association of the inflammation-inducible protein ICAM-1 with A/3-
deposition in the cerebellum of patients with DAT and CA using an immunohistochemical 
analysis of DAT and control brain tissues. 
Materials and methods 
Tissue samples 
Brain tissue from patients with clinically diagnosed and neuropathologically confirmed 
DAT and from normal controls were obtained from autopsy material. A definite diagnosis 
of DAT was based on a combination of neuropathological [31] and clinical criteria. Tis-
sue samples from frontal, parietal and temporal cortex were obtained from 9 control 
patients (6 female and 3 male; age 73.7 + 14.1 y; post-mortem delay (PMD) 3.1 ± 1.2 
h) and 32 DAT patients (20 female and 12 male; age 77.5 ± 11.3 y; PMD 2.3 ± 1.6 h). 
Samples from cerebellum were obtained from 8 control patients (5 female and 3 male; 
age 74.5 ± 15.0 y; PMD 2.9 ± 0.5 h) and 16 DAT patients (11 female and 5 male; 75.4 
+ 11.7 y; PMD 3.3 ± 0.9 h). Tissue samples were frozen in liquid nitrogen immediately 
after removal. 
Antibodies 
MAb CL203 (anti-ICAM-1 domain 4) was a kind gift of Dr. S. Ferrane (Valhalla, NY, 
USA); MAb CA7 (anti-ICAM-1 domain 5) was a kind gift of Dr. R. Rothlein 
(Boehnnger Ingelheim, Ridgefield, CO); MAb 6C6 (anti-A/3) was a kind gift of Dr. D.L. 
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Schenk (Athena Neurosciences, San Francisco, CA) The M Abs PN-E4 (anti-ICAM-1 
domain 1), PN-E8 (anti-ICAM 1 domain 1) and PN-E12 (anti ICAM-1 domain 1 or 2) 
have been desenbed before [23] 
Immunohistochemical staining 
Cryosections (4 μπι) were fixed in acetone for 5 minutes and subsequently in acetone 
containing 0 15% H 20 2 for another 5 minutes to block endogenous peroxidase activity 
Sections were incubated overnight at 4°C with primary antibodies and successively with 
the ABC detection kit (Vector, Burlingame, CA) according to the manufacturer's 
descnption Each incubation was followed by washing with phosphate buffered saline 
(PBS) Diaminobenzidin (DAB) was used as chromogen and the sections were 
counterstained with hematoxylin Staining with the five different anti-ICAM-1 antibodies 
was similar with variations only in the intensity of staining Congo red staining was 
performed by successive dehydration of acetone-fixed tissue sections (4 μπι) with 
increasing concentrations of ethanol After a 20 minutes preincubation period in a solution 
of 3% NaCl in 80% ethanol, sections were incubated for 20 minutes in the same solution 
containing 0 5% Congo red Finally, the sections were dehydrated in ethanol and xylol 
Results 
Cerebrovascular amyloidosis (CA) 
CA was detected in capillaries and small- to medium-sized arterioles in tissue sections of 
cerebral cortex in 19 out of 32 DAT patients (59%) by staining with the anti-A/3 MAb 
6C6 (Figure 1A,D) Serial section analysis revealed that many of the Appositive vessels 
were also identified by Congo red staining (Figure 1B,E), with concomitant bright 
birefringence under polarized light (Figure IF), although, in comparison with Aß 
îmmunostaining, a smaller part of the vessel wall was stained for Congo red ICAM-1, 
however, was only expressed by endothelial cells and by cells in a perivascular position, 
but was not associated with A/3-deposition in the vessel wall (Figure 1C,G) There 
seemed to be an increased endothelial and perivascular ICAM 1 staining in A/3-containing 
vessels compared to the staining observed in unaffected vessels in DAT (Figure IG) or 
control brain tissue (not shown) CA was also demonstrated by 6C6 staining in 
leptomemngeal arteries and arterioles of 9 out of 16 DAT cases (56%) (Figure IH), 
where the deposition of A/3 was observed in the tunica media As in cortical vessels, 
these deposits were not labeled by any of the five anti ICAM-1 M Abs ICAM-1 staining 
was restricted to endothelial cells and some perivascular granular staining was observed as 
well, probably reflecting the presence of macrophages (Figure II) CA was neither 
observed in the cerebral cortex nor in the leptomeninges of any of the control patients 
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Figure 1. Immunohistochemical staining of a capillary (Α-C), an intracortical arteriole (D-G) and 
a leptomeningeal artery (Η-I) in serial sections of the cerebral cortex from a case of DAT. Vessels 
of various sizes contained Aß deposits as shown by 6C6 staining (A,D,H). In H, 6C6 only stained 
the tunica media, whereas the intima remained unstained. Congo red staining demonstrated the 
presence of fibrillar Aß in capillaries and arterioles (B,E) with bright birefringence under 
polarized light (F). The anti-ICAM-1 MAb PN-E8 stained endothelial cells (arrowheads, C,G,I) as 
well as cells in a perivascular position (arrows) (C,G). Unidentified perivascular granular ICAM-
1 reactivity was observed in I (arrows). A group of small vessels, unaffected by Aß deposition 
(asterisk, D), is also stained for ¡CAM-1 (asterisk, G). Note the absence of ICAM-1 reactivity in 
the Aß deposits. Magnifications: Α-C, x430; D,E,G, x240; F, xl20; H,I, xl70. 
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Figure 2. Immunohistochemical staining of leptomeningeal vessels and diffuse senile plaques in 
serial sections of DAT cerebellum (Α-C) and cerebral cortex (D). Diffuse senile plaques and 
leptomeningeal vessels were stained with the anti-Aß MAb 6C6 (A). Congo red staining revealed 
the presence of Aß fibrils in the leptomeningeal vessels, but not in the diffuse senile plaques (B). 
Cerebellar diffuse senile plaques and vascular Aß deposits were not labeled by PN-E8 (anti-ICAM-
1), but endothelial cells (arrowheads) and a cell type in a perivascular position (arrow) were 
stained for ¡CAM-1 (C). Diffuse and classic senile plaques of the cerebral cortex were labeled by 
6C6 (D) and by the anti-ICAM-1 MAb CL203 (E). Magnifications: A-Ε, ХІ25. 
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Figure 3. Immunohistochemical staining of dyshoric angiopathy in serial sections of DAT cerebral 
cortex with the anti-Aß МАЪ 6C6 (A) and the anti-ICAM-1 MAb PN-E8 (B). Magnifications: A,B, 
x250. 
In the cerebellum, CA was found in the leptomeningeal vessels of 8 out of 16 
DAT patients with 6C6 staining (50%, Figure 2A). Aß-positive cortical vessels were 
demonstrated in 6 of these cases (38%). Similarly as described above for cerebrocortical 
blood vessels, the majority of the cerebellar Aß-positive vessels were identified with 
Congo red staining (Figure 2B), but ICAM-1 staining was never observed in association 
with the Aß-deposits (Figure 2C). In general, the pattern of ICAM-1 expression on 
endothelial cells and perivascular cells was similar to the patterns observed in unaffected 
vessels of DAT or control cerebellum. In the cerebellum of one control patient, CA was 
demonstrated in a few leptomeningeal vessels (not shown). 
Dyshoric angiopathy (DA). 
DA, or fine radiating deposits of amyloid extending into the neighbouring parenchyma, 
was demonstrated only around parenchymal vessels in cerebrocortical sections of DAT 
patients (12 out of 32 cases, 38%) (Figure ЗА) and was not observed in the cerebellum of 
any of these patients. In control patients, DA was neither observed in the cerebellar nor 
in the cerebral cortex. In contrast to the absence of ICAM-1 reactivity in the Aß-
containing vessel walls (see Figure 1C,G), perivascular tissue affected by DA was 
immunopositive for ICAM-1 (Figure 3B). 
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Figure 4. Immunohistochemical staining of classic senile plaques in serial sections of DAT 
cerebellum with the anti-Aß MAb 6C6 (A), Congo red (B,D,E) and the anti-ICAM-1 MAb CL203 
(C). A high power magnification (D) of the classic senile plaque, indicated by the arrow in B, is 
shown under polarized light in E. Magnifications: Α-C, x250; D-Ε, x850. (See also colour display 
on page 166, bottom). 
Cerebellar senile plaques. 
Senile plaques were demonstrated by 6C6 staining in the molecular layer of the 
cerebellum in 10 out of 16 DAT patients (63%) (Figure 2A). All these plaques were of 
the diffuse type, as was demonstrated by the complete absence of Congo red staining in 
serial sections. Blood vessels affected by CA in the same sections, however, were 
strongly stained by Congo red (Figure 2B). The diffuse senile plaques in the cerebellum 
were not stained for ICAM-1 (Figure 2C). A small number of classic senile plaques was 
detected by 6C6 and Congo red staining of serial sections in the granular and Purkinje 
70 
cell layers of the cerebellum in only 3 DAT patients (19%) (Figure 4A,B,D,E). These 
cerebellar classic senile plaques were diffusely stained for ICAM-1 (Figure 4C) ICAM-1 
staining was found in areas extending beyond the A/3-deposits In cerebellar tissue 
sections from two control patients few diffuse senile plaques were demonstrated, but 
classic senile plaques and senile plaque-associated ICAM-1 were completely absent from 
these sections. As a positive control for our ICAM-1 staining procedures, numerous senile 
plaques of both diffuse and classic type in the cerebral cortex of DAT patients were 
positively stained for ICAM-1 (Figure 2D,E). 
Discussion 
Our findings demonstrated striking differences between the pathological lesions in the 
cortex and cerebellum in DAT brains Consistent with other reports [10-12], we observed 
that, unlike in the cerebral cortex, classic senile plaques with a central amyloid core were 
completely absent from the cerebellar molecular layer Diffuse senile plaques in this 
cerebellar layer were devoid of ICAM-1 reactivity, whereas ICAM-1 could be identified 
in the classic senile plaques in the Purkinje cell and granular layer of the cerebellum. As 
described previously [23], ICAM-1 reactivity in these classic senile plaques extended 
beyond the site of A/3 deposition, indicating that ICAM-1 is expressed in larger tissue 
areas than would be anticipated on the basis of A/3 staining The distribution of ICAM-1 
in the DAT cerebellum is in contrast to the situation in the cerebral cortex, where both 
types of senile plaques are invariably accompanied by ICAM-1 reactivity [23]. 
Similar to α,-ACT [20], ICAM-1 was absent from cerebrovascular A/3 deposition 
in both the cerebral and the cerebellar cortex Although a study reported the presence of 
inflammatory compounds in CA [18], we conclude that the formation of CA, in contrast 
to senile plaque formation in the cerebral cortex, is not associated with the production of 
an inflammation-inducible protein like ICAM-1. Many of the A/3-positive cerebral and 
cerebellar vessels contained fibrillar material, indicating that A/3 fibnllization in the 
cerebrovasculature may occur in the absence ot inflammatory proteins In vitro studies 
have suggested that A/3 fibril formation may be accelerated by c^-ACT [28], but this 
process seems irrelevant to CA formation It may be possible that specific characteristics 
of vascular cells or components of the vascular basement membrane, especially HSPG 
[32] or apohpoprotein E [33-35] influence the formation of A/3 fibrils In addition, the A/3 
produced in the cerebrovasculature may differ in length from A/3 produced in the neuropil 
[14,16,17], possibly leading to a preferential production of the more amyloidogenic A/3M2 
[36], but several conflicting reports have been published concerning this subject 
[14-17,37]. Strikingly, if the amyloid deposition extended beyond the vessel wall into the 
nearby neuropil (dyshonc angiopathy (DA) or drusige Entartung), we observed ICAM-1 
immunoreactivity, similar to that described for o^-ACT [20], indicating that interaction 
between A/3 and neuroglial tissue is essential for its induction 
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The cellular source of the A/8-associated ICAM-1 is yet uncertain A number of 
cells may express ICAM-1, either constitutively or after proper stimulation In the brain 
vasculature, endothelial cells and pericytes can express ICAM-1 [23,38-40], and in the 
brain parenchyma, astrocytes and neural cells can do so [23,41,42] ICAM-1 expression 
can be induced by a variety of inflammatory mediators, such as lipopolysaccharide, 
interferon γ, tumor necrosis factor-α and interleukin 1 (IL-1) [38,40,43,44] Microglial 
cells are capable of IL-1 production [45,46], and it has been demonstrated that in DAT 
brains these cells show enhanced IL-1 immunoreactivity [25,47-49] Astrocytes are the 
most likely source of ICAM-1 and α,-ACT in DAT brains [42,50], and it is possible that 
astrocytic ICAM-1 and a,-ACT production is induced by IL-1 secreted by microglial cells 
[48] Apparently, vascular cells, such as pericytes and endothelial cells, are not stimulated 
to produce ICAM-1 to the same extent as astrocytes in the neuropil 
Complement factors and aY ACT have been demonstrated in the diffuse senile 
plaques of hereditary cerebral hemorrhage with amyloidosis - Dutch type [51], but reports 
about their expression in either cerebral or cerebellar diffuse senile plaques of DAT 
brains are still contradictory [18,52,53] Similar to ICAM-1, the proteoglycan HSPG is 
found in all types of senile plaques in the cerebral cortex, but not in diffuse senile plaques 
of the cerebellum [54] Our results indicate that in the cerebellum ICAM-1 production 
may play a prominent role at the level of classic senile plaque formation, whereas it 
probably only marginally contributes to the formation of diffuse senile plaques in this 
brain region It has been recently speculated [48] that microglial cells of the cerebellum, 
in contrast to their counterparts in the cerebral cortex, are relatively defective in 
producing the proper stimulating factors for astrocytic production of a,-ACT which may 
also relate to ICAM-1 production Interactions between microglial cells and astrocytes 
may be essential for the induction of inflammatory reactions in senile plaques These 
interactions may not occur in the molecular layer of the cerebellum, in contrast to the 
situation in the cerebral cortex Accordingly, neural and glial cells remain 
morphologically unchanged in diffuse senile plaques in the cerebellum [10-12,55] In the 
Purkinje cell and granular layer of the cerebellum, however, microglial cells and 
astrocytes may interact more closely, resulting in the induction of ICAM-1 
We conclude that ICAM-1 production is not uniformly involved in the process of 
A/3 formation, the involvement being basically dependent on the site of A/3 production in 
the DAT brain and the possibility of local interactions between microglial cells and 
astrocytes It can be argued that production of inflammatory compounds like α,-ACT and 
ICAM 1 occurs as a reaction to A/3 production m the brain, but it is important to note 
that in that case these reactions only take place in specific regions of the brain, that do 
not include the cerebellar molecular layer and the brain vasculature Furthermore, it 
seems unlikely that production of inflammatory compounds occurs as a reaction to A/3 
fibril formation, since inflammation-induced proteins are abundantly present in diffuse 
senile plaques in the cerebral cortex, that are devoid of fibrils Conversely, our findings 
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are compatible with the hypothesis that inflammatory reactions may contribute to the 
process of Aß fibrillization, although this remains to be established in the case of ICAM-
1 production. However, other factors may also contribute to the formation of fibrillar A/3, 
such as HSPG and ApoE, and this may be of particular importance for the pathogenesis 
of CA. 
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Abstract 
One of the major histopathological lesions in brains of patients with dementia of the 
Alzheimer type (DAT) is the senile plaque Although previous studies have shown that 
senile plaques are often accompanied by microglial cells, the role of these cells in DAT 
pathology is still unclear In an ïmmunohistochemical and immuno-electron microscopical 
analysis of DAT and control brain tissues we addressed to this issue by using two 
monoclonal antibodies (MAbs KP1 and 25F9) directed against lysosomal antigens in 
monocytes and macrophages Whereas KP1 stained lysosomes in both resting and 
activated microglial cells, 25F9 staining was predominantly found in lysosomes of 
activated microglial cells m classic senile plaques The number and size of 25F9-positive 
lysosomes in activated microglial cells was increased compared to 25F9 staining in 
unaffected areas in DAT and control sections We conclude that MAb 25F9 is a unique 
and useful lysosomal marker, with a higher specificity than other known markers, for 
activated microglial cells associated with classic, but not with diffuse, senile plaques 
Introduction 
Senile plaques, neurofibrillary tangles, and cerebrovascular amyloidosis are the 
neuropathological hallmarks of dementia of the Alzheimer type (DAT) [1] The major 
component of the senile plaques is the 4 kDa amyloid beta protein (A/?) that is split from 
the much larger beta amyloid precursor protein (APP) [2-4] Classic senile plaques are 
composed of a central amyloid core of fibrillar A/3, with a surrounding corona of altered 
neuntes, whereas in diffuse senile plaques predominantly non-fibnllar A/3 is found and 
neuntic changes are absent In addition to A/3, a number of senile plaque-associated 
proteins has been identified, that are indicative of an acute phase reaction These proteins 
comprise al-antichymotrypsin, interleukin-6, several complement factors, and intercel-
lular adhesion molecule-1 (ICAM-1) [5-10] 
Until now it is unclear what cells actually produce A/3 and the inflammatory 
compounds of senile plaques Clusters of microglial cells have been identified in 
association with classic senile plaques and amyloid fibrils [11-16] Since microglial cells 
are thought to be closely related to cells of the monocyte/macrophage lineage [17,18], 
they may play a prominent role in the inflammatory processes occurring in the classic 
senile plaques [19] 
It was the purpose of the present ïmmunohistochemical and immuno-electron 
microscopical study to identify markers that are more specific for microglial cells 
involved in the neurodegenerative processes occurring in DAT brains We used the 
following monoclonal antibodies (MAbs) KP1, directed against CD68, a lysosomal 
membrane molecule expressed by monocytes and macrophages [20] and 25F9, detecting a 
85 kDa differentiation antigen on more than 50% of mature macrophages and monocytes 
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in culture, but absent from freshly isolated monocytes [21]. The 25F9 epitope is 
expressed by alveolar macrophages, Kupffer cells in the liver, macrophages of the skin 
and the lymphatic system. Macrophages stained with 25F9 are found in chronic 
inflammatory reactions such as BCG-granulomas and sarcoidosis. MAb 25F9 has been 
proposed as a marker for macrophages in a late stage of differentiation [21], which 
prompted us to investigate its distribution in human DAT and control brain tissue 
Materials and methods 
Tissue samples and antibodies 
Brain tissue from 41 patients with a diagnosis of dementia of Alzheimer type (DAT, 14 
men, 27 women; age- 78 0 ± 10 4 y; post-mortem delay 2 1 ± 1 4 h) and 13 normal 
controls (5 men, 8 women; age 71.5 ± 118 y, post-mortem delay. 3.2 ± 2.6 h) was 
obtained at autopsy A definite diagnosis of DAT was based on a combination of 
neuropathological [22] and clinical entena Tissue samples from frontal, panetal, 
occipital and temporal cortex, cerebellum and hippocampus were snap-frozen in liquid 
nitrogen immediately after removal Furthermore, brain autopsy material of multiple 
sclerosis (MS) plaques was obtained from 2 patients (both female, age. 41 and 59 y, post­
mortem delay: 4 5 and 7 5 h) The antibodies used in this study are listed in Table 1. 
lmmunohistochemical staining 
Acetone-fixed sections (4 μπι) from frozen tissue on aminopropyltnetoxysilane-coated 
glass slides were stained directly with rhodamin-labeled RCA-1 diluted in PBS containing 
1% BSA or indirectly with primary MAbs, using peroxidase-labeled rabbit anti-mouse 
antibodies (RaMPO, Dako) as secondary antibodies and diaminobenzidin (DAB) as 
chromogen, essentially as described previously [23]. Alternatively, the ABC detection 
system (Vector) was used according to the manufacturer's description. Staining with 
polyclonal antibodies was followed by successive incubations with swine anti-rabbit 
antibodies and peroxidase anti peroxidase (PAP) complex (Dako) 
Semi-quantitative analysis of parenchymal 25F9 reactivity in DAT sections was 
performed as follows All sections were scored by three independent observers (M.M.V., 
P.W. and R M W.d W.), blind to diagnosis, on a relative scale from 0 (staining absent) 
to + + + (abundant staining). 25F9 staining associated with vessels was not included in 
this analysis. The average of individual scores was determined. Sections with differences 
in sconng exceeding one scale unit were re-evaluated by the three observers to obtain 
consensus 
Congo red staining was performed by fixing tissue sections (4 μπι) in acetone for 
10 minutes and successive dehydration with increasing concentrations of ethanol After a 
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Table 1. Antibodies used in this study and their specificities 
Antibody 
KP1 
25F9 
L243 
12-10 
P2-1 
F12 
6F2 
6C6 
LCA 
WT14 
HLA-DR 
A/S 
RCA-1 
MAb/PAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
MAb 
PAb 
PAb 
Lectin 
Specificity 
CD68 
Activated macrophages 
HLA-DR 
HLA-DR 
APP (N-termmus) 
APP (C-terminus) 
GFAP 
A/3 
CD45 
CD14 
HLA-DR 
A/3 
Microglial sugar 
moieties 
Dilution 
1 100 
1 200 
1 100 
" 
1 20 
10 ¿tg/ml 
-
10 uglmi 
1 40 
-
1 40 
1 300 
20 ¿ig/ml 
Source 
Dako (Glostrup, Denmark) 
BMA (Augst, Switzerland) 
Becton Dickinson (Mountain View 
CA) 
Dr W Tax, Dept ot Nephrology 
University Hospital Nijmegen 
Dr W E Van Nostrand |49] 
Dr J E Gardella (Stony Brook 
New York) |50| 
Sanbio (Uden, The Netherlands) 
Dr D Schenk (Athena Neurosci 
San Francisco, CA) [51| 
Dako 
Dr W Tax 
Dr H Ploegh 
Dr W E Van Nostrand 
Vector (Burlingame, CA) 
20 minutes preincubation period in a solution of 3% NaCl in 80% ethanol, sections were 
incubated for 20 minutes in the same solution containing 0 5% Congo red Finally, the 
sections were dehydrated in ethanol and xylol 
Double-staining procedures 
Several DAT cases were selected for double-immunostaining with 25F9 in combination 
with anti-A/3 antibodies as follows. Acetone-fixed sections (4μπι) were treated with 20% 
normal goat serum for 20 minutes and incubated with 25F9 for 1 hour. Subsequently, the 
sections were incubated with peroxidase-labeled goat anti-mouse antibodies (Dako) for 30 
minutes and stained with DAB The sections were successively treated with 0 5% AuCl, 
for 5 minutes, 4% formalin for 30 minutes, 50% formic acid for 30 minutes and 
incubated with ajiti-A/3 overnight at 4°C Subsequently, the sections were incubated with 
biotin-conjugated goat-anti-rabbit antibodies (1:200, Vector) for 30 minutes, and a 
mixture of avidin and alkaline phosphatase-conjugated biotin (Vector). Each incubation 
was followed by a washing step. A positive reaction was visualized using Fast Blue as 
chromogen. Secondary antibodies were tested for the absence of cross-reactivity and 
nonspecific staining 
Double-immunostaining with 25F9 in combination with the 6F2, F12 or P2-1 was 
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performed essentially as described previously [10] with some minor modifications. In the 
first cycle, the sections were incubated as above with 25F9 as primary antibody, RaMPO 
as secondary antibody and DAB as chromogen Subsequently the sections were incubated 
with a mixture of unlabeled rabbit-anti-mouse antibodies (Dako) and FITC-labeled sheep-
anti-mouse antibodies (Cappel, Boxtel, The Netherlands) to block residual free binding 
sites on the mouse antibodies from the first cycle. The blocking was checked by 
immunofluorescence microscopy and by omitting secondary antibodies from the first 
cycle In this way it could be verified that blocking was successful. The second staining 
cycle was started by preincubating the sections with 20% normal horse serum. Primary 
antibodies of the second cycle (P2-1, F12) were incubated for 1 hour. Finally, the 
sections were treated with biotinylated horse anti-mouse antibodies and with a mixture of 
avidin and alkaline phosphatase-conjugated biotin (Vector) The alkaline phosphatase 
reaction was performed with Fast Blue as chromogen. Reversing the order of incubation 
of the primary antibodies did not affect the results Secondary antibodies were tested for 
the lack of cross-reactivity and nonspecific staining Serial sections were stained with 
single MAbs for comparison of individual staining patterns with the double-stained 
sections Thus, it was verified that the staining patterns for each MAb were identical and 
no additional structures were stained 
Immuno-electron microscopy 
A pre-embedding immunoperoxidase technique was used to demonstrate the ultrastructural 
localization of the reaction product after staining with KP1 or 25F9 Autopsy material 
with a maximum size of 4x6x2 mm was fixed immediately after removal for 4 hours at 
room temperature (RT) in freshly prepared 2% paraformaldehyde in Sorensen buffer (pH 
7 4) After washing at RT in PBS for 1 hour and in 2.3 M sucrose solution for 45-60 
minutes, the tissue was immediately frozen and stored in liquid nitrogen. Sections of 30 
¿¿m were cut using a cryomicrotome and washed in PBS at RT for 1 5 hours The 
sections were incubated overnight using a rotary shaker at 4°C with KP1 or 25F9 diluted 
in PBS containing 1% BSA, which also served as a negative control. After extensive 
washing in PBS for 1 5 hours, incubation in RaMPO for 1 5 hours and another extensive 
washing for 1 5 hours at RT in PBS, the sections were incubated for 7 minutes in 0.6 
mg/ml DAB solution containing 0 6% Ni(NH4S04)2 and subsequently developed for 8-10 
minutes in the same solution containing 0 01% H202 Sections were poslfixed in 1% Os04 
for 10-15 minutes at RT, dehydrated, embedded in Epon 812, placed on a glass slide and 
covered with a glass slip. After overnight polymerization, the coverslip was removed, and 
an Epon-filled capsule was placed on selected sections. After another overnight 
polymerization, the capsule retaining the section was removed Ultrathin sections of the 
Epon-embedded material were examined on a JEOL 1200 EX/II electron microscope 
(Tokyo, Japan) at 45-50 kV 
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Results 
Immunohistochemical analysis of KP1 and 25F9 in brain sections 
Control brains 
In the various regions of cerebral cortex KP1 showed staining of small granules in 
numerous small cells dispersed in the neural tissue as well as staining of cells in a 
perivascular position The cells in the neural tissue often showed a ramified morphology 
(Figure 1A) Staining with 25F9 was much less abundant Predominantly, granules in 
cells in a perivascular position were stained, but within the neuropil of the cerebral cortex 
only sporadic staining was observed (Figure IB) 
KP1 and 25F9 staining patterns in white matter were similar to that observed in 
DAT white matter Also, the staining characteristics of these MAbs in control cerebellum 
were similar to that observed in DAT brains (see below) 
In all regions investigated, staining for leukocyte common antigen or CD14 was 
weak compared to KP1 staining Also, staining for the lectin RCA-1 was very faint on 
microglial cells, whereas endothelial cells in the same section were intensely labeled by 
this marker (not shown) 
DAT brains 
As in control brains, KP1 identified intracellular granules in hippocampal and cortical 
gray matter, but the staining showed a more heterogeneous pattern than that observed in 
control brains Apart from the abundantly present small granules, larger granules were 
also stained Moreover, clusters of cells with granular staining were frequently observed 
(Figure 1С) The 25F9 reactivity in the gray matter was markedly enhanced compared to 
that in control brains (Figure ID), and was mostly represented by clusters of granules 
All 25F9-positive cells were KP 1-positive, but only a limited number of KP1 positive 
cells expressed the 25F9 antigen, as was shown by staining of serial sections (Figure 
1C,D) 
In DAT and control brain tissue sections the 25F9 reactivity in the neural tissue 
was analysed in a semi-quantitative manner (Figure 2) In DAT brains, 25F9 reactivity 
was markedly enhanced compared to that in control brains, although there was 
considerable heterogeneity in the amount of 25F9 reactivity within the group of DAT 
brains In only 30% of the control brains weak to moderate 25F9 reactivity was observed, 
whereas in 80% of the DAT brains 25F9 reactivity varied between moderate to abundant 
staining In addition, in none of the DAT samples 25F9 reactivity was absent, whereas 
this was the case in nearly 40% of the controls 
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Figure 1. Immunohistochemical staining of cerebral cortex sections with KPl (A,C) and 25F9 
(B,D). A: KPl staining of some perivascular cells (arrowheads) and of small granules in cells 
dispersed in the neural tissue of control brains (arrows). Inset: KPl staining of a cell with a 
ramified morphology. B: 25F9 staining of granules in perivascular cells in control brain tissue 
(arrows). C: KPl staining of small and clusters of coarse granules in DAT brain tissue. D: 25F9 
staining of clusters of granules in DAT brain tissue (serial section to C). Sections were 
counterstained with hematoxylin. Magnifications: Α-D, x260; inset A, x400. 
KPl reactivity in the white matter of DAT brains (Figure ЗА) was comparable to 
that in control brains and revealed staining of cells dispersed in the neural tissue as well 
as cells in a perivascular position. 25F9 stained granules in perivascular cells in the white 
matter and, in addition, a minor population of cells scattered through the neural white 
tissue (Figure 3B). 
In DAT and control cerebellum, KPl stained cells lining blood vessels and a few 
cells dispersed in the molecular and granular layer (see below; Figure 6). In cerebellar 
white matter the KPl-positive cells were more numerous than in the gray matter (Figure 
3C). 25F9 reactivity in the cerebellum was generally restricted to some perivascular cells 
in the cortex (not shown) and white matter, and was only sporadically found in dispersed 
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Figure 2. Semi-quantitative analysis of 
parenchymal 25F9 reactivity in control (n = 13) and 
DAT (n=41) brain tissue sections. Scoring of 25F9 
staining was on a relative scale as indicated on the 
right as follows: -, absent; +/-, weak; + , 
moderate; + +, strong; + + +, abundant. Scores 
were derived from the individual scores of three 
independent observers. Staining associated with 
blood vessels was not included. 
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Figure 3. Immunohistochemical staining of DAT cerebral (A,В) and cerebellar (C,D) white matter 
with KP1 (A.C) and 25F9 (B,D). Few cells were labeled with 25F9 compared to KP1. 
Magnifications:AD, x260. 
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cells in the white matter (Figure 3D) and the granular layer 
In double-immunostaining of sections of DAT cerebral cortex, it was observed that 
the 25F9-positive cells did not express the astrocyte marker glial fibrillar acidic protein 
(GFAP) (Figure 4A) Furthermore, in all the tissues examined no morphological evidence 
was found for a neuronal localization of the 25F9-positive granules Using immunoblot 
ting procedures, it was not possible in our hands to determine the molecular weight of the 
25F9 antigen in DAT or control brain tissue, probably due to the low levels of 25F9 
antigen relative to total brain protein 
MS brains 
We also performed KP1 and 25F9 staining on MS brain tissue, since microglial cells are 
known to play a prominent role in MS lesions In several of these lesions, granular KP1 
reactivity was abundantly present in cells within and surrounding MS plaques. MAb 25F9 
also stained granules in a large number of cells in these MS lesions, but these cells were 
less numerous than the KPl-positive cells (not shown) 
Relation of 25F9-positive cells with senile plaques 
We performed double-immunostaining experiments with KP1 or 25F9 in combination with 
anti-A/3 or anti-APP antibodies on a number of DAT cases Numerous senile plaques 
were visualized with anti-A/3 antibodies in the gray matter of all the DAT brain tissues 
selected for double-staining A large number of cells containing small KPl-positive 
granules was randomly distributed throughout the tissue without a specific association 
with senile plaques In addition, clusters of KP1 reactivity, that were observed only in 
DAT brains, appeared to co-localize almost exclusively with senile plaques (Figure 4B) 
Nearly all 25F9-positive cells were found within or immediately around senile 
plaques (Figure 4C,D) Only a small fraction of 25F9-positive cells, never exceeding 
10%, was not associated with senile plaques Numerous small, diffuse A/3 deposits were 
devoid of 25F9-positive microglial cells The percentage of senile plaques that contained 
25F9-positive microglial cells varied between 5% and 70% in the investigated sections 
All selected DAT brain tissues showed immunostaining of dystrophic neuntes for 
APP with both the M Abs F12 and P2-1 Señal section analysis showed that the staining 
patterns of these MAbs co-localized exactly (not shown) Compared to A/3-
lmmunostaining fewer plaques were stained by the anti-APP MAbs and the number of 
stained plaques varied greatly among the brain tissues investigated Double-staining 
analysis showed that in all samples 80-90% of the APP containing plaques also contained 
25F9-positive microglial cells (Figure 4E) 
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Я^иге 4. Double-immunostaining of DAT brain 
tissue with 25F9 and markers for astrocytes and 
senile plaques. A: Astrocyte staining for GFAP 
(6F2, blue) and staining for 25F9 (brown). B: 
Staining of senile plaques with anti-Aß (blue) and 
of KP 1-positive cells (brown). Note the presence of 
clusters of KP I-positive granules in senile plaques. 
C,D. Staining of plaques with anti-Aß (blue) and 
of 25F9-positive cells (brown). 25F9-positive cells 
within (C) and immediately around (D) senile 
plaques. E: Staining of a senile plaque with anti-
APP (P2-I, blue) containing several 25F9-positive 
cells (brown). Note the weak APP staining in a 
blood vessel (arrow) accompanied by a 25F9-
positive perivascular cell (arrowhead). 
Magnifications: A.C-E, x260; В, xl30. (see also 
colour display on page 167). 
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F, 
fïgure 5. Immunohistochemical staining of serial sections of DAT hippocampus. Staining with 
25F9 (A) and PAb HLA-DR (B). Note the corresponding location of the 25F9 and HLA-DR 
staining. The same vessel in either section is indicated with V. Counterstaining with hematoxylin. 
Magnifications: A,B, x260. 
Congo red staining on frozen sections revealed a relatively weak, but distinct, 
reactivity with birefringence under polarized light in senile plaque amyloid, whereas 
cerebrovascular amyloid in the same sections was strongly stained. All Congo red-positive 
plaques identified in cortical and hippocampal gray matter contained 25F9-positive cells 
as determined by double-staining and by serial section analysis. Serial section analysis 
revealed that cells, especially those in clusters, with 25F9-positive granules also expressed 
HLA-DR (Figure 5A,B). Staining with the anti-HLA-DR PAb was superior to staining 
with either of the two anti-HLA-DR MAbs. 
In four out of eight DAT cerebellar tissues senile plaques lacking amyloid cores 
were identified in the molecular layer using 6C6 and Congo red staining, whereas in 5 
out of 8 samples cerebrovascular amyloidosis was demonstrated using the same staining 
techniques. Serial section analysis of the cerebellar plaques showed that 25F9 reactivity 
was completely absent from these deposits, whereas HLA-DR and few KP 1-positive cells 
were randomly distributed over the tissue (Figure 6A-D). 
Immuno-electron microscopy analysis of KP] and 25F9 staining in DAT brain tissue 
At the ultrastructural level KP1 stained two different structures: granules with the 
morphological aspect of lysosomes, and extracellular lipofuscin. The abundantly present 
intraneuronal lipofuscin remained unstained, however. Lysosomal structures of varying 
sizes were stained, and the number of lysosomes varied per cell. In these structures, KP1 
staining resulted in accentuation of the membrane (Figure 7A). In control experiments, in 
which the first M Ab was substituted by PBS, neither microglial lysosomes nor 
extracellular lipofuscin were stained (not shown). 
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Figure 6. Immunohistochemical staining of serial sections of DAT cerebellum. Staining with 6C6 
(A), 25F9 (B), KPl (C) and PAb HLA-DR (D). Note the absence of 25F9 reactivity in cerebellar 
diffuse plaques. Counterstaining with hematoxylin. Magnifications: AD, x260. 
The ultrastructural staining patterns of KPl and 25F9 showed some similarities. 
As observed with KPl, 25F9 also stained lysosomal structures, but with 25F9 a more 
diffuse staining was found, indicating that probably not only the membranes were stained. 
At high magnification the 25F9-positive perivascular cells appeared to be located either 
within or outside the basal lamina of blood vessels (Figure 7B,C). The large 25F9-
positive structures observed at the lightmicroscopical level in DAT neural tissue often 
appeared as large clusters of lysosomes, shaped like a bunch of grapes (Figure 7D). 
Defined cell outlines could not always be readily identified in these preparations. Finally, 
as observed with KPl, 25F9 stained extracellular lipofuscin-like structures, but not the 
abundant intraneuronal lipofuscin (Figure 7E,F). 
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Figure 7. Immuno-electron microscopie analysis of KPl (A) and 25F9 (B-G) staining in DAT 
brain tissue. A: KP] staining of microglial lysosomal structures with accentuation of membranes. 
B: 25F9 staining of lysosomes in perivascular cells. Note that these cells are located within the 
vascular basal lamina. C: 25F9 staining of lysosomes in a cell, located outside the vascular basal 
lamina and in close proximity to putative amyloid fibers. D: 25F9 staining of clusters of 
lysosomes. E: 25F9 staining of extracellular lipofuscin (arrow) and of lysosomes (arrowhead). F: 
Intraneuronal lipofuscin remains unstained with MAb 25F9. Magnifications: A,D, xl5,000; B, 
χό,ΟΟΟ; С, x8,000; E,F, x7,200. 
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Discussion 
In this study we describe the distribution of cells stained with KP1, a marker for 
macrophages in general, and of cells stained with 25F9, a marker of late stage 
differentiation of macrophages, in brain tissue cryosections In both normal and DAT 
brain tissue KP1 stained small, often ramified, cells scattered throughout the gray and 
white matter of the central nervous system, compatible with microglial cells as described 
in previous reports [24,25] Perivascular cells, that are claimed to have the closest relati-
onship to monocytes [26,27], were likewise stained by KP1 Previously reported variable 
staining of microglial cells with this MAb [28] might be caused by the paraffin-
embedding of the material, as this treatment is described to impair KP1 staining [25] 
A subset of KPl-positive microglial cells, especially present in DAT brains, also 
stained with 25F9 The microglial identity of the 25F9-positive cells was confirmed by 
staining for HLA-DR and the absence of staining for GFAP Microglial cells expressing 
the 25F9 antigen were localized mainly in association with classic senile plaques, that 
were identified by the presence of a Congo red-positive amyloid core and APP-positive 
dystrophic neuntes [29-31] In line with these observations, 25F9-positive microglia] cells 
were absent from cerebellar diffuse senile plaques 
It has been described before that paraformaldehyde or PLP fixation of brain tissue 
is optimal for the detection of resting ramified microglial cells, expressing monocyte and 
macrophage markers [32-34] Using acetone fixed cryosections, we were able to 
demonstrate ramified microglial cells with KPI and HLA-DR staining, with a more 
intense staining of microglial cells in classic senile plaques, indicating that our staining 
techniques were sufficiently sensitive to demonstrate the distribution of microglial cells 
stained with KPI or 25F9 On frozen sections, staining with other possible microglial 
cells markers (CD 14, LCA, RCA 1) was relatively weak compared to descriptions in 
previous reports, which may be explained by differences in tissue processing and fixation 
[12,32,35,36] 
From several studies it is known that microglial cells associated with classic senile 
plaques are in an activated state, characterized by shortening and thickening of cell 
processes and enhanced expression of /32-integrins, HLA-DR and ICAM 2 
[10,14,19,32,33,35,37-39] As staining with 25F9 identified microglial cells preferentially 
associated with classic senile plaques, we assume that 25F9 antigen expression is related 
to microglial cell activation, although staining with this intracellular marker precluded an 
evaluation of the morphology of the characteristic shortened cell processes Whereas the 
level of /32-integnns and HLA DR is higher on activated than on resting microglial cells, 
the 25F9 antigen seems to be almost exclusively synthesized after activation ot microglial 
cells, and seems to parallel the synthesis of antigens recognized by the antibodies AMC30 
and ADI 1/8 that can be detected in paraffin embedded formalin-fixed tissue only [40,41] 
Moreover, only a limited number of cells in the white matter is stained by 25F9, whereas 
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these cells strongly express /32-integrins and HLA-DR [32,33]. This indicates that 25F9 is 
a more specific marker for activated microglial cells in classic senile plaques than /32-
ïntegrins and HLA-DR. 
Expression of the lysosomal 25F9 antigen by activated microglial cells suggests 
that these cells are in a state of enhanced lysosomal or phagocytic activity, which is in 
agreement with upregulated Fc and complement receptor expression of these cells 
[32,35,42,43]. In MS brains, where microglial cells are known to be actively involved in 
phagocytosis [24], these cells abundantly expressed the 25F9 antigen, again indicating the 
relation between 25F9 expression and phagocytosis. 
The role of microglial cells in the brains of DAT patients is still the subject of 
much debate. In several reports it was suggested that microglial cells may produce A/3 or 
may be involved in A/3 fibril formation [11-16], and in vitro studies indicated that they 
are capable of producing APP [44,45]. In contrast to their association with classic senile 
plaques, clusters of microglial cells have no specific topographical relationship with 
diffuse senile plaques [35,39,46]. Furthermore, microglial cells do not express APP 
mRNA in situ [47], arguing against the involvement of these cells in A/3 production. Our 
results indicate that activated microglial cells are stimulated to enhance their lysosomal 
activity, probably to degrade components of the classic senile plaques by phagocytosis. 
Indeed, in vitro studies have demonstrated that they can internalize and degrade A/3 [48], 
resulting in a balance between production and removal of A/3. Apart from the 
internalization of A/3, microglial cells might also be involved in the phagocytosis of 
lipofuscin released from neurons resulting in the observed 25F9 reactivity of some 
extracellular lipofuscin granules, as shown immuno-electron microscopically in this study. 
In summary, this study provides evidence for a role of activated microglial cells in 
the phagocytosis of components of the classic senile plaque. In addition, our results show 
that 25F9 is a unique and useful lysosomal marker for the specific demonstration in 
cryosections of activated microglial cells, in classic senile plaques. MAb 25F9 seems to 
be more specific for the demonstration of activated microglial cells in these plaques than 
other known markers, that also detect resting microglial cells. 
Acknowledgments 
We thank the Joseph and Kathleen Bryan Brain Bank (Duke University Medical Center, 
Dept. of Pathology, Durham, NC, USA) for kindly providing brain tissue specimens. 
Brain tissue was also obtained from the Netherlands Brain Bank, Amsterdam (Coordinator 
Dr. R. Ravid). We thank Dr. K. Renkawek for neuropathological diagnosis, Drs. R. 
Koopmans, J.H.M. Cox-Claessens and G. Woestenburg (Psychogeriatric Centers 
"Joachim en Anna" and "Margriet", Nijmegen, The Netherlands) for their cooperation in 
autopsy procedures, Drs. J.E. Gardella, H. Ploegh and W. Tax for generously providing 
antibodies, and Dr. P. Eikelenboom for his stimulating discussions. 
91 
References 
1. Khachatunan ZS. Diagnosis of Alzheimer's disease. Arch Neurol (1985) 42:1097-1104 
2. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome sharing of a unique cerebrovascular 
amyloid fibnl protein. Biochem Biophys Res Commun (1984) 122:1131-1135. 
3. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo 
EH, Schenk D, Teplow DB, Selkoe DJ. Amyloid ¡8-peptide is produced by cultured cells during normal 
metabolism Nature (1992) 359:322-325. 
4. Kang J, Lemaire H, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K, Multhaup G, Beyreuther K, 
Müller-Hill В. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. 
Nature (1987) 325.733-736. 
5. Shoji M, Hirai S, Yamaguchi H, Hangaya Y, Ishiguro K, Matsubara E. Alpha 1-antichymotrypsin is 
present in diffuse senile plaques. Am J Pathol (1991) 138:247-257. 
6. Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor 
alpha-1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease Cell (1988) 52:487-501 
7. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk В. Detection of interleukin-6 and 
Cf-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 
(1992) 66:223-230. 
8. Eikelenboom Ρ, Stam FC. Immunoglobulins and complement factors in senile plaques. An 
immunohistochemical study. Acta Neuropalhol (1982) 57:239-242. 
9. Akiyama H, Kawamata T, Yamada T, Tooyama I, Ishn T, McGeer PL. Expression of intercellular 
adhesion molecule (ICAM)-l by a subset of astrocytes in Alzheimer disease and some other degenerative 
neurological disorders. Acta Neuropathol (1993) 85:628-634 
10. Verbeek MM, Otte-Höller I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RMW Accumulation of 
intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease Am J 
Pathol (1994) 144:104-116. 
11. Probst A, Brunnschweiler H, Lautenschlager С, Ulrich J. A special type of senile plaque, possibly an 
initial stage. Acta Neuropathol (1987) 74:133-141. 
12. Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen S-H. Alzheimer's disease. A double-labeling 
immunohistochemical study of senile plaques. Am J Pathol (1988) 132:86-101 
13. Wisniewski HM, Wegiel J, Wang КС, Lach В. Ultrastructural studies of the cells lorming amyloid in 
the cortical vessel wall in Alzheimer's disease. Acta Neuropathol (1992) 84:117-127 
14. Perlmutter LS, Scott SA, Barrón E, Chui НС. МНС class Il-positive microglia in human brain, 
association with Alzheimer lesions. J Neurosa Res (1992) 33:549-558. 
15. Wegiel J, Wisniewski HM. The complex of microglial cells and amyloid star in three-dimensional 
reconstruction. Acta Neuropathol (1990) 81:116-124. 
16. Wisniewski HM, Wegiel J, Wang КС, Ku|awa M, Lach В. Ultrastructural studies of the cells forming 
amyloid fibers in classical plaques. Can J Neurol Sci (1989) 16 535-542. 
17. Ling E-Α, Wong W-C. The origin and nature of ramified and amoeboid microglia. A historical review 
and current concepts. Glia (1993) 79-18. 
18. Theele DP, Streit WJ A chronicle of microglial ontogeny. Glia (1993) 7 5-8. 
19. Rozemuller JM, van der Valk Ρ, Eikelenboom P. Activated microglia and cerebral amyloid deposits in 
Alzheimer's disease. Res Immunol (1992) 143:646-649. 
20. Pulford KAF, Rigney EM, Micklem KJ, Jones M, Stress WP, Gatter КС, Mason DY. KPl. a new 
monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue 
sections J Clin Pathol (1989) 42.414-421 
21. Zwadlo G, Brócker E, von Bassewitz D, Feige U, Sorg С. A monoclonal antibody to a differentiation 
antigen present on mature human macrophages and absent from monocytes J Immunol (1985) 
134:1487-1492. 
22. Mirra SS, Heyman A, McKeel D, Sumí SM, Cram BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle 
G, Berg L. The consortium to establish a registry for Alzheimer's Disease (CERAD) Part II 
Standardization of the neuropathology assessment of Alzheimer's disease Neurology (1991) 41 479-486 
23. Verbeek MM, Otte-Höller I, Wesseling P, Ruiter DJ, de Waal RMW. Induction of o-smooth muscle 
actin expression in cultured human brain pericytes by TGF/J1. Am J Pathol (1994) 144 372-382. 
92 
24. Ulvestad E, Williams К, Mork S, Aniel J, Nyland H. Phenotypic differences between human 
monocytes/macrophages and microglial cells studied in situ and in vitro. J Neuropathol Exp Neurol (1994) 
53:492-501. 
25. Maal-Schieman MLC, Rozemuller AJ, van Duinen SG, Haan J, Eikelenboom Ρ, Roos RAC. Microglia 
in diffuse plaques in Hereditary Cerebral Hemorrhage with Amyloidosis (Dutch). An immunohistochemical 
study. J Neuropathol Exp Neurol (1994) 53:483-491. 
26. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone-marrow derived and present 
antigen in vivo. Science (1988) 239:290-292. 
27. Graeber MB, Streit WJ, Bunnger D, Sparks L, Kreutzberg GW. Ultrastructural location of major 
histocompatibility complex (MHC) class II positive perivascular cells in histologically normal human brain. 
J Neuropathol Exp Neurol (1992) 51:303-311. 
28. Esin MM, Morris CS. Immunocytochemical study of macrophages and microglial cells and 
extracellulair matrix components in human CNS disease. J Neurol Sci (1991) 101:59-72. 
29. Rozemuller AJM, Roos RAC, Bots GTAM, Kamphorst W, Eikelenboom Ρ, Van Nostrand WE. 
Distribution of /3/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with 
amyloidosis-Dutch type and Alzheimer's disease. Am J Pathol (1993) 142:1449-1457. 
30. Sho]i M, Hirai S, Yamaguchi H, Hangaya Y, Kawarabayashi T. Amyloid /3-protein precursor 
accumulates in dystrophic neuntes of senile plaques in Alzheimer-type dementia. Brain Res (1990) 
512:164-168. 
31. Tagliavini F, Ghiso J, Timmers WF, Giaccone G, Bugiani О, Frangione В Coexistence of Alzheimer's 
amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest (1990) 62:761-767. 
32. Akiyama H, McGeer PL. Brain microglia constitutively express ß-2 integnns. J Neuroimmunol (1990) 
30:81-93 
33. Tooyama I, Kimura H, Akiyama H, McGeer PL. Reactive microglia express class I and class II major 
histocompatibility complex antigens in Alzheimer's disease Brain Res (1990) 523:273-280. 
34. Mattiace LA, Davies P, Dickson DW Detection of HLA-DR on microglia in the human brain is a 
function of both clinical and technical factors. Am J Pathol (1990) 136:1101-1114. 
35. Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther К, Masters CL. A4 protein in Alzheimer's 
disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp 
Neurol (1989) 48:674-691. 
36. Manno|i H, Yeger H, Becker LE A specific histochemical marker (lectin Ricinus communis 
agglutinin-1) for normal human microglia, and application lo routine histopalhology Acta Neuropathol 
(1986)71:341-343. 
37. McGeer PL, Itagaki S, Tago H, McGeer EG Reactive microglia in patients with senile dementia of the 
Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosa Lett (1987) 
79.195-200. 
38. Dickson DW, Lee SC, Mattiace LA, Yen SC, Brosnan С Microglia and cytokines in neurological 
disease, with special reference to AIDS and Alzheimer's disease Glia (1993) 7:75-83. 
39. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to 
amyloid deposits of Alzheimer disease. J Neuroimmunol (1989) 24· 173-182. 
40. Haga S, Akai К, Ishii T. Demonstration of microglial cells in and around senile (neuntic) plaques in the 
Alzheimer brain. Acta Neuropathol (1989) 77:569-575. 
41. Cras P, Gheuens J, Liibke U, Boons J, Vandermeeren M, van Heuverswi|n H, Martin J-J A 
monoclonal antibody raised against Alzheimer cortex that specifically recognizes a subpopulation ot 
microglial cells. J Histochem Cytochem (1990) 38· 1201-1207. 
42. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. Microglial cells around amyloid plaques in 
Alzheimer's disease express leukocyte adhesion molecules of the LFA-1 family Neurosa Lett (1989) 
101:288-292. 
43. Peress NS, Fleit HB, Perillo E, Kuljis R, Pezzullo С Identification of FcRI, Il and III on normal 
human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. J Neuroimmunol 
(1993)48:71-80. 
44. Haass C, Hung AY, Selkoe DJ. Processing ot /3-amyloid precursor protein in microglia and astrocytes 
favors an internal localization over constitutive secretion. J Neurosa (1991) 11:3783-3793. 
45. Konig G. Mönning U, Czech С, Prior R, Banati R, Schreiler-Gasser U, Bauer J, Masters CL, 
Beyreuther К Identification and differential expression of a novel alternative splice isoform of the /JA4 
93 
amyloid precursor protein (APP) mRNA in leukocytes and brain microglial cells. J Biol Chem (1992) 
267:10804-10809. 
46. Cras P, Kawai M, Siedlak S, Mulvihill P, Gambetti Ρ, Lowery D, Gonzalez-DeWhilt P, Greenberg В, 
Perry G. Neuronal and microglial involvement in /3-amyloid protein deposition in Alzheimer's disease. Am J 
Pathol (1990) 137:241-246. 
47. Scott SA, Johnson SA, Zarow C, Perlmutter LS Inability to detect beta-amyloid protein precursor 
mRNA in Alzheimer plaque-associated microglia Exp Neurol (1993) 121:113-118. 
48. Shaffer LM, Donty MD, Younkin SG, Brunden KR. Removal of liquid-phase and substrate-bound 
amyloid β peptide (A/3) by microglia and other CNS cell types. Neurobiol Aging (1994) 15:S152 (Abstract). 
49. Van Nostrand WE, Wagner SL, Suzuki M, Choi BH, Farrow JS, Geddes JW, Colman CW, 
Cunningham DD. Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid /3-protein 
precursor. Nature (1989) 341:546-549. 
50. Gardella JE, Gorgone GA, Muñoz PC, Ghiso J, Frangione B, Gorevic PD. β Prolein precursor 
expression in human platelets and a megakaryocyte cell line. Lab Invest (1992) 67:303-313. 
51. Tamaoka A, Kalana RN, Lieberburg I, Selkoe DJ. Indentification of a stable fragment of the Alzheimer 
amyloid precursor containing the /3-protein in brain microvessels Proc Nail Acad Sci USA (1992) 
89:1345-1349. 
94 
Chapter 5 
Induction of «-smooth muscle actin expression 
in cultured human brain pericytes by 
transforming growth factor-/31 
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Abstract 
Pericytes are cells localized at the abluminal side of the microvascular endothelium and 
are completely enveloped by a basement membrane Pericytes have close contact with 
endothelial cells and are probably involved in the regulation of endothelial cell functions 
Previous studies suggested a role for pericytes in microvascular proliferation in tumors 
To study this cell type, we isolated human brain pericytes (HBP) from microvessel 
segments derived from autopsy brain tissue These cells were characterized in vitro using 
a panel of monoclonal antibodies (MAb) HBP were reactive with MAb directed against 
the high molecular weight-melanoma associated antigen (HMW-MAA) and ICAM-1, but 
only a minority of the cells expressed α-smooth muscle actin (a-SMA, 0 10%) or 
vascular cell adhesion molecule (VCAM)-l (10-50%) In histologically normal human 
brain microvessels in situ, pericytes consistently lacked staining for these four markers 
Tissue with microvascular proliferation, however, showed a marked pericyte staining for 
both a-SMA and HMW-MAA The expression of a-SMA in vitro could be slightly 
upregulated by incubation with serum-containing medium An increase in a-SMA expres­
sion up to 40% of the total cell population was seen when pericytes were treated with 
transforming growth factor (TGF) /31, whereas basic fibroblast growth factor (bFGF) 
slightly inhibited a-SMA expression Incubation with other factors (platelet-derived 
growth factor (PDGF)-AA, heparin, interferon (IFN)-7, tumor necrosis factor (TNF)-a) 
had no effect on the a-SMA expression at all TGF /31 thus induces smooth muscle like 
differentiation in pericytes in vitro, and might play a role in the activation of pericytes 
during angiogenesis in vivo 
Introduction 
Situated at subendothelial sites in the vessel wall, pericytes are a prominent and ubiqui­
tous cellular component of the microvasculature, comparable to smooth muscle cells in 
the tunica media of arteries and veins [1 4] One of the major functions of pericytes is 
their capacity to influence endothelial cell proliferation [4-7] Pericytes, with their long 
processes, have close contact with endothelial cells via pores in the basal lamina [8] and 
may thus exert direct effects on the endothelium Based on earlier studies on angiogenesis 
in tumors [4,9-13] and in healing wounds [7,9,10] an active role for pericytes in 
cooperation with endothelial cells was postulated Pericytes may even be involved in the 
earliest stages of neovascularization [9 11] and may precede endothelial cells in the newly 
forming capillary sprouts [12] 
Another function of pericytes that has been described is the control of local blood 
pressure Like smooth muscle cells, they may respond to factors secreted by endothelial 
cells [14], and regulate the blood vessel diameter by contraction or relaxation [15 17] 
Pericytes contain a variety of proteins typical for contractile cells, like tropomyosin [15], 
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cyclic guaríosme monophosphate-dependant protein kinase [18], muscle-type myosin [16] 
and α-smooth muscle actin (a-SMA) [19,20] Furthermore they contain non-muscle β 
and γ-actin and non muscle myosin [16,19,20] The intermediate filaments vimentin and 
desmin are variably presented in pericytes, depending on tissue and species source 
[4,10,21,22] A pronounced expression of the high molecular weight-melanoma associated 
antigen (HMW-MAA, identical to chondroitin sulphate proteoglycan) was found on 
activated or proliferating pericytes in tumors and granulation tissue, but the proteoglycan 
was virtually absent on pericytes in normal brain tissue [10] 
A problem in studying pericytes is their identification both in tissue and in culture 
a-SMA has been widely used as a marker for pericytes [5,10,19,20] However, the 
expression of a-SMA in pericytes seems to be dependent on several conditions In the 
first place, differences are observed between pericytes derived from various tissues 
Normal retinal and cerebral pericytes in situ do not contain a-SMA [4,23], whereas 
pericytes from other organs do express this protein [19,20,23] In the second place, the 
expression of a-SMA by pericytes largely depends on the specific localization within the 
microvascular bed [4,23] Pericytes from rat mesentery midcapillanes lack a-SMA, 
whereas pericytes from pre- and postcapillary do contain this type of filament In the 
third place, the expression of a-SMA may differ between in vitro and in situ Cultured 
pericytes from bovine retina start to express a-SMA [19-21,24,25] This expression may 
be the result of a change in differentiation state caused by activation or unrestricted 
proliferation 
In this study, we describe the use of cultured human brain pericytes (HBP) as a 
model system of pericyte activation. The cells were characterized using a panel of 
monoclonal antibodies, which distinguished HBP trom a number of other cell types Of 
these markers, a-SMA and HMW-MAA were studied in detail for their potency to serve 
as markers for pericyte activation and proliferation in relation to angiogenesis In 
addition, a number of external mediators was tested for their ability to influence the 
pericyte phenotype m vitro 
Materials and methods 
Patients 
Brain tissue material used for the isolation procedure was obtained after a rapid autopsy 
procedure (post mortem delay between 2 and 6 h) from the following cases A 1-year old 
child, with an unidentified neurological syndrome, four cases of senile dementia of the 
Alzheimer type (SDAT) (age 81-94), one case of a cerebrovascular accident (age 85), one 
case of an unidentified metabolic disorder (age 49) and one neuropathologically unaffected 
case (age 81) Brain tumor biopsy material was collected from 10 cases of glioblastoma 
multiforme (GBM) 
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Isolation and maintenance of HBP from post mortem brain tissue 
Fragments of human frontal cortex were obtained from autopsy 2 to 6 h after death and 
immediately collected in cold phosphate buffered saline (PBS), supplemented with 
antibiotics (penicillin (100 IU/ml), streptomycin (100 μg/ml), gentamicin (40 ^g/ml), 
fungizon (10 ^g/ml) and tobramycin (40 - 100 Mg/ml)) After 30 - 60 minutes at 4°C, the 
tissue was washed with PBS, the leptomeninges were removed and the tissue was cut into 
small pieces. The material was homogenized (10 strokes in a loose-fitting Dounce 
homogemzer) in Earl's modified essential medium (EMEM). The homogenate was 
centnfuged twice for 5 minutes at 1000 rpm and once at 1000 rpm for 1 minute The 
pellet was resuspended in EMEM containing 15% dextran T70 (M
r
 70,000; Pharmacia, 
Uppsala, Sweden) and centnfuged at 5500xg for 10 minutes [26] The sedimented capil­
laries were washed three times in PBS containing 10% newborn calf serum (NCS, Gibco, 
Paisley, Scotland) Finally, the capillaries were treated with 1 mg/ml collagenase for 0.5 -
2 h at 37 °C. At regular intervals during this incubation period the digestion mixture was 
gently agitated and the microvessels were checked microscopically for their morphology 
The digested capillary clumps were collected by centrifugaron at 1000 rpm for 1 minute, 
washed once with PBS/10% NCS and seeded on fibronectin-coated culture dishes Cell 
outgrowth occurred after 5 to 7 days The isolated HBP were maintained with EMEM 
containing 10% human serum (HS, Red Cross Blood Bank Nijmegen, The Netherlands), 
20% NCS, HEPES (10 mM, Flow Laboratories, Irvine, Scotland), endothelial cell 
growth factor (ECGF, 150 Mg/ml), heparin (5 U/ml, Organon Tekmka, Boxtel, The 
Netherlands), glutamin (2 mM, Flow Laboratories), and antibiotics as described above 
(this culture medium will be referred to as EMEM-HS) Upon reaching confluence cells 
were passed at a 1:2 split ratio using trypsin (0 5 mg/ml, Difco, Detroit, MI, USA) and 
EDTA (0 2 mg/ml) to detach the cells 
Isolation of human umbilical cord arterial smooth muscle tells (HUASMUC) 
Pieces of an artery were dissected from human umbilical cord, obtained within 30 
minutes after birth. Connective tissue was carefully removed to avoid fibroblast growth in 
the culture system. The arteries were cut into small fragments, allowed to attach to a 
fibronectin coated culture plate and EMEM-HS was added Cell outgrowth was observed 
after 10 days. HUASMUC were maintained as described above for HBP 
Antibodies 
Monoclonal antibodies (MAb) used were (see Table 1) EN4 and 6F2 (Sanbio, Uden, The 
Netherlands); W6/32 and OKT9 (ATCC cell lines, Rockville, MD, USA), anti-MHC 
Class II (Becton Dickinson, Mountain View, CA, USA), SM-1 (Sigma, St. Louis, MO, 
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Table 1. Immunocytological identification ofHBP and control cell types 
Cell Type 
Antibody 
2A7 
SM-I 
EN4 
4B9 
PN-E12 
MUC18 
RV202 
RD301 
W6/32 
12 10 
OKT9 
6F2 
HHF35 
8E7 
Antigen 
HMW-MAA 
α-SMA 
Not known 
vWF 
VC AM-1 
ICAM-1 
FXIII 
Not known 
Vimentm 
Desmin 
HLA-ABC 
HLA-DR 
CD38 
GFAP 
α,γ-actin 
Not known 
HBP 
+ 
+ 2 
-
-
+ 1 
+ + + 
-
-
+ + + 
-
+ + 
-
+ 
-
-
+ + 
HUVEC 
-
-
+ + + 
+ + + 
-
+ 3 
ND 
+ + + 
-
+ + 
-
+ 
-
ND 
-
H FF 
+ I-" 
-
-
-
-
+ /-' 
-
ND 
+ + + 
-
+ 
-
_s 
-
ND 
+ 
HUA 
+ 
+ 1 6 
-
-
+ + 4 
-
+ 
+ 
+ -M 
-
+ + -
-
+ + -
-
-
+ + 
ND = Not determined Scores were on a relative scale ranging from - (staining absent) to + + + 
(very strong staining) '0 to 1 % of the cells are stained 4 to 10 % of the cells are stained 40 
to 50 % of the cells are stained "50 to 90 % of the tells are stained '++, when cultured in 
EMEM-HS Ч + +, when cultured in DMEM-NCS (all cells) Not specified >90% of the cells 
are stained 
USA); HHF35 (Enzo Biochem Ine , NY, USA), PN-E12, RV202 and RD301 (produced 
in our own laboratory), WT32 and 12.10 (kind gifts of Dr W. Tax, Dept. of Nephrolo­
gy, University Hospital Nijmegen, Nijmegen, The Netherlands); CL203 (kind gift of Dr. 
S. Ferrane, New York Medical College, Valhalla, NY, USA); 4B9 (kind gift of Dr. T. 
Carlos, Harborview Medical Center, Seattle, WA, USA [27]), MUC18 (kind gift of Dr. 
J Ρ Johnson, Institute of Immunology, Munich, Germany [28]) Polyclonal antibodies 
(PAb) used were von Willebrand Factor/Factor VHI-related antigen (vWF-FVIII, CLB, 
Amsterdam, The Netherlands), anti-coagulation Factor XIII (FXIII, Behring, Marburg, 
Germany). 
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Production of monoclonal antibodies 
Hybndomas were produced and tested essentially as previously described by Westphal et 
al [29] with the use of HBP instead of human umbilical cord venous endothelial cells 
(HUVEC). Antibody reactivity was tested in an ELISA with glutaraldehyde-fixed cultured 
HBP and HUVEC. Selected hybridomas were cloned once by limited dilution. 
¡mmunocytochemical staining of cultured cells 
Cultured cells were grown on glass slides that were previously coaled with gelatin and 
treated with glutaraldehyde. At confluence they were fixed in acetone for 10 minutes and 
air-dried. The fixed cell cultures were incubated for 1 h at room temperature in the dark 
with primary antibodies. After the primary incubation, the preparations were washed 
twice for 8 minutes with PBS and incubated with the secondary antibody for 30 minutes 
at room temperature in the dark. The secondary antibody was peroxidase conjugated 
rabbit anti-mouse IgG (dilution 1:80, Dako, Denmark) in case of primary monoclonal 
mouse antibodies, and peroxidase conjugated swine anti-rabbit IgG (dilution 1:160, Dako) 
in case of polyclonal antibodies. All dilutions were made in PBS/1% BSA, which also 
served as a negative control. The peroxidase reaction was performed by incubating the 
preparations 5 minutes with 0.6 mg/ml diaminobenzidin (DAB, Sigma) in PBS with 
0.015% H202. After a short rinse in tap water, the slides were incubated 5 minutes in 
0.5% CuSQ, in saline solution. The slides were again washed with tap water and then 
counterstained with haematoxylin for 1-3 minutes and thoroughly washed with tap water 
for 10 minutes. Finally, the preparations were dehydrated in 96% alcohol followed by 
xylol. 
Control cells were: HUVEC, isolated as described by Jaffe [30] and HUASMUC 
(isolated as described above), both maintained in EMEM-HS. Human foreskin fibroblasts 
(HFF, ATCC cell culture) were maintained in Dulbecco's minimal essential medium 
(DMEM) with 10% NCS and glutamin (to be referred to as DMEM-NCS). 
lmmunohistochemical staining of tissue sections 
Autopsy brain tissue was obtained 2 to 6 h after death from the cases mentioned above. 
Placenta was obtained within half an hour after delivery. Small pieces of tissue were snap 
frozen in liquid nitrogen and stored at -140 °C. Brain tumor biopsy material (GBM) was 
snap frozen in liquid nitrogen immediately after removal and stored at -80°C. 
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Sections from frozen tissue (4 μπι) on aminopropyllnetoxysilane-coated glass 
slides were fixed with acetone for 6 minutes at room temperature, followed by another 4 
minutes of fixation in acetone supplied with 0.15 % H202 to block endogenous peroxidase 
activity. The subsequent staining procedure and the antibodies used are the same as 
described above 
α-Smooth muscle actin modulation in HBP 
HBP were grown on 2 cm2 gelatin-coated and glutaraldehyde-treated glass slides in 
DMEM-NCS Human serum and ECGF were not included in the culture medium to 
exclude disturbing effects of these factors. Four hours after seeding of the cells the 
medium was replaced by DMEM-NCS to which bFGF (10-100 ng/ml), TGF-/31 (2 
ng/ml), PDGF-AA (5 ng/ml), TNF-a (50 ng/ml), IFN-7 (200 U/ml) or heparin (50 
IE/ml) was added where indicated DMEM with or without the addition of NCS was used 
to test the a-SMA expression in growing or growth-arrested cells, respectively. The 
culture medium was changed every other day. Cells were grown for 3 to 8 days 
Afterward they were successively washed with DMEM, fixed with acetone and stained as 
described above A Kontron Vidas1'1'"' image analysis system (Kontron GmbH, Eching, 
Germany), connected to a Sony RGB CCD camera on top of a Zeiss microscope, was 
used for quantitative analysis of a-SMA expression of cultured HBP Every glass slide 
was sampled at 25 randomly chosen positions. The number of haematoxylin-stained nuclei 
in a 100 χ microscopic field was determined and considered as the total number of cells 
in a field. In the same sample the number of a-SMA-positive cells was determined. The 
percentage positive cells in an experiment was recorded as the ratio of the total number of 
positive cells in 25 fields and the total number of cells in the same 25 fields. TGF-01 and 
PDGF-AA were a kind gift of Dr E.J J. van Zoelen (Dept of Cell Biology, University 
of Nijmegen, Nijmegen, The Netherlands), TNF-a was a kind gift of Boehnnger 
Ingelheim (Ingelheim, Germany), and bFGF was a kind gift of Scios Inc. (Mountain 
View, CA, USA). 
Results 
Isolation and culture of HBP and HUASMUC 
The method described for isolating HBP from post mortem human brain tissue was rapid 
and reproducible and was successful in all cases studied, including several cases of 
SDAT HBP could be recognized by their polymorphic shape and overlapping processes 
indicating the absence of contact inhibition (Figure 1A). The isolated cells lacked the 
monolayer growth pattern characteristic for endothelial cells, they showed a growth 
pattern different from that displayed by HUASMUC (Figure IB), and they lacked the 
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Figure 1. Phase-contrast photomicrographs of HBP (A) and HUASMUC (B) cultures. Magnifica­
tions: ХІ20 
extremely elongated shape of fibroblasts in culture (not shown). In very dense cultures 
HBP tended to grow very compact and formed a densely packed layer of cells (not 
shown). 
lmmunocytochemical identification of cultured HBP 
The obtained staining patterns in HBP, HUVEC, HFF and HUASMUC are summarized 
in Table 1. Figure 2 shows the HBP staining reactions that could be used to discriminate 
between HBP and the other cell types, i.e. HMW-MAA (Figure 2A), VCAM-1 (Figure 
2B), ICAM-1 (Figure 2C) and a-SMA (Figure 2D,E). Only a small and varying fraction 
of the HBP (0.1-10%) contained a-SMA. VCAM-1 was expressed by 10-50% of the 
HBP. 
In clones of HBP, obtained by limiting dilutions (1 cell/well or less), still a small 
fraction of cells in the resulting clones was a-SMA-positive. Also, HBP cultured for more 
than 20 passages were still partially positive for a-SMA (results not shown). We therefore 
concluded that the a-SMA reactivity in HBP cultures was not due to contaminating 
smooth muscle cells. Cultures of HBP were also not contaminated with glial cells as was 
demonstrated by the lack of GFAP staining (Table 1). 
From Table 1 it is clear that the panel did not include a pericyte-specific marker. 
Also, our own efforts to produce MAbs directed against HBP, did not result in pericyte-
specific MAb. Two groups of antibodies directed against HBP, that were unreactive with 
HUVEC, were produced. One group (including MAb 2A7) was directed against HMW-
MAA; the other group (including MAb 8E7), recognizing two unidentified proteins of 
130 and 140 kDa under non-reducing conditions, was also reactive with HUASMUC and 
HFF. 
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Figure 2. lmmunocytochemical staining of cultured HBP with MAbs directed against HMW-MAA 
(A), VCAM-1 (B), ICAM-1 (C) and a-SMA (D,E). D: untreated cells; E: TGF-ßl-treated cells (2 
ng/ml, 5 days). Note the increased number of a-SMA-positive cells after treatment with TGF-ßl in 
E. Cell preparations were stained with DAB and counterstained with hematoxylin. Magnifications: 
ХІ20 
Immunohistological analysis of pericytes in human tissue 
In contrast to the findings with cultured cells, staining of autopsy brain tissue showed that 
pericytes, situated around capillaries, were only very incidentally and very weakly 
visualized with anti-HMW-MAA antibodies and not labeled at all with the a-SMA MAb 
SM-1, MAb 8E7 and anti-VCAM-1 MAb (not shown). A strong a-SMA reactivity and a 
moderate staining for HMW-MAA and MAb 8E7 was only seen in smooth muscle cells 
lining arterioles and larger blood vessels (results not shown). 
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Figure 3. Immunohistochemical staining of pericytes in glioblastoma multiforme (A,B) and 
placenta (C,D) with MAbs directed against HMW-MAA (A,C) and a-SMA (B,D). A,B: Pericytes 
in an area with microvascular proliferation expressed HMW-MAA and a-SMA. C,D: A number of 
pericytes around fetal capillaries were positively stained for HMW-MAA or a-SMA (arrows), 
whereas others remained unstained (arrowheads). The sections were stained with DAB and 
counterstained with hematoxylin. Magnifications: x225 
We further studied the HMW-MAA and a-SMA expression of pericytes in tissues 
with a high level of angiogenesis, i.e GBM and placenta. In all GBM studied 
periendothelial cells in areas with microvascular proliferation were intensely stained by 
anti-HMW-MAA (Figure ЗА). In these areas a less abundant but unequivocal a-SMA 
expression was observed in periendothelial cells in the majority of the tumors (Figure 
3B). In placental villi, a large number of, but not all, periendothelial cells around fetal 
capillaries were stained with HMW-MAA and a-SMA M Ab (Figure 3C,D). 
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Figure 4. Modulation of the proliferation and α-SMA expression of HBP by serum and growth 
factors. A: TGF-ßl-containing (2 ng/ml) and serum-free medium partially inhibited HBP prolifera-
tion during a 5-day period. B: TGF-ßl (2 ng/ml), and, to a lesser extent, serum increased a-SMA 
expression in HBP (Incubation period 5 days). C: bFGF (10 to 100 ng/ml) decreased a-SMA 
expression of HBP. (Incubation period 5 days). (Α-C: A representative experiment from a series of 
3 or more experiments is shown). 
Modulation of proliferation and a-SMA expression in cultured HBP 
The effects of proliferation and of several growth factors and cytokines on the a-SMA 
content and HMW-MAA expression of cultured HBP was tested. We observed a slight, 
but not significant, decrease in HMW-MAA expression when HBP were cultured under 
growth inhibiting conditions, i.e. in serum-free medium or in medium containing TGF-
ßl . Incubation of HBP for 5 days under these conditions did not affect cell viability. 
Also, proliferation of the cells was not completely blocked (Figure 4A). After incubation 
with serum-free medium, α-SMA expression was completely abolished in most of the 
experiments (Figure 4B). Incubation of the cells with DMEM-NCS for 5 days stimulated 
HBP proliferation (Figure 4A) and had variable effects on the α-SMA expression of cell 
cultures from different donors. The number of a-SMA-positive cells remained either 
unchanged (not shown) or was slightly increased (Figure 4B), compared to incubation in 
serum-free medium. 
Incubation with TGF-/31 (2 ng/ml), however, resulted in a strong and consistent 
increase in the number of a-SMA-positive cells in all tested cultures (Figure 4B and 
compare Figure 2E with 2D), up to 40% of the total cell number. 
bFGF (10-100 ng/ml) tended to decrease the α-SMA expression in HBP, but the 
effects were only significant when the number of positive cells in control cultures 
exceeded 5% (Figure 4C). PDGF-AA (5 ng/ml), IFN-7 (200 U/ml), TNF-a (50 ng/ml), 
and heparin (50 IE/ml) did not affect the α-SMA expression of HBP (not shown). 
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Discussion 
In this study a rapid method is described for the isolation and characterization of HBP 
This method was reproducible for autopsy brain tissue and yielded viable cells that could 
be grown for at least 20 passages. 
Characterization and identification of HBP was achieved by staining the cells with 
a number of MAbs. In several reports the use of a single marker, like o-SMA 
[5,10,19,20], coagulation factor XIII [31], HLA-DR [31,32] or desmin [4] for the 
identification of pericytes m situ was suggested. From our results we conclude that so far 
the use of a single marker is not sufficient to identify pericytes in vitro, but that a panel 
of markers should be used. 
Our observation that the majority of HBP both in situ and in vitro does not contain 
a-SMA limits the use of this intracellular marker for the identification of pericytes This 
is supported by reports describing findings in normal brain and retina tissue in which 
pericytes fail to express a-SMA [4,23] This and the increasing number of cell types that 
can be induced to contain a-SMA [24,33-37], leads us to the conclusion that a-SMA 
should be considered as a marker for smooth muscle cell differentiation rather than as a 
unique marker for smooth muscle cells or pericytes 
Our observations on HMW-MAA expression by cultured HBP are in accordance 
with a previous report [10]. In our hands, however, desmin and HLA-DR failed to serve 
as markers for HBP in culture. The lack of staining in cultured HBP for Factor XIII does 
not support the observations of Némes [31], who suggests FXIII as a specific marker for 
pericytes, based on studies on sections of normal brain tissue and hemangiopericytoma. 
An explanation for these differences may be the different behaviour of pericytes in vitro 
and in vivo. On the other hand, our results show that smooth muscle cells in vitro are 
FXIII-positive This would support the idea that the tumor cells in hemangiopericytoma 
may originate from differentiated smooth-muscle cells [38], and not from pericytes 
The results of the present study confirm that HBP, HUVEC and HUASMUC share 
several antigenic determinants Repeated fusion experiments did not result in the produc-
tion of pencyte-specific antibodies. Epitopes on pericytes always seemed to be shared 
with either endothelial cells, fibroblasts or smooth muscle cells. Despite the similarities 
with other cell types, pericytes may still be regarded as a distinct cell type, because the 
marker pattern displayed by cultured pericytes as described in this study shows unique 
properties for pericytes. It should be noticed, however, that all our experiments were 
performed on gelatin-coated glass slides Other extracellular matrix components (eg, 
fibronectin, collagen, laminin) may influence HBP marker expression differently. In 
addition, further research on cultured pericytes from other human tissue sources than 
brain is needed to evaluate if the characterization results of HBP in vitro described in this 
study are more broadly applicable 
We were not able to visualize pericytes in sections of normal or SDAT brains with 
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the pericyte markers listed in Table 1, including a-SMA. This may have several reasons. 
First, pericyte cross sections may be too small to be visualized. Second, they may express 
certain markers only during activation or proliferation, eg, when they are exposed to 
culture conditions This last point implies that the expression of certain markers in HBP 
may be stimulated by environmental factors. 
In situ this was observed in tissue with angiogenic properties, eg, GBM and 
placenta, in which pericytes express HMW-MAA and a-SMA, as was also noted in other 
reports [9,10,39,40] These results suggest that in situ HMW-MAA and a-SMA expres­
sion in репсу tes may be correlated with proliferation. Our in vitro results and the in situ 
observations indicate that HMW-MAA expression in HBP is induced when these cells are 
stimulated to proliferate. 
The a-SMA expression of HBP seems to be regulated by a different mechanism. 
Our results indicate that proliferation per se does not induce a-SMA expression, but that 
soluble factors may be responsible. Differences in culture conditions may therefore 
explain a number of inconsistencies in the literature concerning the a-SMA expression of 
cultured cells [4,10,19] Several factors have been described that can influence the a-
SMA expression in cells, like transfer to culture flasks [36] IFN-7 decreased the a-SMA 
expression in smooth muscle cells and fibroblasts [34,35], heparin induced a-SMA 
expression in fibroblasts [33] and TGF-/31 induced a-SMA expression in bovine and rat 
endothelial cells [24,37] and human fibroblasts [41,42]. Therefore, we studied the effects 
of these factors on the a-SMA expression in cultured HBP Of these stimulating agents, 
TGF-/31 consistently increased the number of α-SMA-positive HBP in all tested cultures 
Our data are in support of recent suggestions that TGF-/31 may be the factor re ponsible 
for the transition from fibroblast to the α-SMA-positive myofibroblast, a cell type that is 
abundantly present in granulation tissue. This transition could be induced in vitro by 
exposing fibroblasts to TGF-/31, and was antagonized by bFGF [41,42]. Although 
similarities thus exist between fibroblasts and pericytes in their regulation of a-SMA 
expression, the exact relationship between these cell types remains to be established [43] 
In the present study proliferation of HBP was partially blocked by TGF-/31 
treatment, therefore the a-SMA inducing effect of TGF-/31 was mainly due to its differen­
tiating effects, rather than to a stimulation of HBP proliferation Variable and uncon­
trolled levels of activated TGF-/3 isoforms in culture sera may explain the variations 
observed in a-SMA expression in vitro in the literature 
In normal brain tissue, HMW-MAA and a-SMA reactivity of pericytes was 
generally undetectable, which is in agreement with earlier studies [9,10,23]. In areas with 
microvascular proliferation (GBM, placenta), however, pericytes expressed a significantly 
increased level of HMW-MAA and a-SMA. The lack of a-SMA staining in pericytes in 
some tumors or in specific areas in GBM can be explained in two ways 1) Not all tumors 
produce TGF-01 and 2) TGF-/31 exists in a latent and an active form, implicating that a 
lack of a-SMA reactivity in areas of microvascular proliferation may also be the result of 
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the lack of conversion of TGF-/31 in its active form. The same may apply for placenta, 
because TGF-/31 is produced in this tissue as well [44]. Further evidence for this 
hypothesis comes from the observation that pericytes in apparently unaffected tissue 
surrounding neoplasms may contain a-SMA [9,10]. According to this theory, factors 
produced by the tumor may also diffuse into and act on its nearby environment. 
In summary, our findings suggest that TGF-/31 may be an important factor 
involved in the regulation of angiogenesis at the level of the microvascular pericyte. 
Future studies should reveal if brain tumor angiogenesis and corresponding a-SMA 
expression is associated with the production of active TGF-/3 isoforms or other activating 
agents. 
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Interferon-7 induces intracellular accumulation of 
the amyloid beta precursor protein and inhibits 
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and smooth muscle cells 
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Abstract 
The amyloid beta protein (Aß), deposited in the tunica media of leptomeningeal vessels of 
patients with dementia of the Alzheimer type (DAT), is assumed to be produced by 
smooth muscle cells Processing of the amyloid beta precursor protein (APP) into A/3 
probably occurs in an intracellular compartment after re-internalization of cell surface 
APP Primary cells derived from affected brain regions may serve as useful tools to study 
physiological APP processing We isolated and cultured smooth muscle cells from human 
leptomeningeal vessels as well as human brain pericytes from cerebrocortical capillaries 
Both these cell types are candidate for producing vascular amyloid in DAT brains and 
were therefore used to study the intracellular localization of APP and the production of its 
secreted derivatives Human microvascular endothelial cells were used as unrelated 
control cells Using immunofluorescence and immunoelectron microscopy we 
demonstrated that APP is found in both endosomes and lysosomes in pericytes and 
smooth muscle cells, and in the ER and Golgi compartments of endothelial cells The 
cytokine IFN-γ as well as the lysosomotropic drug chloroquine caused an accumulation of 
APP in multivesicular body (MVB)-like organelles, and this shift was accompanied by a 
reduced secretion of APPS It has previously been suggested that excessive A/3 production 
in DAT brains is related to abnormal intracellular APP trafficking, and our studies show 
that inflammatory mediators, such as IFN-7, may contribute to this process by 
concentrating APP in a MVB-hke compartment 
Introduction 
The brains of patients with dementia of the Alzheimer type (DAT) and hereditary cerebral 
hemorrhage with amyloidosis - Dutch type (HCHWA-D) are characterized by deposits of 
the amyloid beta protein (A/3) in senile plaques and the cerebral vascular wall [1] This 
protein of 39 to 43 amino acids is proteolytically cleaved from the large membrane-
spanning amyloid beta precursor protein (APP) [2,3] 
Normal secretory processing of the full-length 751 and 770 amino acids isoforms 
of APP results in the production of soluble APP (APPS), which is identical to protease 
nexin-2 [4,5], a process that may occur at the cell surface [6] Since the cleavage site is 
located between amino acids 16 and 17 of the A/3 sequence, this process precludes A/3 
generation However, the majority of APP molecules seems to be alternatively processed 
via an intracellular proteolytic degradation pathway, which may result in the production 
of Aß [7-10] Although the exact site of A/3 formation has not yet been identified, an 
involvement of the endosomal/lysosomal system has been suggested [11-13] Mature full-
length APP may be re-in tem ah zed from the cell surface to endosomes or lysosomes 
[13-15] to serve as a precursor molecule for A/3 production However, A/3 production 
during the secretory pathway has been suggested as an alternative mechanism [14-17] 
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In brains of DAT and HCHWA-D patients, cerebrovascular amyloidosis (CA) is 
observed in several types of cortical and leptomeningeal arteries and arterioles of the 
cerebral and cerebellar cortex [18,19], and mainly consists of A/3 fibrils deposited 
between smooth muscle cells (SMCs) in the tunica media [20,21]. The presence of APP, 
amyloidogenic C-terminal fragments of APP and, recently, non-fibnllar A/3 have been 
demonstrated in capillaries [22] and in SMCs [20,21,23], indicating that SMCs are 
involved in the generation of A/3 In capillaries, pericytes are a ubiquitous and prominent 
cell type localized abluminal to endothelial cells [24,25]. Their phenotypical relation with 
SMCs and their position close to microvascular A/3 deposits suggests that, just like SMCs, 
pericytes may be involved in amyloid formation in cerebral capillaries. 
Inflammatory processes have been implicated in the pathogenesis of DAT by the 
identification of several inflammation-associated components in senile plaques, like a,-
antichymotrypsin, complement factors and intercellular adhesion molecule-1 [26-28] In 
addition, clusters of activated microglia are present in classic senile plaques, expressing 
enhanced levels of complement receptors and the major histocompatibility complex 
(MHC) Class II molecules [29-33]. The cytokine IFN-γ is a factor capable of inducing 
MHC Class II expression, and recently it has been demonstrated that IFN-γ in 
combination with A/3 induces microglial N02 production, thereby provoking neuronal 
injury [34]. It is not known, however, to what extent IFN-7 may affect APP metabolism. 
Most of the data on APP metabolism have been gathered by studying a variety of 
APP-transfected cells that were denved from peripheral or non-human sources. It was the 
aim of this study to investigate APP metabolism in the cells that are suspect for the 
production of A/3 in the human cerebral vessel wall, i.e human brain pericytes (HBP) 
and leptomeningeal smooth muscle cells (HLSMC). Both HBP and HLSMC are sensitive 
to IFN-γ treatment, resulting in induction of MHC Class II expression [35], and are 
therefore suitable for studying the effects of IFN-γ on APP metabolism. Besides, since 
this is considered to be of crucial importance to its metabolism, we studied the 
intracellular localization of APP in these cells. 
Materials and Methods 
Cells 
Human umbilical vein endothelial cells (HUVEC) and human brain pericytes (HBP) were 
isolated and cultured as described previously [36,37]. Human microvascular endothelial 
cells (HMEC-1) were a kind gift of Dr. E. Ades (Centers for Disease Control and 
Prevention, Atlanta, GA) [38]. HLSMC were isolated by collagenase digestion (1 mg/ml, 
30 minutes, 37 °C) of dissected leptomeningeal vessels from human autopsy brain 
material (6 cases; age 69 to 90 y, post mortem delay 3 to 5 h) and subsequent seeding of 
the vessel fragments on fibronectin-coated culture plates Isolated cells were characterized 
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by positive staining for α-smooth muscle cell actin, the high molecular weight-melanoma 
associated antigen (HMW-MAA) and vascular cell adhesion molecule-1 (VCAM-1), as 
described previously for smooth muscle cells isolated from umbilical artery [36] Cells 
were treated with interferon-γ (IFN-γ, a kind gift of Boehnnger Ingelheim, Ingelheim, 
Germany) or chloroquine (Sigma Chemical Co , St. Louis, MO) where indicated 
Antibodies 
The monoclonal antibody (MAb) P2-1 (anti-APP, N-terminal) was a kind gift of Dr. 
W.E Van Nostrand (Irvine, CA) [5], MAb 12-10 (anti-МНС Class II) was a kind gift of 
Dr. W Tax (Nijmegen, The Netherlands), MAb F12 (anti-APP, C-terminal) was a kind 
gift of Dr. J.E. Gardella (Stony Brook, NY), polyclonal antibodies (PAb) directed against 
MHC Class II molecules were a kind gift of Dr H Ploegh (Amsterdam, The 
Netherlands), PAb R57 (anti-APP, C-terminal) was a kind gift of Dr D.L Miller (New 
York), PAbs directed against lamp-1 and lamp-2 (lysosomal membrane antigens) were a 
kind gift of Dr. S. Carlsson (Umeâ, Sweden) [39]. Anti-rab4 MAb was purchased from 
Santa Cruz Biotechnology (Breda, The Netherlands) 
Immunofluorescence staining of cultured cells 
Cultured cells were grown on glass slides that were previously coated with gelatin and 
treated with glutaraldehyde. At confluence, they were washed once in PBS and then fixed 
in acetone for 10 minutes and air-dried. Fixed cells were stained at room temperature as 
follows After incubation with primary antibodies for 1 h, cells were incubated with 
fluorescein-isothiocyanate (FITC)-conjugated swine anti-rabbit or sheep anti-mouse 
antibodies (Cappel, Boxtel, The Netherlands) for 30 minutes in case of primary PAbs or 
MAbs, respectively Alternatively, biotinylated horse anti-mouse antibodies in 
combination with Texas red-conjugated avidin (Vector, Burlingame, CA) was used for 
staining with primary MAbs. All dilutions were made in PBS supplemented with 0 5% 
BSA and 0.1% cold water fish skin gelatin (PBS-C) (Aunon, Wageningen, The 
Netherlands), which also served as a negative control. Each incubation was followed by 
extensive washing with PBS. For double immunostaining, cells were incubated with 
primary MAbs and PAbs simultaneously, and secondary antibodies were also incubated 
simultaneously Finally, cells were incubated with Texas red conjugated avidin as above. 
Secondary antibodies were tested for lack of cross-reactivily and non-specific binding 
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Immuno-electron microscopy (¡EM) of cultured cells 
Cells were cultured on Transwells (Costar, Cambridge, MA) and washed twice with 
serum-free medium prior to fixation For morphological examination, cells were fixed 
with 2% glutaraldehyde in PBS for 60 minutes, washed with PBS and treated with Os04 
as indicated below For IEM, cells were fixed in penodate-lysine paraformaldehyde (PLP) 
for 15 minutes, washed three times with PBS, and briefly dipped in 10% methanol in 
PBS After a wash in PBS, cells were subsequently incubated with P2-1 diluted in PBS-C 
for 2 to 4 h at room temperature, washed with PBS, and incubated with ultrasmall (1 nm) 
gold labeled goat anti-mouse F(ab')2 IgG(H + L) antibodies (Aunon) diluted in PBS С 
overnight at 4 °C and again washed in PBS Subsequently, cells were treated with 0 5% 
glutaraldehyde in PBS, washed in PBS, incubated with 0 5% Os04 in PBS, washed again 
in PBS and thoroughly washed with distilled water Silver enhancement was performed 
according to Danscher [40] tor 18 minutes, after which the cells were extensively washed 
in distilled water, dehydrated and embedded in Epon 812 Filters were dissected from the 
Transwells with a diamond knive (kind gift of Drukker, Cuijk, The Netherlands) 
Ultrathin sections were stained with uranyl acelate and examined with a JEOL 1200 EX/II 
electron microscope (Tokyo, Japan) at 50 kV 
Western blotting analysis 
Cultured cells were collected by trypsinization or scraping with a policeman and were 
lysed with lysis buffer (0 1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, 0 5% 
sodium deoxycholate, 100 μΐτιοΙ/L 4 2-(aminoethyl-benzenesulfonylfluonde), 1 mmol/L 
benzamidine, 500 IE/ml aprotinin and 20 μιτιοΐ/ΐ leupeptin in PBS) at 0 °C for 30 
minutes After centrifugation at H.OOOxg, the protein content of diluted supernatant was 
determined according to Lowry's method [41] Samples were diluted 1 1 with non-
reducing sample buffer and boiled for 5 minutes Equal protein amounts were loaded and 
fractionated on 7 5% SDS-polyacrylamide gels and subsequently electrophoretically 
transferred to a nitrocellulose membrane in blotting buffer (25 mM Tns-HCl (pH 8 6), 
192 mM glycin, 20% methanol and 0 02% SDS) Blots were washed for 15 minutes in 
PBS containing 0 05% Tween-20 (PBST), preincubated with blocking solution (5% low 
fat milk powder, 0 01% antifoam A (Sigma) in PBST) for 2 to 4 h, washed three times 
with PBST and incubated overnight with primary antibody diluted in PBST After three 
washes with PBST, blots were incubated with peroxidase-labeled rabbit anti-mouse 
antibodies (Dako, Glostrup, Denmark), in case of primary MAbs, or swine anti-rabbit 
antibodies (Dako) in case of primary PAbs (both diluted 1 2000 in PBST) for 1 to 2 h and 
washed three times in PBST Detection was performed by chemiluminescence according 
to the manufacturer's description (Boehnnger Mannheim, Almere, The Netherlands) and 
exposure to Kodak X OMAT-R films APPS levels were measured during 7 days by 
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incubating confluent cell cultures with EMEM containing 0 1% BSA [42], supplemented 
with additives where indicated Small aliquots of the culture medium were centnfuged at 
13,000xg at 4 °C for 5 minutes and the supernatant was diluted with an equal volume of 
sample buffer, subjected to electrophoresis and blotting procedures as described above. 
Samples taken from cell cultures were replaced by an equal volume of the appropriate 
fresh medium All experiments were repeated at least three times Representative 
experiments are shown 
Results 
Immunocytochemical analysis 
HBP, HLSMC, HMEC 1 and HUVEC were immunocytochemically stained with the anti-
APP MAb P2-1 This epitope could be detected after acetone fixation, but was sensitive 
to paraformaldehyde or glutaraldehyde fixation In case of paraformaldehyde fixation, the 
antigen could be retrieved by brief methanol (10%) treatment In resting HBP and 
HLSMC, APP was predominantly observed in small granules (Figure 1A,C) with a 
variable, but generally faint, reactivity of the ER and Golgi compartment In HMEC-1 
and HUVEC, APP was predominantly localized in the ER and Golgi compartment, 
illustrated by the pen-nuclear staining of these cells (Figure IE), but few intracellular 
granules were stained as well Staining for APP with MAb F12 was similar to P2-1 
staining (not shown) 
Exposure of HBP and HLSMC to the cytokine IFN-γ (200 U/ml, 3 days) resulted 
in the formation of large APP-positive intracellular granules (Figure 1B,D) Similar 
granules, but smaller in number, were also observed in ΙΡΝ-γ-treated HMEC-1 and 
HUVEC (Figure IF) APP staining of the small granules in HBP and HLSMC and of the 
Golgi compartment in HMEC-1 or HUVEC was still present after IFN γ treatment APP 
immunoreactivity in the large intracellular granules became visible after 1 day exposure to 
IFN-γ, became more abundant after 2 to 3 days of treatment and increased even further 
after prolonged exposure In cells that were treated for 3 days with IFN-γ, and 
subsequently incubated in medium without the cytokine, the large APP positive granules 
gradually disappeared within two days 
Treatment of HBP and HLSMC with the lysosomotropic drug chloroquine (10-25 
μΜ overnight or 50-100 μΜ during 1 to 4 h) resulted in a more intense staining for APP 
and an increase in the number and size of intracellular granules stained for APP (see 
below) Similar treatment of HMEC-1 also resulted in the appearance of large APP-
positive granules, but fewer than in the other cell types 
116 
Figure 1. Immunofluorescence staining of resting (A,C,E) and IFN-y-treated (200 U/ml, 3 days; 
B,D,F) cultures of HBP (A,B), HLSMC (C,D) and HMEC-l (E,F) with P2-1. Large, APP-positive 
intracellular organelles were formed in all cell types after exposure to IFN-y. Scale bar: 3 μχη. 
In all cell types, APP could not be demonstrated at the surface of resting, IFN-7-
or chloroquine-treated cells by immunofluorescence. This observation was confirmed by 
the failure to stain unfixed suspended cells with P2-1 and FITC-conjugated secondary 
antibodies. This procedure was used previously with success to analyse membrane 
expression by HBP and HUVEC of VCAM-1, HMW-MAA, MHC Class I and II 
molecules and endoglin [35,43]. 
APP immunoreactivity in multivesicular body-like organelles after exposure to IFN-y or 
chloroquine demonstrated by 1EM 
The identity of the intracellular APP-positive granules observed in resting and IFN-7- or 
chloroquine-treated cells, was investigated by using IEM. In untreated cells, APP 
immunoreactivity was scarce and was less prominent than expected from the 
immunofluorescence studies. In HBP and HLSMC, small organelles (diameter 250 to 300 
nm) were stained for APP (Figure 2A,B). In HMEC-l, ER/Golgi-like staining was not 
observed. In all cell types, the cell membrane seemed to be preserved well, but 
membrane expression of APP was not observed in any of the cell types. Both coated pits 
and coated vesicles could be identified in all cell types, but were not immuno-decorated 
for APP (Figure 2A). 
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Figure 2. Ultrastructural analysis of APP expression in cultured cells. Small organelles were 
stained by P2-1 in resting HBP (A) and HLSMC (B). Large intracellular, MVB-iike organelles in 
IFN-y-treated HBP (200 υ Imi, 3 days) (С) and HLSMC (D) were stained with P2-I. 
Morphological examination of IFN-y- (E) or chloroquine-treated (10 μΜ overnight, F) HBP 
revealed the presence of MVB-like organelles (large arrows in E,F). Also coated pits and coated 
vesicles (arrowheads in E,F), non-coated vesicles (small arrows in E,F) and irregularly shaped 
organelles are visible. Note that in A and D coated pits and coated vesicles (arrowheads) 
remained unstained in resting and IFN-y-treated cells. Scale bar: 0.5 μτη. 
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Figure 3. Double-immunostaining 
of resting cultured cells with P2-1 
and anti-lamp-1. In HBP (A,B) and 
HLSMC (C,D) P2-1 staining (A,C) 
partially overlaps with lamp-1 
staining (B,D), but many 
organelles only stained with P2-I 
are visible (arrows). Scale bar: 3 
pm. 
In IFN-7-treated cells (200 U/ml, 3 days), especially in HBP and HLSMC and to 
a minor extent in HMEC-1, large organelles (diameter 500 to 1000 nm) were immuno-
gold-labeled with P2-1 (Figure 2C,D). In glutaraldehyde-fixed cells, with a more optimal 
preservation of the cell morphology than PLP-fixed cells, these large organelles showed 
many vesicular inclusions, resembling a multivesicular body (MVB)-like appearance 
(Figure 2E). The immunogold labeling representing APP was not confined to the 
organelle's outer membrane, but was predominantly found within the organelle. Again, 
like in untreated cells, APP immunoreactivity was not observed at the cell surface of IFN-
γ-treated cells. The number of coated pits and coated vesicles in IFN-7-treated cells was 
markedly increased compared to untreated cells. Like in resting cells, all these coated 
structures remained unstained for APP (Figure 2D). 
Treatment of the cells with chloroquine (10 μΜ, overnight) caused a marked 
dilatation of the ER, an increased incidence of coated and non-coated vesicles and the 
formation of irregularly shaped intracellular organelles, probably swollen lysosomes, in 
HBP and HLSMC (Figure 2F), but not in HMEC-1. Similar to as has been observed after 
IFN-γ treatment, large intracellular organelles were found in chloroquine-treated cells 
(Figure 2F), especially in HBP and HLSMC, but only sporadically in HMEC-1. These 
MVB-like organelles were immunodecorated for APP, but coated pits and vesicles 
remained unstained with P2-1 (not shown). 
APP immunoreactivity in lysosomal and поп-lysosomal organelles 
To identify the nature of the APP containing granules, all three cell types were stained 
with PAbs against lamp-1, lamp-2, a-glucosidase, rab4 and MHC Class II molecules. 
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Figure 4. Double-immunostaining of IFN-y-treateâ (200 Olmi, 3 days) cultured cells with P2-Ì 
and anti-lamp-1. In IFN-y-treated HBP (A,B), HLSMC (C,D) and HMEC-1 (E,F) large 
intracellular, MVB-like organelles stained with P2-1 (arrows in A,C,E), but remain unstained for 
lamp-1 (B,D,F). Scale bar: 3 μτη. 
Both anti-lamp-1 and anti-lamp-2 antibodies stained small intracellular organelles, 
putatively lysosomes, in all cell types. Staining with anti-lamp-1 was stronger than with 
anti-lamp-2 and staining for each of these antigens was more abundant than for a-
glucosidase. All resting cells failed to express MHC Class II molecules. Double-
immunostaining of resting HBP and HLSMC, revealed that lamp-1-or lamp-2-positive 
lysosomes were more numerous than P2-1 -positive organelles. Most of the P2-1-positive 
organelles were negative for lamp-1 (Figure 3A-D), but sometimes P2-1 staining 
overlapped with lamp-1 (or lamp-2) staining. 
Treatment with IFN-γ increased the number of lamp-1- or lamp-2-positive 
organelles. Double-labeling showed that the large APP-positive organelles that were 
formed after IFN-γ treatment of HBP and HLSMC remained unstained for lamp-1 or 
lamp-2 (Figure 4A-D). In HMEC-1, double-immunolabeling with P2-1 and anti-lamp-1 or 
with anti-lamp-2 revealed that clearly distinct cellular compartments were stained in both 
control (not shown) and IFN-7-treated cells (Figure 4E,F). Double-staining of resting or 
IFN-7-treated HBP, HLSMC and HMEC-1 with an antibody directed against a-
glucosidase revealed that APP staining did not overlap with staining for this lysosomal 
enzyme (not shown). Exposure to IFN-γ induced MHC Class II expression in a 
subpopulation of the three cell types. Apart from membraneous staining, that was 
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Figure S. Double-immunostaining 
of chloroquine-treated (25 μΜ, 
overnight) cultured HBP (A,B) and 
HLSMC (C,D) with P2-1 (A,C) and 
anti-lamp-1 (B,D). P2-1 staining 
partially overlaps with lamp-1 
staining, but many organelles only 
stained with P2-1 and not for lamp-
1 can be readily identified. Scale 
bar: 3 μτη. 
confirmed by flow cytometry analysis, intracellular organelles were immuno-positive, but 
these were much less abundant than lamp-1-positive lysosomes. However, all MHC Class 
Il-positive organelles also expressed lamp-1 and were therefore considered lysosomal (not 
shown). P2-1 staining partially overlapped with intracellular MHC Class II staining in 
IFN-7-treated HBP and HLSMC cultures, but not in HMEC-1, just like observed for P2-
1/lamp-l double-staining. The APP-positive large intracellular organelles in IFN-7-treated 
cells were not stained for MHC Class II. Rab4-positive organelles in HBP or HLSMC 
resembled ER or Golgi-like staining, and did not colocalize with P2-1 staining. 
Exposure to chloroquine resulted in swelling of the lysosomes as observed with 
staining for lamp-1. After exposure of HBP or HLSMC to chloroquine (10 to 25 μΜ, 
overnight), P2-1 and lamp-1 staining partially overlapped, but organelles that were only 
stained with P2-1, especially the large APP-positive granules, were frequently observed 
(Figure 5A-D). Similar treatment of HMEC-1, revealed that P2-1 staining did not overlap 
with lamp-1 staining (not shown). 
IFN-y enhances intracellular APP protein levels in HBP, HLSMC and HMEC-1 
Western blotting analysis of cell lysates showed that all cell types expressed APP as a set 
of three proteins. The predominant APP isoform had a relative molecular weight (M
r
) of 
approximately 105 kDa and two minor isoforms with M
r
 of approximately 120 kDa and 
125 kDa were also present. APP expression in HBP, HLSMC and HMEC-1, as detected 
by P2-1, was elevated after exposure to IFN-γ (Figure 6A). Some blots were stripped 
with SDS and 0-mercaptoethanol at 55 °C and re-probed with the anti-C-terminal 
antibodies R57 or F12, with identical results (not shown). The IFN-7-mediated increase 
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Figure 6. Western blot analysis of APP levels in cell lysates. ¡FN-y treatment (200 U/ml during 3 
days) enhanced APP protein levels in HBP, HLSMC, HMEC-1 and HUVEC cultures (A). After 
prolonged exposure of the Western blot of HMEC-I also the 120 and 125 kDa isoforms of APP 
could be identified (not shown). The increase in APP protein levels induced by IFN-y is both dose 
dependent (B) and time dependent (C) (results for cultured HBP are shown as example). The 
lower panels of В and С represent the densitometric quantification of the smallest APP isoform 
from the Western blots in the upper panels. Molecular weights of the marker proteins are 
indicated at the right of each blot in kDa. 
in APP levels of HBP was dose dependent (Figure 6B) and most clearly observed after 
prolonged treatment (24 h or longer, Figure 6C). 
Chloroquine treatment (10 to 25 μΜ, overnight) resulted in a comparable increase 
in the APP content of HBP and HLSMC cultures, but had no effect on APP levels in 
HMEC-1 cultures (not shown). 
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Figure 7. Western blot analysis of APPS secretion by cultured HBP and HLSMC. Increasing levels 
of secreted APPS were recovered from the culture supernatant from HLSMC during 6 days (A). 
Densitometrie quantification of APPS secreted by cultured HBP (B,C). Secreted APPS is reduced by 
treatment with either ¡FN-y (B) or chloroquine (C). Molecular weights in kDa of the marker 
proteins and day of sampling are indicated in panel A. 
IFN-y treatment inhibits APP secretion by HBP and HLSMC 
The amount of APP secreted in the culture supernatant (APPS) was determined in serum-
free medium, but, since survival of both HMEC-1 and HUVEC was not compatible with 
these culture conditions, we concentrated on HBP and HLSMC cultures only. SDS-PAGE 
analysis showed that in supernatants of either culture APPS appeared as two bands with Mr 
of approximately 115 kDa. During a 5 day-period or longer, increasing levels of APPS 
were recovered from the culture supernatant (Figure 7A). Exposure to IFN-7 resulted in a 
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marked decrease of APP, production in both HBP and HLSMC cultures between 1 and 7 
days (Figure 7B). Chloroquine treatment (10 μΜ) resulted in a similar decrease of APPS 
production in 4 out of 5 HBP cultures and in 4 out of 5 HLSMC cultures, which was 
most prominent after 3 to 7 days incubation (Figure 7B). In the remaining cultures no 
effect of chloroquine was observed 
Discussion 
This study demonstrated that in cultured HBP and HLSMC an intracellular re-organisation 
of APP is accompanied by a change in the metabolic fate of this molecule. Under resting 
conditions in either cell type only a part of the full-length APP, that was identified with 
both C- and N-terminal antibodies and had a molecular weight compatible with previous 
reports on SMCs [20,42,44], was localized in lysosomes, but the majority of APP was 
expressed in organelles lacking lysosomal markers, that may represent endosomal 
vesicles. In HMEC-1 and HUVEC, however, APP was primarily localized in the 
ER/Golgi compartment, consistent with previous findings [13]. 
Especially in HBP and HLSMC the cytokine IFN-7 caused a shift of APP 
reactivity to a type of organelle that morphologically showed much resemblance to 
multivesicular bodies (MVBs). MVBs have been described before in cultured HUVECs 
[45] and arterial SMCs [46] and the diameter of these organelles was compatible with 
previous reports [47] In contrast to a previous description of lamp-1 reactivity in MVBs 
[39], the MVB-like organelles in our cells were not labeled for this lysosomal marker 
However, lamp-1 reactivity of MVBs has been described to be a function of MVB 
maturation [47], therefore it is possible that the MVB-like organelles in our cell types are 
of an immature type The shift of APP expression to these organelles was not an aspecific 
reallocation of membrane proteins after IFN-7 treatment, since induction of MHC Class 
II expression in the three cell types by IFN-γ resulted in intracellular accumulation of 
MHC Class II molecules in lysosomes. Besides the shift in APP localization, IFN-γ also 
caused an increase in cellular APP content as well as a marked reduction of APPS 
production. Because the M
r
 of APP, (app. 115 kDa) was higher than that of the smallest 
cellular APP isoform, we assumed that the latter is the non-glycosylated, immature form 
of APP770 and that the major secreted form is mature ΑΡΡπ ο. 
Exposure of several cell types to the lysosomotropic drug chloroquine has been 
described to result in the exclusive accumulation of APP in lysosomes, leading to an 
increase in cellular APP, but leaving its secretion unaffected [16,48] In line with these 
observations, intracellular APP was raised in HBP and HLSMC, whereas in HMEC-1 this 
was not the case In contrast, however, APP, secretion by HBP and HLSMC was 
decreased and furthermore, chloroquine treatment of HBP, HLSMC or HMEC-1, did not 
result in exclusive accumulation of APP in lysosomes since also numerous other non-
lysosomal vesicles contained APP. It is very well possible that chloroquine not only 
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affects lysosomal functioning, but also raises the internal pH of acidic endosomal vesicles 
[49] resulting in the accumulation of APP in these compartments. 
Several models for APP processing have been proposed in recent years. In all 
these models APP is supposed to be, at least partially, expressed at the cell surface, 
where secretase cleavage results in APP, formation [6] and the remaining C-terminal 
fragment is internalized via the endosomal-lysosomal system Furthermore, it has been 
demonstrated that at least part of the full-length APP is recycled from the cell surface to 
intracellular transport vesicles, thus providing a substrate for intracellular A/3 formation. 
We were not able to demonstrate expression of APP at the cell membrane of our cells. 
This may either indicate that only a small fraction of full-length APP is expressed at the 
cell surface, which is in line with previous reports [9,10], or that the residence time of 
APP at the cell surface is very short due to rapid internalization or secretion It seems 
unlikely that our detection methods are not sensitive enough to detect low levels of 
surface-bound APP, since our immunofluorescence techniques have previously been used 
to identify several cell surface markers of HBP and other cell types [35]. Furthermore, 
although our IEM procedures did not preserve all structures expected to contain APP, like 
the ER and Golgi compartments, in HLSMC treated with A/31-42 (25 μΜ, 12 days) APP 
lmmunoreactivity was readily and predominantly observed by us at the cell surface by 
IEM analysis (unpublished observations), indicating that the absence of APP membrane 
expression is not artifactual. It has been suggested that reinternalization of cell surface-
APP is mediated by clathnn-coated pit formation [13,14,50] Although coated pits and 
coated vesicles were frequently observed by IEM in our cells, especially after IFN-7 and 
chloroquine treatment, they were consistently APP-negative Although it can not be 
excluded that some APP is transported in coated vesicles, these data indicate that this 
pathway is probably of minor importance in HBP, HLSMC or HMEC-1 In line with a 
recent report describing the co localization of APP with markers of fluid phase 
endocytosis [51], we consider it more likely that such a non-specific endocytotic 
mechanism occurs in HBP/HLSMC with regard to APP internalization, but this awaits 
further investigation. Our data indicate that inflammatory mechanisms, that are known to 
occur in DAT brains, may alter APP metabolism, possibly contributing to DAT 
pathology 
MVBs have been described to be a type of late endosomes, that may be formed 
by fusion of individual early endosomes, and that may acquire lysosomal characteristics 
by fusion with lysosomes [47]. MVBs thus form an intermediate in the endocytic 
transport of proteins from the cell surface to intracellular transport vesicles The role of 
MVBs in APP metabolism has been discussed in a few reports It has been suggested that 
the APP-positive organelle involved in retrograde axonal transport in cultured neurons 
may be a type of MVB [51], and the MVB may be the major type of organelle involved 
in transport of endocytosed marker proteins [52] Besides, Caporaso [48] described APP 
reactivity in medium-sized invaginated vesicles in rat neuronal axons and dendrites that 
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bear similarities to MVB. An intriguing aspect of MVBs may be their functioning as a 
sorting compartment, in which internalized molecules may be released from the MVB 
membrane, thus being exposed to proteolysis, whereas other proteins remain associated 
with the membrane and can be recycled to the cell surface [53,54]. In case of APP 
processing this may provide a means by which APP is released from the membranes 
allowing processing to A/3 in acidic compartments of the cell. Exposure to IFN-7 or 
chloroquine leads to an increased accumulation of APP in MVB-like organelles, thus 
allowing more APP to be diverted into the A/3 production pathway. It remains to be 
established whether this is indeed the case, since we were yet unable to determine A/3 
secretion by these untransfected HBP and HLSMC cultures. 
Although studies on APP metabolism in several artificial cell systems have 
provided important data, it is not certain whether the proposed mechanisms for APP 
trafficking and degradation are pathophysiological^ relevant. It is clear that CA and 
senile plaques are formed by different cell types. However, APP may be localized in 
different cellular compartments in various cell types, variations may exist in the routes by 
which APP is internalized and different cell types may respond differentially to external 
stimuli like chloroquine. Therefore, more study on the APP metabolism in cells derived 
from human brains, like vascular cells as a model for CA formation on the one hand and 
neuronal or glial cells as model for senile plaque formation on the other, will be required 
to provide more insight into the pathogenesis of DAT and HCHWA-D. 
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Abstract 
Τ cell adhesion to the brain microvascular endothelium and subsequent migration into the 
brain parenchyma is one of the major events in the development of multiple sclerosis 
(MS) Interactions of the Τ cell integrin very late antigen-4 (VLA 4) with its receptor 
vascular cell adhesion molecule-1 (VCAM-1) have been described to be of crucial 
importance for the development of MS We investigated the expression of these adhesion 
molecules in MS brain tissue by immunohistochemical analysis, and studied their 
functional involvement in an in vitro Τ cell adhesion assay A number of other adhesion 
molecules was studied for comparison In cryosections of several MS brains, expression 
of VCAM-1 was demonstrated not only on the endothelium of vessels surrounding MS 
plaques, but also tn perivascular positions, suggesting expression by pericytes Τ cells 
adhered to both cell types in vitro Both leukocyte function-associated antigen (LFA) 
1/intercellular adhesion molecule (ICAM) 1 and VLA-4/VCAM 1 interactions were 
equally involved in the adhesion of Τ cells to TNF-a-stimulated endothelial cells 
However, adhesion of Τ cells to TNF-a-stimulated pericytes was clearly dominated by 
VLA-4/VCAM 1 interactions These results indicate that pericytes, next to endothelial 
cells, may play an important role in regulating Τ cell infiltration into the central nervous 
system 
Introduction 
Τ lymphocyte infiltration into the brain is a key phenomenon in multiple sclerosis (MS) 
[1,2] and human Τ lymphocytic virus type 1 (HTLV-1) associated myelopathy [3,4] 
Acute MS lesions are characterized by the infiltration of Τ and В lymphocytes and 
macrophages into the central nervous system (CNS) representing a local inflammatory 
reaction [1,2,5] Adhesion molecules expressed by the brain microvasculature have been 
described to play a crucial role in the extravasation of Τ lymphocytes Indeed, an 
important role has been assigned to the Τ lymphocyte adhesion molecule very late 
antigen-4 (VLA-4) and its receptor vascular cell adhesion molecule-1 (VCAM-1) [6 8] in 
MS, and in mice suffering from experimental allergic encephalitis (EAE), an experimental 
model with symptoms very similar to MS The expression of VLA 4 is essential for Τ 
cell entry in the brain [9] and the seventy of EAE could be reduced by blocking Τ cell 
infiltration with antibodies directed against the α-chain of VLA-4 [6,9] Furthermore, the 
interaction of VLA-4 with VCAM-1 induced the expression of a Τ cell gelalinase, 
facilitating Τ cell infiltration into the brain [10] 
Massive Τ cell infiltration in the MS brain parenchyma is accompanied by 
breakdown of the blood-brain barrier (BBB) The BBB is primarily formed by the 
capillary endothelial cells, but pericytes, next to astrocytes, may play an important role in 
maintaining this specialized barrier function [11-14] Pericytes are cells localized at the 
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abluminal side of the microvascular endothelium and, with their long processes, have 
close contact with endothelial cells through pores in the basal lamina [15-17] Via these 
cell-cell contacts, they may modulate endothelial cell functions, such as microvascular 
permeability [17-20] Thus, the extravasation of blood nutrients and cells through the 
BBB may, at least in part, be regulated by pericytes 
Using an immunohistochemical analysis of MS brain tissue and an in vitro Τ cell 
adhesion assay, we studied the adhesion molecules expressed by Τ cells that are 
functional in the interaction with their counterstructures expressed by endothelial cells and 
pericytes We found that Τ cell adhesion to cultures of endothelial cells is mediated 
through the interaction of both the leukocyte function-associated antigen LFA-1 with its 
receptor intercellular adhesion molecule-1 (1CAM-1) and through VLA-4/VCAM-1 
interactions, whereas in Τ cell adhesion to pericytes, isolated from human brain 
microvessels, VLA-4/VCAM 1 was the predominant pathway These results indicate that 
pericytes, next to endothelial cells, may play an important role in regulating or guiding Τ 
cell infiltration into the brain 
Materials and Methods 
Immunohistochemical analysis 
Acetone-fixed cryosections (6 /¿m) from frozen tissue on aminopropyltnetoxysilane-coated 
glass slides were stained indirectly with the indicated primary monoclonal antibodies 
(MAbs, Table 1) using peroxidase-labeled rabbit anti mouse antibodies (Dako, Glostrup, 
Denmark) as secondary antibodies, or, alternatively, by using the ABC detection kit 
(Vector, Burlingame, CA) according to the manufacturer's description, and the chromo-
gen diaminobenzidin, essentially as described previously [21,22] Incubation with the 
polyclonal anti-collagen IV antibody was followed by successive incubations with swine 
anti-rabbit antibodies (Dako) and the peroxidase anti-peroxidase complex (Dako) Sections 
were counterstained with hematoxylin Tissue samples of white matter from 4 different 
MS brains (age 41 to 63 years, post mortem delay 4 5 to 7 5 h) and Alzheimer brains 
were obtained from the Netherlands Brain Bank, Amsterdam (Coordinator Dr R Ravid) 
Pericytes and endothelial tells 
Human brain pericytes (HBP) were isolated and characterized as described previously 
[22] Brain tissue material used for the isolation procedure was obtained after a rapid 
autopsy procedure (post mortem delay between 2 and 6 h) from the following cases four 
cases of senile dementia of the Alzheimer type (age 81 to 94), one case of a 
cerebrovascular accident (age 85), one case of an unidentified metabolic disorder (age 49) 
and one neuropathologically unaffected case (age 81) 
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Tabel 1. Antibodies used in immunohistochemistry, immunofluorescence and inhibition assays 
Antibody Antigen (CD) Origin (Reference) 
NKI-L12 
TS1/18 
TS2/18 
Ti l 
10C7 
HP2/1 
4B4 
RR1/1 
F7 16 1 
6D5 
CBR-IC2/2 
TS2/9 
AICD58 
4B9 
ENA-1 
BB1 
WT44 
W6/32 
12 10 
WT1 
WT31 
PN-E2 
2A7 
Coll IV 
LFA-la (CDПа) 
LFA-1/3 (CD 18) 
CD2 
CD2 
CD2 
VLA-4a (CD49d) 
VLA-4/3 (CD29) 
ICAM-1 (CD54) 
ICAM-1 (CD54) 
ICAM-2 (CD102) 
ICAM-2 (CD 102) 
LFA-3 (CD58) 
LFA-3 (CD58) 
VCAM-1 (CD 106) 
E-Selectin (CD62E) 
B7/BB1 (CD80) 
CD44 
MHC class I 
MHC class II 
CD1 
TCR 
Endoglin(CD105) 
HMW-MAA 
Collagen IV 
Prof Dr CG Figdor, University Hospital Nijmegen, 
Nijmegen, The Netherlands 
ATCC, Rockville, MD 
ATCC, Rockville, MD 
Coulter Corporation, Hialeah, FL 
Dr S C Meuer, Deutsches Krebsrorschungszentrum, 
Heidelberg, Germany 
Dr F Sánchez-Madrid, Universidad Autonoma de Madrid, 
Madrid, Spain [46] 
Coulter Corporation, Hialeah, FL 
Dr R Rothlein, Boehringer Ingelheim, Ridgefield, CO 
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Our laboratory [25] 
Our laboratory [22] 
Cappel (Boxtel, The Netherlands) 
Endothelial cells (HUVEC) were isolated from human umbilical cord vein after 
collagenase treatment essentially as described by Jaffe [23] HBP and HUVEC were 
subcultured at 37°C and 5% C 0 2 in Eagle's modified essential medium (EMEM) 
supplemented with 10% heat inactivated human serum, 20% newborn calf serum (NCS, 
Gibco, Paisley, Scotland), 2 mM glutamine (Flow Laboratories, Richmansworth, UK), 
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150 /íg/ml endothelial cell growth factor (isolated from calf brain) [24], 5 U/ml heparin 
(Organon Teknika, Boxtel, The Netherlands) and 40 ^g/ml gentamycin (Schenng-Plough, 
Amstelveen, The Netherlands) in fibronectin-coated tissue culture flasks (Costar, 
Cambridge, MA) [22,25] Cells were detached from culture flasks using a solution of 
0 125% trypsin (Difco, Detroit, MI) and 0 2% EDTA in PBS Passages 6 to 12 (HBP) or 
3 to 9 (HUVEC) were used, and no effect of passage number was observed in our 
experiments 
Τ cells 
Leukocyte-ennched cell suspensions were obtained by cytapheresis of healthy volunteers 
as described previously [26] PBMC were isolated by centnfugation on Ficoll (density 
1 077 g/ml, Pharmacia, Uppsala, Sweden), and monocytes and lymphocytes were 
subsequently separated by counterflow centnfugation Τ cells were isolated from 
lymphocyte fractions by two cycles of rosetting with 2-aminoisothio-uronium bromide-
treated sheep erythrocytes and were cryopreserved in liquid nitrogen until use [26] 
Flow cytometry analysis 
HBP were treated with TNF-a (50 ng/ml) or IFN γ (200 U/ml) (kind gifts of Boehnnger 
Ingelheim, Ingelheim, Germany) for 48 to 72 h where indicated The cells were detached 
from culture flasks by treatment with 0 02% EDTA and subsequent scraping The cells 
were washed with PBS containing 1% BSA and 0 1% NaN3 (washing buffer) and 
incubated in suspension with antibodies at 10s cells per incubation The MAbs used in this 
study and their origin are listed in Table 1 After removing unbound antibodies with 
washing buffer, cells were incubated with FITC-conjugated sheep-anti-mouse F(ab')2 
fragments (Cappel, Organon Teknika) Finally, the cells were fixed in 1% 
paraformaldehyde and analysed with a flow cytometer (Coulter Corporation, Hialeah, 
FL) 
Τ cell adhesion assay 
HBP and HUVEC were grown to confluence on gelatin coated 96-well culture plates and 
were treated with TNF-a (50 ng/ml) for 28 to 48 h where indicated The cells were fixed 
with 0 025% glutaraldehyde to prevent cell detachment, washed three times with PBS and 
stored at -20CC until usage Τ cells were thawed, and washed in EMEM containing 10% 
NCS Subsequently, the Τ cells were labeled with MCr at 37°C for at least 2 h, followed 
by three washes with PBS containing 10% NCS Before the addition of the labeled Τ cells 
(50 μΐ/well, containing 105 cells), an equal volume ol PBS/10% NCS was added to the 
culture wells Τ cells were allowed to adhere to the HBP or HUVEC for 1 h at 37 °C 
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Where indicated, the following additions were made. PMA (0.1 to 1 Mg/ml) was added to 
the Τ cells at the start of the adhesion period. Mn++ (2 mM) was added to the wells for 
the final 15 minutes of the adhesion period. The concentration of Mn+ + was chosen on 
the basis of a previous study [27]. In the inhibition assays, HBP or HUVEC were 
preincubated with the appropriate MAbs (Table 1) for 2 h at 4°C. Τ cells were 
preincubated with the appropriate MAbs for 30 minutes at 0°C to prevent internalization 
or shedding of the MAbs. In these inhibition experiments the plates were incubated with 
51Cr-labeled Τ cells at 0°C for 30 minutes prior to incubation at 37°C for another 30 
minutes. After the adhesion period the plates were washed three times with PBS/10% 
NCS to remove non-adherent Τ cells. Adherent Τ cells were lysed with Triton X-100, and 
the samples were analysed in a gamma counter. Each experiment was calculated as the 
mean of triplicate measurements. No differences were observed in the effects of different 
MAbs directed against the same antigen. 
Results 
Immunohistochemistry 
We performed an immunohistochemical analysis of a limited number of MS cases, 
focusing on adhesion molecules expressed by Τ cells and vascular cells. The brain 
specimens investigated contained chronically active lesions as demonstrated by the 
presence of CD2-positive Τ cells around blood vessels at the edge of the plaques (Figure 
1A). Of these Τ cells, the majority expressed CD8 (Figure IB) rather than CD4 (not 
shown). Also VLA-4 expressing Τ cells (Figure 1С) were more abundant than LFA-1-
positive Τ cells (not shown). VCAM-1 expression was found in a number of vessels 
surrounding the plaques, also extending into nearby grey matter. Careful examination of 
this vascular staining revealed not only that the endothelium was stained, but also that 
perivascular staining could be observed, indicating expression by pericytes (Figure ID). 
As expected, the VCAM-1-positive pericytes were enveloped by a basement membrane, 
visualized by collagen IV staining, as demonstrated by serial section analysis (Figure 
2A,B). In contrast, in brains of control cases or in unaffected areas of MS brains, 
VCAM-1 staining was absent. ICAM-1 and, to a lesser extent, LFA-3 were expressed at 
high levels all over the MS plaques. Vessels within or surrounding the MS plaques were 
only moderately stained for either antigen (not shown). E-selectin staining was absent in 
all cases. 
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Figure 1. Immunohistochemical staining of MS brain cryosections (white matter). Staining of 
perivascular Τ cells for CD2 (A, arrows), CD8 (B, arrows) and VLA-4a (C, arrows). Staining of 
endothelial cells (arrows) and pericytes (arrowheads) for VCAM-1 (D). Magnifications: xS50. 
Expression of membrane antigens on HBP 
Before studying the interactions between Τ cells and HUVEC or HBP, we examined the 
expression of several adhesion molecules on HBP by flow cytometry analysis (Figure 3). 
Flow cytometry analysis of these membrane molecules by HUVEC has been described 
elsewhere [25,28,29]. Unstimulated HBP expressed HLA class I, ICAM-1, VCAM-1 and 
the TGF-/3-binding molecule endoglin (CD 105). Treatment of HBP with TNF-a resulted 
in an increased expression of HLA class I, ICAM-1 and VCAM-1, but had a slightly 
negative effect on endoglin expression. Similar treatment with IFN-γ induced HLA class 
II expression by HBP, and increased HLA class I and ICAM-1 expression, whereas 
VCAM-1 and endoglin expression remained unaffected. 
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Figure 2. lmmunohistochemical staining of serial MS brain cryosections (white matter). Staining 
of pericytes for VCAM-1 (A, arrows) and of basement membrane for collagen IV (B). Note the 
strong staining of the Inner basement membrane for collagen IV (B, arrowheads) and weaker 
staining of the outer basement membrane, enclosing the pericyte cell body (B, arrows). 
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Figure 3. Flow cytometry analysis 
of HBP membrane antigen 
expression. HBP were cultured for 
48 to 72 h In the absence (solid 
lines) or in the presence of TNF-a 
(50 ng/ml, broken lines) and ¡FN-y 
(200 U/ml, dotted lines). TNF-a 
E N D O G L I N increased the expression of HLA 
class I, ICAM-1 and VCAM-1 
molecules by HBP, and slightly 
decreased endoglin expression. 
IFN-y induced HLA class II 
expression and enhanced ICAM-1 
expression by HBP. 
log fluorescence intensity -»• 
LFA-3, CD44 and the high molecular weight-melanoma associated antigen (HMW-MAA) 
(a staining marker for HBP) were constitutively expressed by HBP, and remained 
unaffected by cytokine treatment (not shown). Furthermore, HBP did not express ICAM-
2, E-selectin or B7/BB1, and expression of these molecules was not induced by exposure 
to cytokines (not shown). 
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нвр HuvEc Figure 4. The effect of stimulating agents on Τ cell 
adhesion to HBP and HUVEC. Each bar 
represents the percentage of Τ cells that adhered to 
HBP (black bars) or HUVEC (shaded bars). TNF-
a was added to the HBP and HUVEC cultures for 
28 to 48 h; Mn** (2 mM) was added during the 
final 15 minutes of adhesion and PMA (0.1 to 1 
μg/ml) was added prior to the start of the 
adhesion. The number of experiments in each 
group is indicated beside each bar. The mean ± 
SD of these values is shown. Statistical analysis 
was performed using Student's t-test. Level of significance of the difference with control values is 
indicated as follows: *, p<0.05; **, p<0.01; ***,p<0.001; not indicated: p> 0.05. 
Adhesion of Τ cells to confluent cultures of HBP and HUVEC 
TNF-a-stimulated HBP expressed high levels of various adhesion molecules that are 
known to mediate interactions between Τ cells and endothelial cells. We compared the 
capacity of Τ cells to adhere to HBP or HUVEC. A small number of Τ cells (3-4%) 
adhered to unstimulated HBP or HUVEC (Figure 4). Stimulation of HBP or HUVEC 
with TNF-a resulted in a threefold increase of Τ cell adhesion. Activation of Τ cells had 
a more profound effect on adhesion, however. Treatment with the phorbol ester PMA 
resulted in a three- to fourfold increase of Τ cell adhesion, and applying both PMA and 
TNF-a resulted in а 8- to 10- fold increase in Τ cell adhesion. Τ cell adhesion to either 
cell type was strongly augmented when Τ cells were treated with the divalent cation 
Mn + + which, upon binding, results in the activation of Τ cell integrins [27,30]. Of the 
Mn + +-stimulated Τ cells, 25% or 35% adhered to unstimulated HUVEC or HBP, 
respectively (eightfold increase). Moreover, 60% of these cells adhered to TNF-a-
stimulated HUVEC or HBP (20-fold increase, see Figure 4). 
The effect of M n + + treatment seemed to be time dependent. Τ cell adhesion to 
TNF-a-treated or untreated HBP or HUVEC increased sharply between 0 and 15 minutes, 
reached maximal values between 15 and 45 minutes, and slowly declined again (not 
shown). On the basis of these results, additional experiments were performed with Τ cells 
treated with M n + + for 15 to 20 minutes. 
VLA-4/VCAM-1 interactions in the adhesion of Τ cells to HBP 
The most striking difference in expression of adhesion molecules between HBP and 
HUVEC was the basal expression of VCAM-1 on the former cell type. This prompted us 
to investigate whether Τ cell adhesion to HUVEC or HBP could be related to specific 
interactions between adhesion molecules on either cell type. 
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Figure S. The effect of inhibitory MAbs in Mn' *-stimulated Τ cell adhesion to TNF-a-treated HBP 
(black bars) or HUVEC (shaded bars). A: The effect of anti-T cell MAbs. Control Mabs (WT1, 
WT31, not shown) slightly stimulated Τ cell adhesion to HBP (9%) or inhibited adhesion to 
HUVEC (4%). B: The inhibitory effect of anti-HBFVHUVEC MAbs. Control MAbs were PN-E2 
and 2A7. C: The inhibitory effect of combinations of anti-T-cell and anti-HBP/HUVEC MAbs. D: 
The inhibitory effect of a combination of anti-T cell MAbs (directed against LFA-1, VLA-4 and 
CD2), a combination of anti-HUVEC/HBP MAbs (directed against ICAM-1, ¡CAM-2, LFA-3 and 
VCAM-1) and a mixture of all these MAbs. The number of experiments is indicated beside each 
bar. The mean ± SD of these measurements is shown. Statistical analysis was performed as 
described in the legend of Figure 4. In D, all p-values were < 0.001. 
Adhesion of Mn++-stimulated Τ cells to TNF-a-treated HBP or HUVEC could be 
partially inhibited by MAbs against the a- or 0-chain of LFA-1 and the α-chain of VLA-
4, whereas an anti-VLA-4/3 MAb only had a minor effect (Figure 5A). Moreover, the 
contribution of LFA-1 in Τ cell adhesion to HUVEC seemed to be more important than in 
Τ cell adhesion to HBP. Also, the contribution of the LFA-1 receptor ICAM-1 seemed to 
be higher in Τ cell adhesion to HUVEC than to HBP (Figure 5B), whereas VCAM-1 
seemed to play an equal role in Τ cell adhesion to either cell type. Neither ICAM-2 nor 
LFA-3 seemed to be involved in Τ cell adhesion to HUVEC or HBP. Conversely, by 
using MAbs directed against the counterstructure of LFA-3, i.e. CD2, a small, but 
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insignificant, inhibitory effect was observed in Τ cell adhesion to HUVEC (Figure 5A) 
only 
The use of combinations of MAbs directed against couples of adhesion molecules, 
revealed that VLA-4/VCAM-1 interactions formed the major route for Τ cell adhesion to 
HBP, whereas LFA-1/ICAM and VLA-4/VCAM-1 interactions contributed equally to the 
adhesion of Τ cells to HUVEC (Figure 5C) CD2/LFA 3 interactions were marginally 
involved in Τ cell adhesion to HUVEC, but not to HBP When combinations of anti-
ICAM-1 and/or anti-LFA-la and β MAbs were applied in the inhibition assays an 
unexpected effect on the adhesion of Τ cells to HBP or HUVEC was observed, compared 
with anti-LFA-la MAbs alone (Figures 5A,C) The inhibitory effect was reduced from 
36% to 8% (HBP) and from 58% to 45% (HUVEC), which remains unexplained 
By using a combination of all our MAbs against Τ cell adhesion molecules, the 
adhesion to HBP or HUVEC could be blocked for 70% or 80%, respectively Inhibition 
was 63% and 84%, respectively, when a mixture of anti-HBP or anti-HUVEC MAbs was 
applied Combining these MAb mixtures resulted in a 85% inhibition of the adhesion to 
either cell type (Figure 5D) 
Similar to the adhesion of Τ cells to TNF-a-treated HBP or HUVEC, we observed 
a tendency towards the involvement of VLA-4/VCAM-1 interactions in Mn++-stimulated 
Τ cell adhesion to unstimulated HBP, but these experiments did not result in significant 
differences in adhesion values, because of the low numbers of Τ cells that adhered to 
unstimulated HBP or HUVEC (results not shown) 
Discussion 
Extravasation of Τ cells into the brain parenchyma requires interaction of Τ cell adhesion 
molecules with their counterstructures expressed by the cells constituting the brain 
microvasculature Endothelial cells are the main constituents of the BBB, but pericytes 
may play a complementary role in its maintainance [11 14] After initial close interaction 
with the endothelial cells, Τ cells have to migrate along pericytes for subsequent 
migration into the brain parenchyma Although the interactions between Τ cells and 
perivascular cells are hardly studied, they may be crucial to the process of Τ cell 
infiltration into the CNS Therefore, we analysed the interactions of Τ cells with pericytes 
and compared these with endothelial cells In a previous report we described the isolation 
and characterization of pericytes from human brain microvessel segments and showed that 
these cells expressed high levels of the adhesion molecule ICAM-1 and, to a lesser extent, 
VCAM-1 [22] In this report we show that the expression of either adhesion molecule is 
sensitive to cytokine treatment, in a similar way to that described previously for HUVEC 
[31 33] 
In an in vitro adhesion assay we studied the interactions of Τ cells with HUVEC 
and HBP to identify the adhesion molecules essential for these interactions Because we 
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did not succeed in growing sufficient numbers of endothelial cells from human cerebral 
microvessels, we chose to study HUVEC for the interaction with Τ cells. This choice 
seems to be justified by the observation that HUVEC and cerebral endothelial cells 
respond similarly to cytokine treatment with regard to the expression of adhesion 
molecules [33] and that these latter cells in vitro rapidly lose their specific properties Τ 
cell adhesion to either HUVEC or HBP was augmented after treatment with Mn+ + , PMA 
or TNF-a which is in line with previous reports [27,30,32,34,35]. It has been suggested 
that by this in vitro treatment Τ cell integnns assume the activated conformation required 
for their in vivo high affinity binding to their counterstructures. The adhesion of Τ cells to 
HUVEC was mediated by both the LFA-l/ICAM-1 and VLA-4/VCAM-1 pathways, 
whereas, in contrast, adhesion of Τ cells to HBP was dominated by the VLA-4/VC AM-1 
route. 
A possible role for the Τ cell integnn a4/37 [36,37] in the interaction with VCAM-
1 could not be excluded however, as anti-VLA-40 (/31) M Abs only had a partial 
inhibiting effect compared with the effect of anti-VLA-4a and anti-VCAM-1 M Abs It is 
unlikely that the absence of inhibition by 4B4 is caused by the Mn+ + treatment, as it has 
been described that the interaction of ß\-integnns, expressed by melanoma cells, with 
extracellular matrix components is completely inhibited by this MAb, both in resting [38] 
and Mn + +-treated cells (Ε H J Danen, personal communication). Furthermore, it is clear 
from our findings that the anti-LFA-1 and anti-VLA-4a MAbs also inhibit the interaction 
of Mn++-activated integnns with their respective ligands. The adhesion of Τ cells to HBP 
or HUVEC could be maximally blocked only for 80-85% by using mixtures of MAbs in 
the inhibition assays. These results suggest that the a407 integnn or other presently 
unknown adhesion molecules may play a role as well in the interaction of Τ cells with 
HUVEC and HBP. 
It has been described that the adhesion of Τ lymphocytes to HUVEC is dependent 
on the activation state of LFA-1 [34]. Τ cell adhesion via VLA-4/VCAM-1 would only 
take place when LFA-1 is not available, or not in the activated conformation, to mediate 
adhesion Here we show, however, that two different cell types (HBP and HUVEC), with 
similar expression levels of ICAM-1 and VCAM-1 after TNF-α treatment, interact 
differentially with Τ cells These results suggest that Τ cell adhesion is not only regulated 
at the level of Τ cell integnns, but that HUVEC and HBP may also possess mechanisms 
to regulate the functionality of their adhesion molecules. 
Our results confirm previous reports that both the LFA 1/ICAM-1 and VLA-
4/VCAM-l pathways are involved in Τ cell binding to HUVEC [29,34,39,40] The 
migration of Τ cells through the endothelial cell layer, however, is mainly dependent on 
the LFA-l/ICAM-1 pathway [40]. An alternative mechanism seems to operate once Τ 
cells have escaped from the blood flow and passed the endothelial cell layer Our results 
suggest that the VLA-4/VCAM-1 pathway then predominantly mediates further migration 
of Τ cells along pencytes into the brain parenchyma 
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A number of studies has presented evidence for the involvement of adhesion 
molecules during Τ cell infiltration into the brain, resulting in the development of MS 
Although ICAM-1 expression is upregulated in MS microvessels [41,42], treatment of 
EAE with anti-ICAM-1 antibodies has been reported to yield controversial results [43-45] 
These studies are compatible with our findings that the LFA-1 /ICAM-1 pathway only 
partially mediated the binding of Τ cells to HUVEC. Thus, in EAE animals treated with 
anti-LFA-1 or anti-ICAM-1 antibodies, Τ cells could still extravasate using the VLA-
4/VCAM-l pathway. 
Indeed, unambiguous evidence has been provided for an important role of this 
latter pathway in Τ cell infiltration into the MS or EAE brain VCAM-1 is upregulated in 
the vasculature of mice affected by EAE [7] and in MS microvessels [8,42] and the 
expression of its receptor VLA-4 by Τ cells has been described to be essential for Τ cell 
invasion into the brain [9,10] Furthermore, EAE development could be prevented by 
anti-VLA-4a antibodies [6]. Our data our compatible with this inhibitory effect, indicating 
that under these conditions Τ cells are still able to pass the endothelial cell barrier, but 
that subsequent migration of the Τ cells through the pericyte layer is blocked by the anti­
ca antibodies. The possible involvement of VLA-4/VCAM-1 interactions in MS 
development was supported by our immunohistochemical demonstration of VCAM-1 in 
endothelial cells and in perivascular positions, possibly pericytes, at the edges of MS 
plaques. VCAM-1 expression could not be demonstrated in all plaques, but it indicates 
that VCAM-1 can be upregulated under certain conditions m MS For example, it is well 
known that VCAM-1 expression can be upregulated by cytokines like TNF-a and IL-1 
[28,29], which may be produced especially during the active phases of MS plaque 
development [2]. Furthermore, perivascular Τ cells expressed VLA-4 rather than LFA-1, 
emphasizing the relative importance of VLA-4-mediated interactions in the extravasation 
processes 
In summary, the results described in this study indicate that lymphocytes leaving 
the circulation to migrate into the brain may be actively guided to their goal or, 
alternatively, be retained in a perivascular position by interacting differentially with 
endothelial cells and pericytes In accordance with earlier studies, an important role for 
VCAM-1 in the interaction of Τ cells with the brain vasculature was demonstrated [6,7], 
but in addition we showed that these VCAM-l/VLA-4 interactions are exclusive at the 
level of the pericyte A more detailed knowledge of these control mechanisms may be 
important in developing therapeutic strategies aimed at inhibition of Τ cell infiltration in 
MS brain tissue. 
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Summary and discussion 
Alzheimer's disease is a heterogeneous disorder of the brain that may affect people as 
early as in the fifth decade of life. The pathological lesions of the Alzheimer brain are 
well-descnbed: senile plaques, congophilic angiopathy (CA) and neurofibrillary tangles 
(NFTs) The fibnl-forming components of these lesions have been identified as A/3 and 
tau, respectively. Although it is clear that these lesions are the pathological basis for 
neuronal dysfunctioning and dementia, still many questions regarding the underlying 
mechanisms for their development remain unanswered For example, in the case of senile 
plaque formation, the cell type(s) responsible for Aß production, the process of Aß 
fibnllization and the role of inflammatory processes are not entirely understood. The 
mechanisms leading to NFT formation in relation to senile plaque formation remain 
obscure too. Finally, it is not known whether CA is formed via the same mechanisms as 
senile plaques, whether inflammatory processes play a role and what cell types are 
responsible for the formation of CA The work described in this thesis dealt with some of 
the cavities in the knowledge of the pathogenesis of AD and comprised the following 
subjects 
1 · What is the involvement of inflammatory processes in the formation of senile plaques 
and CA, what is its regional specificity and what is the role of activated microglial cells 
in these processes'' 
2: What is the contribution of pericytes in the pathogenesis of CA in AD9 
3: Finally, since not much is known about human brain pericytes and their functioning, 
this thesis also comprised studies to the role of these cells in brain diseases o'her than 
AD. 
The role of inflammatory processes in the formation of senile plaques and CA. 
It has been suggested that inflammatory processes may be involved in the formation of 
senile plaques, based on the observation that several acute phase proteins, such as a,-
ACT, a2-macroglobulm, complement factors and IL-6 are found in senile plaques 
Besides, clusters of activated microglial cells expressing, amongst others, IL-1, are found 
in classic senile plaques, indicating that the inflammatory process is mediated by IL-1 or 
IL-6. In chapter 2, we conducted an immunohistochemical screening for cytokine-
inducible molecules, with special attention for ICAM-1 in order to gain more insight in 
the process of inflammation It was found that ICAM-1 was a component of all types of 
senile plaques in the cerebral cortex, whereas other cytokine-inducible proteins like 
VCAM-1, E-selectin and endoghn were not found in these lesions Antibodies directed 
against different domains of ICAM-1 all stained senile plaques, indicating that the entire 
molecule was produced, although no differentiation could be made between full-length or 
soluble ICAM-1 The association of ICAM-1 with senile plaques was specific for A/3 
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deposits, since no expression was found in non-A/3 amyloidoses of other organs The 
presence of ICAM-1 in cortical senile plaques supports the hypothesis that local 
inflammatory reactions occur in senile plaques and indicates that its production is an early 
process in the formation of these lesions 
In chapter 3, this investigation was extended to a study of ICAM-1 expression in 
vessels affected by CA, since studies on α,-ACT expression in CA raised some 
controversy about the occurrence of an inflammatory reaction in CA Furthermore, 
ICAM-1 expression was studied in senile plaques of the cerebellum, that, in the molecular 
layer, are predominantly of the diffuse type and do not mature into classic senile plaques 
In contrast to what has been described in chapter 1, ICAM 1 was not expressed in diffuse 
senile plaques of the cerebellar molecular layer However, ICAM-1 was expressed in 
classic senile plaques, that were found in the Purkinje cell and granular layer of the 
cerebellum These observations indicated that expression of inflammation-associated 
proteins like ICAM-1 in senile plaques is dependent on the site of A/3 formation 
Furthermore, it was found that ICAM-1 was not associated with the A/3-deposits of CA, 
but was only expressed by endothelial cells and by cells in a perivascular position, 
possibly pericytes However, cortical vessels affected by dyshonc angiopathy, in which 
the amyloid of CA extended into the nearby neuropil, were surrounded by ICAM-1 
expression On the basis of these results we speculated that specific cellular interactions 
are essential for the induction of ICAM-1 and that this may be different in the various 
regions of the brain It is possible that these cellular interactions include ICAM 1 
production by astrocytes that are triggered to do so by microglial IL-1 production Similar 
to what has been described for the induction of α,-ACT production in senile plaques, 
microglial cells and astrocytes in the molecular layer of the cerebellum may be relatively 
deficient in interacting with each other, in contrast to the situation in areas where classic 
senile plaques form, such as the entire cerebral cortex and the granular and Purkinje cell 
layer of the cerebellum. Interactions between microglial cells and astrocytes are, by 
definition, impossible within the vascular wall, but the cells of the vascular wall are not 
triggered to produce ICAM-1 to the same extent as occurs in senile plaques In contrast, 
in cases of dyshonc angiopathy, an inflammatory reaction seems to be evoked, 
underlining the necessity for glial interactions The absence of ICAM-1 expression in 
senile plaques, that do not evolve into the classic type, indicates that products of 
inflammatory reactions play an important role in the formation of A/3 fibrils in senile 
plaques, but probably not in CA Future studies may involve the effect of ICAM-1 to 
promote A/3 aggregation, similar to as has been described for a, ACT Also, it would be 
worth investigating whether cortical, but not cerebellar, microglial cells may induce 
ICAM-1 production by astrocytes and by what biochemical mechanism ICAM-1 and other 
inflammatory components are produced 
In chapter 4 we investigated the relation of microglial cells to senile plaques, also 
using an lmmunohistochemical approach It is known that activated microglial cells cluster 
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only around classic senile plaques and have a higher expression of a number of membrane 
proteins than resting microglial cells. However, their exact function is not known. We 
investigated the possibility that activated microglial cells have a phagocytic function which 
would be compatible with their relation with monocytes and macrophages. Resting and 
activated microglial cells expressed the lysosomal antigen CD68, but only the latter cell 
type expressed a lysosomal antigen recognized by mAb 25F9. The specificity of 25F9 for 
activated microglial cells was confirmed by the absence of reactivity in microglial cells in 
cerebellar diffuse senile plaques. In agreement with the findings of chapter 3, this 
suggests that cerebellar microglial cells are not stimulated to the same extent as their 
cortical counterparts. Immuno-electron microscopy confirmed the lysosomal localization 
of the 25F9 and CD68 antigens. These results indicated that activated microglial cells are 
in a state of enhanced lysosomal activity, characterized by the synthesis of the 25F9-
antigen, and are possibly triggered to degrade components of the classic senile plaque. In 
vitro studies are needed to investigate whether microglial cells are indeed capable of 
phagocytosing Aß and whether this proceeds or leads to microglial activation. 
Identification of the 25F9 antigen may reveal more about the function of the microglial 
cells expressing this protein. 
Together, it can be concluded from these studies that activated glial cells 
(microglial cells and astrocytes) may cooperate in the production of inflammatory 
components in senile plaques. A cellular activation process seems to be essential since in 
diffuse senile plaques of the cerebellum both cell types do not become activated, as 
demonstrated by the lack of 25F9 reactivity in case of microglial cells, and inflammatory 
components are not produced. However, these factors may be produced before microglial 
cells assume their full-blown activated morphology, since inflammatory components are 
produced in the diffuse senile plaques of the cortex, that do not contain activated 
microglial cells. Thus, in accordance with Selkoe's model, inflammation may occur as an 
early reaction to Aß production, but in addition to this model, we show that there are 
regional differences in this response that may be dependent on the possibility of glial 
interactions. Furthermore, the activation of microglial cells that occurs as a reaction to 
Aß production may be aimed at the removal of Aß by phagocytosis. The development of 
relevant experimental (animal) models may help to understand the pathogenesis of the 
characteristic lesions found in the brains of Alzheimer's disease patients. 
The recently reported beneficial effect of treating AD patients with anti-
inflammatory drugs is not yet understood at the biochemical level. It is possible that such 
treatment inhibits the aggregation of Aß into fibrils, a process that may be mediated by 
acute phase proteins such as a,-ACT. Future studies should include the effect of such 
treatment on APP and Aß production by brain cells. Besides, the effects on microglial 
cells and their activation in particular need to be evaluated, since this activation includes 
the production of a complex array of acute phase proteins, cytokines and nitrogen or 
oxygen radicals. The toxic or protective effects of these substances on the neural 
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environment is not yet clear and more fundamental knowledge of these mechanisms will 
be needed to evaluate and design anti-inflammatory therapies 
The contribution of pericytes in the pathogenesis of CA in AD and their role in brain 
diseases other than AD. 
The second part of this thesis dealt with general functions of pericytes in the brain and 
their role in the formation of CA in Alzheimer's disease in particular In contrast to CA 
formation in leptomeningeal arteries, where smooth muscle cells are thought to be 
responsible for Aß production, it has not yet been established what cell type is 
responsible for A/3 production in cortical microvessels Perivascular cells as well as 
pericytes may, based on their localization in the vascular wall, be the producers of A/3 
To study the role of pericytes in these pathological processes, it is essential to learn more 
about their physiological properties and to establish a cell culture system for these cells 
In chapter 5, we described a method to isolate and culture pericytes from human 
brain autopsy tissue These cells displayed a specific profile of membrane proteins, 
different from endothelial cells, smooth muscle cells and fibroblasts, indicating that they 
are a cell type with unique characteristics Cultured pericytes expressed a number of 
antigens that could not be detected in brain tissue sections, thus reflecting an activated 
state of these cells in vitro Though relatively quiescent in normal brain, pericytes 
displayed a remarkably activated phenotype in microvascular proliferations such as 
observed in glioblastoma multiforme, including strong upregulation of HMW MAA and 
a-SMA expression TGF/31 was identified as a factor that may mediate upregulation of a-
SMA 
In chapter 6, this pericyte culture system was used to study the expression and 
intracellular distribution of APP in comparison with other vascular cells, like smooth 
muscle cells derived from human leptomeninges and endothelial cells We demonstrated 
that the intracellular distribution of APP is different in endothelial cells compared to the 
other cell types APP was localized in lysosomal and non-lysosomal vesicles of pericytes 
and smooth muscle cells, but in the ER and Golgi compartment of endothelial cells Thus, 
the routing and trafficking of APP may be cell-specific that have consequences for the 
degradation into its derivatives Hypothetically, it is possible that this is related to the in 
vivo observation that smooth muscle cells and probably pericytes, but not endothelial 
cells, are the producers of Aß in the vessel wall A common mechanism in all cell types, 
however, was the intracellular retention of APP and the accumulation in large spherical 
organelles after IFN7 exposure This unspecified organelle did not display markers for 
either endosomes or lysosomes, but showed morphologically resemblance with 
multivesicular bodies (MVBs) The accumulation of APP in these organelles was 
accompanied by a reduction in APPS production by smooth muscle cells and pericytes It 
remains to be established, however, whether these MVB-hke organelles are part of either 
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the endocytic or the secretory pathway, and, consequently, whether IFN-7 treatment 
enhanced APP re-intemahzaton or, alternatively, reduced APPS secretion. It was, 
however, not yet possible to detect Aß production by these cells and thus a potential 
increase of A/3 production after IFN7 treatment could not be determined. 
Many different cell types, often transfected with APP, have been used to study 
APP and A/3 production, but APP may be differently metabolized in various cell types. 
Therefore, it is important to study APP metabolism in cell types that have a close 
relationship to the pathological lesions of AD and express physiological levels of APP, 
such as pericytes and smooth muscle cells, or human glial or neuronal cells Future 
studies may reveal whether aberrant intracellular distribution of APP leads to excess A/3 
production, and what alternative mechanisms may lead to its production, as well as the 
identification of the subcellular organelle in which A/3 is produced Such studies may lead 
to the design of factors that reduce A/3 production Sensitive techniques for the detection 
of A/3 and immuno-electron microscopy of APP have to be developed, however 
Furthermore, it is interesting to investigate what factors induce Aß production, probably 
including cytokines, what enzymes are involved in A/3 production and what factors 
determine its specificity for production in the cerebral vascular wall and brain 
parenchyma 
In chapter 7, some findings described in chapter 5 were further investigated It 
was found that pericytes expressed the adhesion molecules ICAM-1 and VCAM-1. The 
expression of VCAM-1 is remarkable, since this molecule is not expressed by resting 
endothelial cells implying a specific function for this adhesion molecule in cellular 
interactions In brains, affected by an inflammatory disease such as MS, perivascular 
expression of VCAM-1 was observed In vitro studies indicated that VCAM-1 was the 
major adhesion molecule mediating interactions of pericytes with T-lymphocytes, that 
abundantly enter the brain in MS This study indicates that pericytes may be actively 
involved in inflammatory processes such as T-lymphocyte infiltration in the brain, 
suggesting that pericytes may function as a secondary gate-keeper in this process They 
may actively contribute to the blood-brain barrier function of endothelial cells, by either 
retaining T-lymphocytes in the vasculature or directing them further into the brain 
parenchyma 
The studies described in the chapters 5, 6 and 7 show that a relatively unstudied 
cell type such as the human brain pericyte may be actively involved in the pathogenesis of 
several brain diseases, such as brain tumors, MS and Alzheimer's disease. Especially the 
contribution of pericytes in the formation of CA in the latter disease may be significant 
So far, pericytes and smooth muscle cells are the only cell types that can be cultured from 
adult human brains, that may thus serve as an important, pathopysiologically relevant, 
model system for the study of amyloid formation Understanding the mechanism of Aß 
production may eventually lead to the development of drugs that interfere with this 
harmful process 
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Samenvatting 
De ziekte van Alzheimer 
In 1907 beschreef de Duitse psychiater Alois Alzheimer de ziektegeschiedenis van een 
vrouw die overleed nadat ze gedurende haar leven in toenemende mate verschijnselen van 
dementie had vertoond. Hij nam enkele veranderingen waar in de hersenen van deze 
patiente, die later karakteristiek bleken, en sindsdien wordt deze vorm van dementie naar 
hem genoemd De ziekte van Alzheimer is de meest voorkomende vorm van dementie, 
ongeveer 50% van alle dementie-patienten lijdt aan deze ziekte. Andere vormen van 
dementie zijn o.a. vasculaire dementie, waartoe multi-infarct dementie behoort, en de 
ziekte van Piek. De ziekte van Alzheimer kan reeds toeslaan op relatief jonge leeftijd 
Deze zogenaamde presemele vorm kan mensen treffen vanaf ongeveer 40 jaar. Het 
grootste deel van de Alzheimer-patienten betreft echter ouderen, de zogenaamde seniele 
vorm van de ziekte van Alzheimer. Dit is een van de meest voorkomende 
ouderdomsziekten, op 65-jange leeftijd lijdt 0,5% van alle mensen aan de ziekte van 
Alzheimer en dit aantal neemt toe tot 10-20% onder 85-jangen en tot 40% op nog hogere 
leeftijd. 
Een groot probleem is het stellen van de diagnose "ziekte van Alzheimer" bij 
demente personen. Deze diagnose kan eigenlijk pas sluitend worden gesteld nadat er 
onderzoek heeft plaatsgevonden aan de hersenen; in de regel dus pas na de dood. Bij dit 
neuropathologische onderzoek kunnen een drietal afwijkingen gevonden worden, die 
kenmerkend zijn voor de ziekte van Alzheimer. In de eerste plaats zijn dit de seniele 
plaques. Seniele plaques hebben verschillende verschijningsvormen, maar ze bestaan alle 
uit microscopisch kleine ophopingen van eiwitten in het hersenweefsel, tussen de 
zenuwcellen en andere cellen in Bij gezonde oudere personen worden seniele plaques niet 
of in veel geringere mate aangetroffen Een belangrijk bestanddeel van de seniele plaque 
is het amyloid beta eiwit (Aß), dat de eigenschap heeft onoplosbare draden (fibrillen) te 
kunnen vormen in de hersenen. "Amyloid" is een oude term die vroeger gebruikt werd 
om allerlei onoplosbare, niet nader gekarakteriseerde, eiwitneerslagen aan te geven. Op 
grond van de verschillen in de struktuur van A/3 worden grofweg twee types seniele 
plaques onderscheiden. In de diffuse seniele plaques is het A/3 in een amorfe, niet-
geaggregeerde vorm aanwezig; in de klassieke seniele plaque daarentegen is A/3 tot 
fibrillen samengeklonterd. Een gangbare veronderstelling is dat de diffuse seniele plaques 
het eerst ontstaan en langzaam veranderen in klassieke seniele plaques, door de vorming 
van A/3-fïbnIIen. Deze fibrillen zijn schadelijk en belemmeren zenuwcellen in het 
doorgeven van signalen wat uiteindelijk tot de dood van deze cellen leidt Functioneel uit 
zich dit in verschijnselen van dementie, vergeetachtigheid, stoornissen in het spraak-, 
oriëntatie- en abstraktievermogen etcetera. 
Aß is ook het belangrijkste bestanddeel van de tweede afwijkende struktuur van de 
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hersenen: het vasculaire amyloid Grote en kleine (capillaire) bloedvaten worden aangetast 
door ophoping van A/3. Ook hier geldt weer dat belangrijke funkties van het bloedvat 
belemmerd worden, zoals het aanvoeren en doseren van voedingstoffen naar de hersenen 
De derde afwijking in de hersenen heeft een direkt nadelig effekt op het funktioneren van 
zenuwcellen. Een eiwit dat aangeduid wordt als tau ontstaat in de zenuwcellen zelf en 
vormt daann kabelachtige strukturen, zogenaamde tangles, die de hele cel kunnen 
opvullen, waardoor deze niet of veel slechter zijn werk zal kunnen doen 
De rol van ontstekingsmechanismen 
Dit proefschrift behandelt enkele aspekten die te maken hebben met de vorming van 
seniele plaques en vasculair amyloid De aanwezigheid van A/3 in seniele plaques werd 
door ons onder meer aangetoond met behulp van immunohistochemische technieken Deze 
techniek maakt gebruik van de mogelijkheid om van weefsel flinterdunne plakjes {coupes) 
te snijden van slechts enkele duizendsten van een millimeter dikte, waarop vervolgens een 
kleurreaktie wordt uitgevoerd die specifiek is voor een bepaald eiwit. Hierdoor is het 
mogelijk de lokatie van allerlei eiwitten in bijvoorbeeld hersenweefsel van 
Alzheimerpatienten zichtbaar te maken. Op deze wijze zijn er ook verschillende andere 
eiwitten dan A/3 aangetoond in de seniele plaques. Een aantal van deze eiwitten behoort 
tot de groep van acute fase eiwitten, die gewoonlijk in het lichaam geproduceerd worden 
na een trauma of bij een ontsteking Deze ontdekkingen hebben geleid tot de hypothese 
dat er in de hersenen van Alzheimerpatienten ook een ontstekingsreaktie plaats vindt 
Echter, in tegenstelling tot "gewone" ontstekingen, die slechts van korte duur zijn, 
moeten deze ontstekingsreakties in de hersenen een chronisch karakter hebben, gezien de 
langdurig voortschrijdende aard van de ziekte Behalve de produktie van deze acute fase 
eiwitten is er nog een andere indikatie dat er ontstekingsreakties plaatsvinden in 
Alzheimer hersenen. Een bepaald type cellen in de hersenen, dat onderdeel uitmaakt van 
het afweersysteem in de hersenen, wordt ter plekke van de klassieke seniele plaques 
geaktiveerd Deze cellen hebben, in tegenstelling tot neuronen, geen funktie in het 
versturen van signalen en worden aangeduid als microglia, een naam die dateert uit de tijd 
dat men niet goed wist welke funktie deze cellen hadden en die zoveel betekent als 
"kleine (micro) cellen die als een soort lijm {glia) de zenuwcellen bij elkaar houden" 
Microglia zijn sterk verwant aan monocyten, dit zijn cellen die een belangrijke funktie 
hebben in het afweersysteem en als zodanig betrokken zijn bij ontstekingsreakties 
Ondanks deze gegevens is het momenteel nog niet geheel duidelijk in welke fase van de 
ziekte deze acute fase eiwitten geproduceerd worden (voorafgaand de produktie van A/3 
of, waarschijnlijker, als reaktie hierop), door welke cellen ze geproduceerd worden 
(microglia of andere cellen), wat de precieze rol is van deze ontstekingsprocessen en van 
de microglia bij de vorming van seniele plaques en vasculair amyloid en wat de exacte 
oorzaak hiervan is 
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Deze vragen hebben geleid tot het onderzoek dat beschreven is in de hoofdstukken 2, 3 
en 4 van dit proefschrift 
In de hoofdstukken 2 en 3 wordt met behulp van immunohistochemische 
kleuringen van hersencoupes het eiwit intercellular adhesion molecule-1 (¡CAM-1) 
zichtbaar gemaakt Van dit eiwit is bekend dat het tijdens ontstekingen in grote mate 
geproduceerd wordt, wat dus een reden vormde voor de bestudering ervan in de hersenen 
van Alzheimer patiënten In hoofdstuk 2 werd de expressie van ICAM-1 bekeken in de 
buitenste laag (cortex) van de hersenen, een gebied waar veel seniele plaques aangetroffen 
kunnen worden. Inderdaad werd expressie van ICAM-1 waargenomen in alle types seniele 
plaques in dit gedeelte van de hersenen Deze bevindingen ondersteunen de theorie dat 
ontstekingsprocessen een onderdeel vormen van de afwijkingen in Alzheimer hersenen 
Tevens, vanwege de expressie van ICAM-1 in de "vroege" diffuse seniele plaques, kan 
gekonkludeerd worden dat ontstekingsreakties snel optreden en dat produkten van deze 
reakties al voorkomen voordat Aß de schadelijke fibnllen heeft gevormd 
In hoofdstuk 3 werden deze bevindingen uitgebreid met een studie naar de 
expressie van ICAM-1 in het cerebellum (kleine hersenen) In dit deel van de hersenen, 
met name in de zogenaamde molekulaire laag, komen ook diffuse seniele plaques voor, 
maar deze veranderen vrijwel nooit in klassieke seniele plaques Het cerebellum kan dus 
uitstekend dienen om het verband vast te stellen tussen ontstekingsreakties en de vorming 
van klassieke seniele plaques Opvallend was dan ook dat ICAM-1 niet tot expressie 
kwam in de diffuse seniele plaques in het cerebellum Echter, in de zogenaamde Purkinje 
en granulaire lagen van het cerebellum werden incidenteel klassieke seniele plaques 
aangetroffen, die in dit geval juist wèl ICAM-1 bevatten Deze gegevens betekenen dat 
componenten van een ontstekingsreaktie, zoals ICAM-1, mogelijk bijdragen tot de 
vorming van de klassieke seniele plaque en dus de vorming van A/3 fibnllen De 
afwezigheid van deze molekulen kan verklaren waarom deze diffuse seniele plaques niet 
transformeren tot klassieke seniele plaques Tevens betekent dit dat de vorming van 
klassieke seniele plaques afhankelijk is van de plaats in de hersenen waar Aß 
geproduceerd wordt Er bleken ook verschillen te zijn tussen de produktie van Aß in het 
hersenweefsel zelf (seniele plaque vorming) of in de bloedvaten van de hersenen 
(vasculair amyloid) Op plaatsen waar Aß in bloedvaten werd aangetroffen, bleek ICAM-
1 niet aanwezig te zijn Kennelijk leidt produktie van A/3 in de bloedvaten niet tot een 
ontstekingsreaktie en verloopt de vorming van Aß fibnllen in bloedvaten niet volgens 
precies dezelfde weg als in seniele plaques 
De rol van microglia cellen werd in hoofdstuk 4 nader onderzocht Het was reeds 
bekend dat deze cellen in groepjes voorkomen rond klassieke seniele plaques en in een 
geaktiveerde staat verkeren Dit is herkenbaar aan het feit dat ze van vorm veranderen en 
grotere hoeveelheden van bepaalde eiwitten produceren, die schadelijk kunnen zijn voor 
zenuwcellen, dan hun niet-geaktiveerde soortgenoten Dit proces vindt niet plaats rond 
diffuse seniele plaques De precieze funktie van deze geaktiveerde microglia is echter nog 
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niet helemaal duidelijk Met behulp van ïmmunohistochemische kleuringen is in dit 
hoofdstuk aangetoond dat het lysosomale systeem van deze cellen ook geaktiveerd is In 
de regel duidt dit op een verhoogde fagocyterende aktivileit van de cellen, wat betekent 
dat deze cellen afvalprodukten verwijderen door middel van opname (fagocytose) en 
afbraak in hun lysosomen Aangezien deze cellen zich bevinden in de nabijheid van de A/S 
fibnllen van klassieke seniele plaques, is het mogelijk dat het hun funktie is om (te 
proberen) deze schadelijke fibnllen op te ruimen Het is echter de vraag of ze daar ook in 
slagen Omdat geaktiveerde microglia niet in diffuse seniele plaques voorkomen, zijn deze 
cellen waarschijnlijk niet de belangrijkste producenten van A/3 in seniele plaques Echter 
het is wel van belang om te weten welke funktie deze cellen precies vervullen evenals het 
belangrijk is om te weten welke cellen in de hersenen A/3 maken en op welke wijze ze 
hiertoe gestimuleerd worden Tevens is het belangrijk om te weten hoe A/3 omgevormd 
wordt tot schadelijke fibnllen, voordat uiteindelijk in het ziekteproces ingegrepen kan 
worden met potentiële medicijnen 
Sinds enkele jaren wordt er op kleine schaal geexpenmenteerd met het toedienen 
van ontstekingsremmende middelen aan Alzheimer patiënten Deze medicijnen blijken het 
ziekteproces enigszins te kunnen remmen, maar kennen vervelende bijwerkingen Tevens 
is gebleken dat onder groepen personen, die om andere redenen onstekingsremmende 
middelen toegediend kregen, bijvoorbeeld patiënten lijdend aan rheumatoide arthritis, de 
ziekte van Alzheimer relatief weinig voorkomt Dit wijst dus op een beschermend effekt 
van deze medicijnen Op grond van het bovenstaande en andere onderzoekingen kan 
verondersteld worden dat de ontstekingsremmende middelen de produktie van eiwitten als 
ICAM-1 (en andere) remmen, met als gevolg een verminderde vorming van A/3-fibnllen 
en een verminderde sterfte van zenuwcellen Ook is het waarschijnlijk dat de aktivatie van 
microglia geremd wordt, met als gevolg een gereduceerde produktie van toxische stoffen 
Samenvattend кал gesteld worden dat ontstekingsmechanismen een belangrijke rol spelen 
bij het ontstaan van seniele plaques en dat dit een potentieel aangrijpingspunt is voor 
therapie van de ziekte van Alzheimer Echter, er zal nog veel fundamenteel onderzoek 
verncht moeten worden voordat de werking van dergelijke medicijnen volledig begrepen 
is en op grotere schaal toegepast kan worden 
De rol van pericyten bij de vorming van vasculair amyloid 
Een van de plaatsen in de hersenen waar A/3 geproduceerd wordt, is de wand van de 
bloedvaten Een bloedvat bestaat uit een enkelvoudige laag van endotheekellen, die de 
binnenbekleding vormen van het vat, en daar omheen cellen die aangeduid worden met 
gladde spiercellen (in het geval van grotere vaten) of pericyten (rond de haarvaten of 
capillairen) A/3 hoopt zich op in hersenbloedvaten van meer dan 70% van de 
Alzheimerpatienten en het bevindt zich aan de kant van de gladde spiercellen of pericyten 
Het ligt dan ook voor de hand te veronderstellen dat deze cellen verantwoordelijk zijn 
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voor de produktie van A/3. In de hoofdstukken 5, 6 en 7 wordt de algemene funktie van 
pericyten bestudeerd evenals de mogelijkheid dat deze cellen betrokken zijn bij de 
produktie van A/3. 
Teneinde pericyten goed te kunnen bestuderen, is het noodzakelijk een systeem op 
te zetten waarin deze cellen buiten de hersenen gemanipuleerd kunnen worden. In 
hoofdstuk 5 wordt een techniek beschreven waarmee pericyten geïsoleerd kunnen worden 
uit hersenweefsel van overledenen. Gekweekte pericyten produceren een uniek palet van 
eiwitten, dat deze cellen onderscheidt van andere celtypen, zoals endotheelcellen, gladde 
spiercellen en fibroblasten. Gekweekte pericyten produceren daarnaast een aantal eiwitten 
die niet geproduceerd worden door pericyten in hersenweefsel van gezonde personen. Dit 
betekent dat gekweekte pericyten zich in een geprikkelde toestand bevinden die 
overeenkomsten vertoont met die van pericyten in bepaalde hersentumoren (glioblastoma 
multiforme). Zulke hersentumoren zetten de cellen van bloedvaten in de hersenen aan tot 
groei, met als gevolg dat zowel endotheelcellen als pericyten geaktiveerd raken en als 
gevolg hiervan andere eiwitten gaan produceren. 
Met de techniek om pericyten te kunnen kweken uit humaan hersenweefsel in 
handen, is het mogelijk deze cellen te bestuderen in verband met hun rol bij de produktie 
van A/3 in Alzheimer hersenen. A/3 is slechts een klein eiwit van 39-42 aminozuren (de 
bouwstenen van eiwitten) lang, dat, zo is uit eerder onderzoek gebleken, ontstaat doordat 
een groter eiwit in stukken geknipt wordt. Dit grotere eiwit wordt het amyloid precursor 
protein (APP) genoemd en bestaat uit 695-770 aminozuren. APP is een zogenaamd 
transmembraan eiwit, dat wil zeggen dat het verankerd zit in het (buiten-)oppervlak van 
de cel, met een groot gedeelte aan de buitenkant van de cel en een klein stukje dat door 
het oppervlak van de cel naar binnen steekt. De "normale" verwerking van APP vindt 
plaats door het gedeelte aan de buitenkant van de cel eraf te knippen, waarbij "oplosbaar 
APP" gevormd wordt (APPJ. Tijdens dit proces van doormidden kippen van APP, wordt 
het A/3-gedeelte ook in tweeën gesplitst. Dit deel zit namelijk half "verscholen" in de 
zogenaamde membraan en half aan de buitenkant van de cel. Er moet dus nog een ander 
mechanisme bestaan dat leidt tot de vorming van Aß. Zijn verscholen positie in de 
membraan maakt APP erg ontoegankelijk voor enzymen die het APP zodanig in stukken 
kunnen knippen dat A/3 gevormd wordt. Vermoedelijk vindt deze verwerking van APP tot 
A/3 dan ook plaats via een ingewikkelde route in de cel, waarbij het APP langs 
verschillende delen van de cel gevoerd wordt en stapsgewijs afgebroken wordt tot Aß. In 
hoofdstuk 6 wordt bestudeerd op welke plaats in de cel APP zich bevindt en wat het 
effekt is op de afbraak van APP van stoffen, die deze lokalisatie beïnvloeden. De 
verdeling van APP bleek verschillend te zijn in cellen die waarschijnlijk betrokken zijn bij 
de vorming van A/3 in de hersenen (pericyten en gladde spiercellen) in vergelijking met 
cellen die hierbij niet betrokken zijn (endotheelcellen). Tevens kon een verschuiving van 
de lokalisatie van APP in de cel in verband gebracht worden met een verlaagde produktie 
van APP,. De effekten op Aß produktie konden helaas met gemeten worden. Dit soort 
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studies zijn belangrijk omdat op deze wijze meer inzicht verkregen kan worden in de 
wijze waarop A/3 uit APP gevormd wordt en waar in de cel dit gebeurt Indien dit bekend 
is, kunnen er strategieën ontwikkeld worden om deze processen op gunstige wijze te 
beïnvloeden Het is tevens belangrijk om dit soort studies uit te voeren met cellen die de 
aktuele situatie in de hersenen zo dicht mogelijk benaderen, zoals beschreven in dit 
hoofdstuk voor pencyten en gladde spiercellen uit de hersenen 
In het afsluitende hoofdstuk 7 wordt in een kweeksysteem de interactie van 
pencyten met cellen van het immuunsysteem (T lymfocyten, of Τ cellen) bestudeerd in 
vergelijking met de funktie van endotheelcellen hierbij De ziekte multipele sclerose 
ontstaat doordat Τ cellen de hersenen binnendringen Hiervoor moeten ze zich een weg 
banen langs de cellen die de bloedvatwand vormen, eerst langs endotheelcellen en 
vervolgens langs pencyten Uit het onderzoek blijkt dat de interaktie tussen Τ cellen en 
pencyten enerzijds en tussen Τ cellen en endotheelcellen anderzijds, op verschillende 
mechanismen berust Dit onderzoek levert aanwijzingen op dat pencyten aktief betrokken 
kunnen zijn bij het toelaten van cellen die het hersenweefsel willen binnendringen en dat 
ze een aanvullende funktie kunnen hebben op de belangrijke rol van endotheelcellen in dit 
proces 
Uit het onderzoek beschreven in de hoofdstukken 5, 6 en 7 blijkt dat pencyten een 
belangrijke rol kunnen spelen bij onderdelen van het ziekteproces van diverse 
hersenziekten, zoals hersentumoren, de ziekte van Alzheimer en multipele sclerose Met 
name bij de bestudering van de ziekte van Alzheimer kunnen pencyten fungeren als een 
geschikt modelsysteem om de processen die leiden tot de vorming van vasculair amyloid 
in de hersenen van patiënten lijdend aan deze ziekte, beter te doorgronden 
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Abbreviations 
A0 
α,-ACT 
AD 
APLP 
ApoE 
APP 
APPS 
BBB 
bFGF 
CA 
CFA 
CNS 
CRP 
CSF 
CTF 
DA 
DAB 
DAT 
ECGF 
EAE 
EDTA 
ELISA 
ER 
FCS 
FITC 
GBM 
GFAP 
HBP 
HCHWA D 
HFF 
HLA 
HLSMC 
HMEC 
HMW-MAA 
HS 
HSPG 
HUASMUC 
HUVEC 
amyloid bela prolein 
α,-antichymotrypsin 
Alzheimer's disease 
amyloid precursor-like protein 
apolipoprotein E 
amyloid precursor protein 
soluble amyloid precursor protein 
blood-brain barrier 
basic fibroblast growth factor 
congophihc angiopathy, cerebrovascular amyloidosis 
complete Freund's adjuvant 
central nervous system 
C-reactive protein 
cerebrospinal fluid 
C-terminal fragment 
dyshonc angiopathy 
diaminobenzidin 
dementia of Alzheimer type 
endothelial cell growth factor 
experimental allergic encephalitis 
ethylene diamine tetraacetic acid 
enzyme-linked immunosorbent assay 
endoplasmatic reticulum 
fetal calf serum 
fluorescein isothiocyanate 
glioblastoma multiforme 
glial fibrillar acidic protein 
human brain pencyte(s) 
hereditary cerebral hemorrhage with amyloidosis-Dutch type 
human foreskin fibroblast 
human leukocyte antigen 
human leptomeningeal smooth muscle cell(s) 
human microvascular endothelial cell(s) 
high molecular weight-melanoma associated antigen 
human serum 
heparan sulphate proteoglycan 
human umbilical artery smooth muscle cell(s) 
human umbilical vein endothelial cell(s) 
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ICAM 
IEM 
IFN-γ 
IL 
kDa 
KPI 
lamp 
LCA 
LFA 
M
r 
a2-M 
MAb 
мне 
mRNA 
MS 
MVB 
NAD 
NCS 
NFT 
NSAID 
PAb 
PAGE 
PBS 
PHF 
PLP 
PMA 
PMD 
PN-2 
PS 
SDAT 
SDS 
o-SMA 
SP 
TGF-0 
TNF-a 
VCAM 
VLA 
intercellular adhesion molecule 
immuno-electron microscopy 
interferon-γ 
interleukin 
kilodalton 
Kunitz protease inhibitor 
lysosome-associated membrane protein 
leukocyte common antigen 
leukocyte function-associated antigen 
relative molecular weight 
a2-macroglobulin 
monoclonal antibody 
major histocompatibility complex 
messenger ribonucleic acid 
multiple sclerosis 
multivesicular body 
non-Alzheimer dementia 
newborn calf serum 
neurofibrillary tangle 
non-steroidal anti-inflammatory drugs 
polyclonal antibody 
Polyacrylamide gel electrophoresis 
phosphate buffered saline 
paired helical filament 
periodate-lysine-paraformaldehyde 
phorbol 12-mynstate 13-acetate 
post-mortem delay 
protease nexin-2 
presenilin 
senile dementia of Alzheimer type 
sodium dodecyl sulphate 
α-smooth muscle actin 
senile plaque 
transforming growth factor-/? 
tumor necrosis factor-α 
vascular cell adhesion molecule 
very late antigen 
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Nawoord 
Vanzelfsprekend was dit proefschrift niet tot stand gekomen als ik niet de deskundige hulp 
en nuttige adviezen van verschillende personen had gekregen Zonder anderen tekort te 
willen doen voor hun bijdrage aan dit boekwerkje, wil ik de volgende personen met name 
noemen en bedanken 
Irene Otte Holler Je creatieve invallen hebben geleid tot een scala van mooie 
dubbelkleuringen die dit proefschrift opsieren, en gelukkig zijn er ook diverse 
bewijzen van het vele gezwoeg achter de electronenmicroscoop terug te vinden in 
dit boekje 
Rob de Waal Dankzij jouw begeleiding werd het onderzoek, na een moeizame start, in 
de juiste banen geleid Je enthousiasme bleek altijd door de snelle correcties van 
manuscripten en de vele gelegenheden om over het onderzoek te discussieren 
Hans Westphal Je vele goede tips en ideeën op experimenteel gebied hebben het 
onderzoek een duwtje in de rug meegegeven en heeft er toe geleid dat zelfs de Τ 
cel in dit boekje voorkomt De gedeelde interesse in bepaalde tv-programma's was 
misschien wel net zo belangrijk en zorgde er in elk geval voor dat er ook genoeg 
gelachen werd 
Pieter Wessehng Als neuropathologische vraagbaak stond(en) je deur(en) altijd open om 
binnen te vallen met vragen of coupes op hersengebied Deze bezoeken leidden 
niet zelden tot discussies waarin geen invalshoek onbelicht bleef, waarmee je er in 
elk geval voor zorgde dat ik mijn ogen open bleef houden voor minder voor de 
hand liggende opties 
Dirk Ruiter Ondanks dat hersenen en melanomen slechts weinig met elkaar gemeen 
hebben, volgde je het onderzoek toch altijd met grote interesse en wist je, waar 
nodig, de juiste stimulans te geven 
Jeroen van der Laak Het was gezellig om een kamer te delen met een informatici, die je 
van allerhande triviale computerproblemen af kon helpen en bovendien ook nog 
onovertroffen software schrijft1 
Reagan Pieters Het was leuk en leerzaam om je als HLO-stagiaire te hebben begeleid en 
hopelijk denk jij er net zo over 
Wim Jansen, Roel Westerhof en Ane Maat Bedankt voor alle bewezen 
(middernachtelijke) diensten bij obdukties 
Piet Eikelenboom Met je brede kennis van zaken en je vakkundige adviezen heb je 
enkele artikelen en ons onderzoek als geheel een extra duw in de goede richting 
gegeven, wat uiteindelijk zelfs resulteerde in het huidige samenwerkingsverband 
Bill Van Nostrand Thanks a lot for providing me generously with all kinds of antibodies, 
proteins and peptides, and above all, for allowing me to have a great time at your 
lab in Irvine Hang ten, dude' 
Pa en Ma 
Jacky 
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dienstverband betekende de definitieve ommezwaai naar celbiologisch onderzoek, want 
onder begeleiding van dr. V.W.M, van Hinsbergh werd in deze periode onderzoek 
verricht naar de invloed van basic fibroblast growth factor op de permeabiliteit van 
endotheelcellen en de produktie van tissue plasminogen activator door deze cellen. In 
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assistent in opleiding op de afdeling Pathologie van het Academisch Ziekenhuis Nijmegen 
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R.M.W. de Waal en Prof.dr. DJ. Ruiter het in dit proefschrift beschreven onderzoek 
uitgevoerd. Vanaf 1 februari 1995 kreeg dit onderzoek een vervolg in de vorm van een 
door NWO gesubsidieerd projekt getiteld "The role of neuroinflammatory mechanisms in 
the pathogenesis of Alzheimer's disease". Tevens werd er een NWO reisstipendium 
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laboratorium van dr. W.E. Van Nostrand, Department of Microbiology and Molecular 
Genetics, University of California, Irvine, USA. 
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Colour illustrations 
Page 166, top (Chapter 2, figure 4). Staining of AD brain tissue with microglial and astrocyte 
markers Cryosections were stained with MAb NK1-L12 (anti-LFA-1a), MAb CBR-IC2/2 (anti-
¡CAM-2) and MAb 6F2 (anti-GFAP) Microglial cells were stained for ICAM-2 (A) and LFA-la 
(В) С Double-staining of AD brain tissue with anti-ICAM-2 (purple) and anti-GFAP (brown) 
Note that most of the ICAM-2 positive cells (small arrows) were not stained by the astrocyte 
marker GFAP (large arrows) A small number of cells showed staining for both markers 
(arrowheads) All sections were stained with DAB as chromogen with or without the addition of 
nickel ammonium sulphate (purple and brown reaction product, respectively) Magnifications 
x375 (see also page 56) 
Page 166, bottom (Chapter 3, figure 4). ¡mmunohistochemical staining of classic senile plaques in 
serial sections of DAT cerebellum with the αηιι-Αβ MAb 6C6 (A), Congo red (B,D,E) and the 
anti-ICAM-1 MAb CL203 (C) A high power magnification (D) of the classic senile plaque, 
indicated by the arrow in B, is shown under polarized light in E Magnifications Α-C, x250, D-
E, x850 (see also page 70) 
Page 167 (Chapter 4, figure 4). Double-immunostaining of DAT brain tissue with 25F9 and 
markers for astrocytes and senile plaques A Astrocyte staining for GFAP (6F2, blue) and 
staining for 25F9 (brown) В Staining of senile plaques with anti-Aß (blue) and of KP 1-positive 
cells (brown) Note the presence of clusters of KP ¡-positive granules in senile plaques C,D 
Staining of plaques with anti-Aß (blue) and of 25F9-positive cells (brown) 25F9-positive cells 
within (C) and immediately around (D) senile plaques E Staining of a senile plaque with anti-
APP (P2-1, blue) containing several 2^F9-positive cells (brown) Note the weak APP-staming in a 
blood vessel (arrow) accompanied by a 25F9-positive perivascular cell (arrowhead) 
Magnifications A.C-E, x260, В, xl30 (see also page 86) 
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To gain a better 
understanding of 
Alzheimer's Disease 
hTAU 
• The first assay for the early detection of 
TAU protein in the CSF of Alzheimer 
patients. 
• Various antibodies for the immuno-
histochemical detection of phosphorylated 
and non-phosphorylated TAU (AT-8, 
AT-180, AT-270, HT-7, BT-2,...). 
INNOGENETICS 
Apo E 
• DNA test to determine the ApoE genotype 
for risk evaluation in Alzheimer's Disease. 
• Monoclonal antibody to human Apo E. 
Other Neurological 
Markers 
• MAP2, GAP43, NSE, GFAP, 
Neurofilament,... 
For more information, contact us at: 
I N N O G E N E T I C S nv 
Canadastraat 21 - Haven 1009 
B-2070 Zwijndrecht 
Tel.: ++ 32 3 252 37 11, fax: ++ 32 3 252 37 99 
Email: sales.alz@innogenetics.be 
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